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Summary 
 
Background 
 
Remote ischaemic preconditioning (RIPC) is the phenomenon where brief non-harmful 
ischaemia to a remote organ can confer protection to the heart against a future insult. 
Most commonly delivered with a sphygmomanometer on the arm, RIPC has been 
shown to confer protection when delivered prior to primary or elective percutaneous 
coronary intervention (PCI). The mechanism by which this occurs is not clearly defined.  
Coronary microcirculatory function is an important determinant of patient prognosis at 
the time of PCI. Platelets play an important role in the pathophysiology of coronary 
atherosclerosis related thrombotic events, with platelet inhibition an integral component 
of the clinical management of patients with coronary artery disease (CAD) including 
those undergoing PCI. Given the important role of both the microcirculation and platelet 
inhibition at the time of PCI, this project was designed to investigate the effect of RIPC 
on these two prognostically important factors.  
 
Methods and results 
 
This thesis has examined 1) the effect of RIPC on coronary artery physiology and 2) the 
effect of RIPC on platelet activation in response to platelet agonists and the interaction 
between these effects and antiplatelet medications.  
  x  
 
To study the effect of RIPC on coronary artery physiology and microcirculatory 
function, a randomised blinded placebo controlled trial was performed. Patients with a 
clinical indication for fractional flow reserve (FFR) measurement (n=30) were 
randomised to receive RIPC or sham treatment while on the catheterisation table. A 
comprehensive coronary physiology study was performed with a temperature-pressure 
sensor coronary guidewire before and immediately after the allocated treatment. The 
index of microcirculatory resistance (IMR) and coronary flow reserve (CFR) were 
measured as markers of microcirculatory function. RIPC was associated with a 
significant reduction in the calculated IMR (median (interquartile range), 22.6 (17.9-
25.6) vs 17.5 (14.5-21.3), P=0.007) and a significant increase in the CFR (mean ± 
standard deviation, 2.6 ± 0.9 vs 3.8 ± 1.7, P=0.001). These changes were associated 
with a reduction in hyperaemic transit time (0.33 (0.26-0.40) vs 0.25 (0.20-0.30), 
P=0.01) indicating an increase in coronary blood flow. There was no effect on FFR. 
Sham treatment had no effect on any coronary physiology parameter.  Analysis of 
plasma stored from blood collected before and after RIPC/sham treatment found no 
changes in plasma nitrite, cyclic guanosine monophosphate (cGMP) or adrenomedullin 
with RIPC. There was a reduction in plasma 6-keto-PGF1α (the metabolite of 
prostacyclin) with RIPC.  
The effect of RIPC on platelet activation was studied in a separate randomised 
controlled trial where patients referred for coronary angiography (n=60) were 
randomised prior to their procedure to RIPC or sham treatment. Venous blood was 
collected from the contralateral arm before and immediately after their allocated 
treatment, prior to cardiac catheterisation.  Platelets were stimulated in whole blood 
with adenosine diphosphate, protease activated receptor-1 agonist (SFLLRN), thrombin 
with and without collagen, and analysed by flow cytometry for expression of CD62P 
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(marker of α-granule release), CD63 (marker of dense granule and lysosome release) 
and conformationally active glycoprotein IIb-IIIa (GPIIb-IIIa) (PAC-1 binding). RIPC 
was associated with decreased platelet PAC-1 binding in response to SFLLRN (50.4% 
(31.3-73.2) vs 49.3% (23.0-67.7), P=0.002) and thrombin and collagen (79.5 ± 11.9% 
vs 68.9 ± 22.5%, P<0.001). Similar effects were seen in patients on both aspirin and a 
P2Y12 receptor inhibitor. Despite their role in regulating GPIIb-IIIa activation, there was 
no effect of RIPC on plasma cyclic adenosine monophosphate and cGMP levels or 
intra-platelet phosphorylated vasodilator stimulated phosphoprotein levels.  
RIPC was also assessed for its effects on the generation of procoagulant platelets 
(n=60), identified by the uptake of 4-(N-(S-glutathionylacetyl)amino) phenylarsonous 
acid (GSAO, an intracellular cell death marker) and staining for CD62P 
(GSAO
+
/CD62P
+
). RIPC decreased circulating levels of procoagulant platelets in the 
circulation (2.0% (1.3-2.4) vs 1.3% (1.1-2.1), P=0.01), whereas sham had no effect. In 
the subgroup of patients on aspirin monotherapy, RIPC was associated with a reduction 
in procoagulant platelet formation in response to SFLLRN (11.4±5.2% vs 8.9±2.8%, 
P=0.04) and thrombin (12.9±5.9% vs 8.7±3.2%, P=0.04). In order to determine the 
mechanism behind the RIPC-mediated attenuation of procoagulant platelet formation, 
further patients were studied to assess for the effects of RIPC on platelet mitochondrial 
membrane potential using a fluorescent potential-sensitive probe (TMRE). RIPC was 
associated with a significant reduction in platelet mitochondrial membrane 
depolarisation in response to a range of thrombin (P=0.001) and thrombin and collagen 
(P=0.01) concentrations.  
To investigate whether RIPC modifies the plasma microRNA profile, plasma stored 
from blood collected before and after RIPC/sham in the platelet cohort was analysed. 
Plasma microRNA was extracted from paired plasma samples collected from 4 patients 
  xii  
 
treated with RIPC. The plasma microRNA profile before and after RIPC was compared 
with a card based quantitative polymerase chain reaction (qPCR) array system and 
identified 6 candidate species which appeared to be increased with RIPC. A validation 
study was performed in the entire randomised platelet cohort (n=60) by extracting 
microRNA from paired plasma samples collected from patients before and after 
treatment with either RIPC or sham, and measuring the levels of the 6 candidate species 
with specific reverse transcription and qPCR reactions. This demonstrated no definite 
difference with RIPC over sham treatment in any of the 6 microRNA species.  
 
Conclusion 
 
RIPC leads to rapid improvements in coronary microcirculatory function as 
demonstrated by validated catheterisation based coronary physiology measurements. 
Additionally, RIPC attenuated platelet GPIIb-IIIa activation in response to potent 
platelet agonists which are present at the site of complicated atherosclerotic plaques. 
Attenuation of GPIIb-IIIa activation was evident in patients on contemporary 
antiplatelet therapy, suggesting benefit additional to these medications. RIPC also 
reduced the level of circulating procoagulant platelets. Reductions in procoagulant 
platelet activity appeared to be due to RIPC-mediated reduction in platelet 
mitochondrial membrane depolarisation. These novel actions of RIPC are likely to 
contribute to the beneficial effects of RIPC during elective and primary PCI. 
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Chapter 1: General introduction 
 
On a global scale, of the non-communicable diseases, cardiovascular disease is the 
leading cause of mortality and morbidity (1,2), and coronary artery disease (CAD) is 
responsible for more than half of cardiovascular deaths.  Guideline recommended 
therapy includes antiplatelet medications and lipid lowering therapy (3,4) as well as 
revascularisation with percutaneous coronary intervention (PCI) and coronary artery 
bypass graft surgery (CABG) for selected individuals (5). 
Despite optimal medical therapy and revascularisation with both PCI and CABG, 
patients with CAD are at ongoing risk of cardiovascular death, myocardial infarction 
(MI) and need for repeat revascularisation (6).  Additionally, PCI and CABG are 
associated with myocardial injury, which includes ischaemia reperfusion (IR) injury, 
which is detectable as an elevation in serum troponin after the procedure (7,8). Post 
procedural myocardial injury is associated with a worse prognosis (9-11). 
Given the significant impact that CAD has on patient quality of life and longevity, the 
search for strategies that provide clinical benefit additional to current treatment 
paradigms are active areas of investigation. While most treatment modalities focus on 
preventing progression of CAD and preventing or minimising myocardial ischaemia 
through prevention of coronary thrombus formation and revascularisation, there is 
currently a paucity of therapies to protect the heart from ischaemic insult. Remote 
ischaemic preconditioning (RIPC) has been proposed to protect the myocardium against 
injury, including at the time of primary PCI for ST elevation myocardial infarction 
(STEMI), or elective PCI for management of refractory angina. However, clinical trials 
of RIPC have yielded inconsistent results. Consideration of the mechanisms implicated 
in RIPC may help explain discrepant results and outline future studies to identify which 
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patient populations may benefit from this simple, low-cost, non-invasive intervention. 
Additionally, novel therapies which recapitulate the favourable effects of RIPC could be 
developed in their own right once mechanisms are elucidated. 
The primary aim of this thesis is to explore mechanisms by which RIPC may contribute 
to reduced myocardial injury, especially in patients undergoing PCI for CAD. The main 
focus will be on coronary artery physiology and platelet activation, factors that 
significantly influence the outcome of patients undergoing PCI. 
 
1.1 Remote ischaemic preconditioning 
 
First described in 1993 (12), RIPC describes the phenomenon whereby brief non-
harmful insults to remote tissues can protect against future IR injury in a tissue or organ 
of interest such as the heart. Whilst many of the early studies of RIPC were performed 
in animal models, the observation that RIPC can confer cardiac protection through an 
ischaemic stimulus to the limbs has facilitated its clinical application in humans 
including its use prior to PCI and CABG.   
RIPC involves the delivery of repeated non-harmful ischaemia to a tissue remote from 
the heart. In contemporary clinical studies, RIPC is most commonly delivered with a 
sphygmomanometer inflated on the upper limb to 200 mmHg (or a supra-systolic 
pressure) for 5 min, followed by deflation for 5 min with the cycle performed three to 
four times (13-23). Delivery of ischaemia to upper and lower limbs may differ in 
relation to RIPC (24) and variations in the interval between RIPC and subsequent 
cardiac procedure may also influence the effectiveness of RIPC (25).   
While RIPC describes delivery of intermittent limb ischaemia prior to the onset of 
myocardial ischaemia, remote ischaemic perconditioning (RIPerC) refers to intermittent 
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limb ischaemia occurring after onset of myocardial ischaemia such as is the case during 
efforts to condition the myocardium during acute myocardial infarction, prior to 
primary PCI. Remote ischaemic postconditioning refers to intermittent limb ischaemia 
occurring after myocardial reperfusion. Figure 1.1 demonstrates the temporal 
association between the types of conditioning and the onset of myocardial ischaemia. 
 
 
 
Figure 1.1 Cardiac ischaemic conditioning 
Temporal relationship between preconditioning, perconditioning and postconditioning and the onset of 
myocardial ischaemia with examples of clinical scenarios where the conditioning stimulus may be used. 
CABG, coronary artery bypass grafting; MI, myocardial infarction; PCI, percutaneous coronary 
intervention;  
Adapted from Hausenloy D, 2016 (26). 
 
1.2 Potential mechanisms 
 
1.2.1 Neural pathways 
There are two predominant theories explaining the cardioprotective effects of RIPC. 
The humoral hypothesis proposes that a substance is released from the remote organ or 
tissue after RIPC and this is transferred to the heart in the circulation. Conversely, 
advocates of the less widely studied neural hypothesis suggest that RIPC protection is 
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transduced from the remote organ or tissue via somatosensory nerves to the spinal cord 
and then to the heart via autonomic nerves (27) (Figure 1.2).    
 
 
 
Figure 1.2 Mechanisms potentially involved in remote ischaemic preconditioning  
ATP, adenosine triphosphate; MAPK, mitogen activated protein kinases; mPTP, mitochondrial 
permeability transition pore; RIPC; remote ischaemic preconditioning; RISK, reperfusion injury salvage 
kinase; SAFE, survival activating factor enhancement; 
 
The neural RIPC hypothesis is supported by several animal studies. For example, 
transection of the femoral nerve prior to RIPC delivered to the hind limb of a rabbit 
abolished the protection RIPC conferred against cardiac IR injury (28). Further to this, 
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administration of the nicotinic acetyl choline ganglion blocker hexamethonium to rats 
attenuated RIPC-mediated reduction in infarct size after cardiac IR injury (29). It has 
also been suggested that opioid receptors may be involved in RIPC related neural 
pathways, as demonstrated by attenuation of RIPC-mediated protection with the use of 
specific opioid receptor antagonists (30-32).  
 
1.2.2 Circulating mediators  
There is evidence that RIPC induces a protective circulating factor that travels to the 
target organ in the blood. Plasma from animals subjected to RIPC may be used to 
transfer cardioprotection to other animals and between species suggesting a protective 
factor in the blood (30,31,33-35). The circulating mediator(s) of RIPC appears to be 
hydrophobic, resistant to freezing and thawing with a molecular weight between 15 and 
30 kDa (30,36). A number of molecules have been implicated in RIPC-mediated 
cardioprotection. Most studies have used specific inhibitors to elucidate the pathways 
involved in RIPC. Most, if not all of these pathways relate to myocyte biology, but 
some relate to vascular tone. 
The human plasma proteomic profile is significantly altered by RIPC. One study found 
51 proteins found to be differentially expressed in response to RIPC, including 
upregulation of albumin, α1-antitrypsin, apolipoprotein A1, haptoglobin, lipoprotein 
B100 and transferrin (37). In the same study, antithrombin III complex, complement 
C1r and immunoglobulin M, amongst other proteins, were found to be down-regulated 
after RIPC. The changes in plasma proteins due to RIPC were apparent immediately 
and increased further up to 24 h after the treatment. Similarly, a study of RIPC in 
children undergoing cardiac surgery found that RIPC was associated with upregulation 
of 48 peptides corresponding to 6 proteins compared to control (38). In contrast to the 
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previously described study, the difference in the plasma proteome between the RIPC 
and control groups was most marked at 6 h after surgery and returned towards baseline 
at 24 h. There is animal data suggesting that metabolic disturbances such as diabetes 
mellitus can affect humoral signalling (39). 
The results of these proteomic studies demonstrate the wide spectrum of changes 
induced by RIPC and help explain the difficulty in identifying a single mediator. It is 
likely that multiple pathways are involved to provide protection to the heart and other 
organs against IR injury. Some of the more extensively studied candidate circulating 
mediators of RIPC are outlined in Table 1.1. 
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Table 1.1: Potential circulating mediators of remote ischaemic preconditioning  
Mediator Species Effect in RIPC References 
Adenosine Rabbits Adenosine in dialysate from rabbits 
treated with RIPC involved in 
protection of cardiomyocytes against 
simulated IR injury. Adenosine also 
reduced infarct size after cardiac IR 
injury. The adenosine A1 receptor 
appears to be involved in RIPC. 
(31,34) 
Aldehyde 
dehydrogenase-2 
Humans 
and   
rabbits 
RIPC associated attenuation of 
endothelial      dysfunction after IR 
injury to the forearm not seen with 
genetic polymorphism of ALDH-2 
gene or with Disulfiram (ALDH-2 
inhibitor). ALDH-2 inhibitor 
abolished RIPC induced 
cardioprotection against IR injury. 
(40) 
Apolipoprotein A1 Rats Upregulated by RIPC and 
administration mimicked RIPC 
cardioprotection. Human HDL 
administered to mice reduced 
myocardial infarction size. 
(41) 
Nitrite Mice Upregulated by RIPC and 
administration mimicked RIPC 
cardioprotection. Dependent on 
eNOS and myoglobin to reduce 
nitrite to NO.  
(42) 
Stromal cell 
derived factor-1α 
Rats RIPC increased levels in rat plasma 
with cardioprotection blocked by 
SDF-1α receptor antagonist and 
mimicked by SDF-1α administration. 
(43) 
    
Chapter 1 
 
8 
 
 
ALDH-2, Aldehyde dehydrogenase-2; eNOS, endothelial nitric oxide synthase; HSP-70, heat shock 
protein-70; IPC, ischaemic preconditioning; IR, ischaemia reperfusion; NO, nitric oxide; RIPC, remote 
ischaemic preconditioning; SDF-1α, Stromal cell derived factor-1α; 
 
RIPC appears to increase the levels of factors such as adenosine, apolipoprotein A1, 
bradykinin, nitrite and stromal cell derived factor-1α in both human and animal studies. 
Pretreatment of experimental animals with these factors mimicked RIPC induced 
cardioprotection against IR injury (34,41,43). Additionally, the enzyme aldehyde 
dehydrogenase-2 (ALDH-2) is involved in RIPC mediated cardiac protection in rabbits 
and in attenuation of endothelial dysfunction in human volunteers (40). This raises the 
potential issue of variable effect of RIPC in populations where ALDH-2 polymorphisms 
are relatively common (47). 
Exosomes Humans 
and rats 
Plasma exosomes (containing CD63, 
CD81 and HSP-70) increased by 
RIPC and confer protection against 
cardiac IR injury in recipient rats.  
(44) 
MicroRNA-144 Humans 
and mice 
RIPC increased plasma microRNA-
144. An antagomir of microRNA-
144 and administration of 
microRNA-144 abolished and 
mimicked RIPC induced 
cardioprotection respectively.  
(45) 
MicroRNA-24 in 
exosomes 
Rats Expression of microRNA-24 
associated with exosomes increased 
with RIPC, associated with reduced 
infarct size and reduced cellular 
oxidative stress. Effects abolished by 
microRNA-24 antagomirs or 
inhibitors. 
(46) 
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Exosomes are a subpopulation of cell-derived microparticles or extracellular vesicles 
which are 50-100 nm in size and have also been proposed to be mediators of RIPC (48). 
Plasma exosomes containing heat shock protein-70 (HSP-70) are increased by RIPC 
and can transfer RIPC-mediated cardioprotection from one animal to another (44). The 
addition of protective exosomes to cardiomyocytes in vitro leads to rapid activation of 
cellular kinases such as ERK 1/2 (extracellular signal regulated kinases) demonstrated 
by the attenuation of myocyte protection against IR injury by pharmacological 
inhibitors of ERK 1/2 (44). 
Micro ribonucleic acid (miRNA) are short (~22 nucleotides) evolutionary conserved 
segments of RNA, which regulate protein translation and that have important and 
emerging regulatory roles in cell biology and cardiovascular medicine (49). MicroRNA, 
and in particular miRNA-144 has been shown to be involved in RIPC probably through 
down regulation of mammalian target of rapamycin in the mouse heart, promoting 
improved cell survival (45). RIPC, local ischaemic preconditioning (IPC) and ischaemic 
postconditioning appear to have different effects on miRNA. While local ischaemic 
preconditioning is associated with a rise in myocardial miRNA-1 and miRNA-21 in the 
rat heart, RIPC and ischaemic postconditioning reduced miRNA-1 in the myocardium 
and had no effect on miRNA-21 (50). In patients undergoing CABG, miRNA-338-3p 
levels in right atrial tissue samples were found to be higher in patients who received 
RIPC compared to control (51).  
 
1.2.3 The role of platelets in remote ischaemic preconditioning 
Platelet-derived microparticles have been proposed to be potential mediators of RIPC. 
Platelet microparticles isolated from rats that had received RIPC reduced the extent of 
cerebral infarction when transfused into recipient rats (52). In a mouse model of hepatic 
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IR injury, the protective effect of RIPC was abolished when mouse platelets were 
depleted using anti-CD41 antibodies or when platelet activation was inhibited by a 
platelet activating factor inhibitor (53). The results of these studies suggest that platelets 
have a direct role in mediating the protective effects of RIPC.  
 
1.2.4 The effect of remote ischaemic preconditioning on platelets 
RIPC has been shown to attenuate platelet activation in both human and animal studies. 
In a rat model of femoral artery injury, RIPC was associated with a lower rate of 
thrombus formation and reduced distal embolisation (54). Additionally, in 19 patients 
undergoing ablation for atrial fibrillation, RIPC reduced CD41 expression, CD62P and 
monocyte-platelet aggregate formation in response to the platelet agonist adenosine 
diphosphate (ADP) and the ablation procedure (55). CD62P is a marker signifying 
platelet α granule release and CD41 is a component of the glycoprotein IIb-IIIa 
complex. In another study of patients with stable CAD, RIPC attenuated the rise in ADP 
induced platelet-monocyte aggregates and CD41 expression occurring after an exercise 
stress test (56). RIPC has also been demonstrated to attenuate platelet-monocyte 
aggregate formation and CD41 and CD62 expression which increased in response to 
cardiac catheterisation (57). In another study of healthy volunteers, upper limb 
ischaemia reperfusion injury caused an increase in platelet-monocyte aggregate 
formation which was attenuated by RIPC (18).  
A discussion regarding the importance of platelet inhibition in patients with CAD and 
the evidence to suggest that attenuation of platelet activation may be a contributor to 
RIPC mediated benefits can be found in chapter 4. 
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1.2.5 Cellular mechanisms 
The cellular mechanisms underpinning IPC have been extensively studied and efforts to 
define the mechanisms involved in RIPC have stemmed from what is known about IPC. 
It appears that the cellular signalling patterns, while demonstrating some similarities, 
differ between RIPC and IPC.  
HSP-70, which is markedly elevated in the myocardium after infarction, stimulates 
inflammatory cytokine release and the innate immune response. HSP-70 was 
downregulated by both RIPC and IPC in a rat model (50). Conversely, Bcl-2, a factor 
promoting cell survival, was not altered by RIPC in this study.  
Hypoxia inducible factor-1 (HIF-1) is a central molecule in mediating the response to 
IR injury. Under conditions of hypoxia, HIF-1 and its subunit HIF-1α regulate the 
transcription of genes leading to protective cellular responses. The delivery of RIPC 
prior to cardiopulmonary bypass was associated with higher levels of HIF-1α in right 
atrial tissue (58). RIPC was also associated with an increase in IL-1b, IL-8 and TNF-α 
levels in this study, suggesting that RIPC may modulate systemic inflammation. 
Supporting an effect of RIPC on inflammatory cytokines, a study of patients undergoing 
cardiac surgery found an association between conditioning and a rise in serum 
interleukin-1α (59).  
In a rat model of cardiac IR injury, IPC was more efficacious than RIPC in protecting 
against cardiac injury and they differed in their cellular effects (60). While IPC led to 
increased myocardial phosphorylation of protein kinase C (PKC) and other MAPK in 
animal models, RIPC did not (60,61). Contrary to these findings, in a rabbit model, 
RIPC was shown to increase phosphorylation of ERK 1/2 and activate PKC-ε within 
left ventricular tissues (30). PKC-ε has been suggested to be an integral component of 
the pathway underpinning both IPC and RIPC (62). 
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The reperfusion injury salvage kinase (RISK) and survival activating factor 
enhancement pathway (SAFE) are intracellular pro-survival pathways which have also 
been studied in the setting of RIPC. The SAFE pathway has been shown to be more 
important than the RISK pathway in cardioprotection conferred by RIPC (33). Signal 
transducer and activator of transcription 5 (STAT 5) phosphorylation, a component of 
the SAFE pathway, has been shown to be associated with RIPC-mediated reduction in 
myocardial injury in patients undergoing CABG (63). The STAT 5 pathway appears to 
be affected by the use of propofol, which may be important when RIPC is utilised in the 
setting of CABG (64).  
The upregulation of the vasoactive factors nitrite, the major metabolite of nitric oxide, 
and adenosine by RIPC (31,34,42) raises the possibility of vascular effects of RIPC. In a 
study involving healthy volunteers and patients with stable coronary artery disease, 
using flow mediated dilatation of the brachial artery as a measure of endothelial 
function, RIPC attenuated endothelial dysfunction caused by IR injury to the upper limb 
(24). This protection was abolished by administration of the glibenclamide, a non-
selective potassium-ATP channel inhibitor, suggesting that potassium-ATP channels 
were involved.  The contribution of  potassium-ATP channels to RIPC-mediated cardiac 
protection has also been suggested by animal data (65). These data are complementary 
to evidence of an important interaction between cGMP dependent pathways and 
mitochondrial BK potassium channels in cardiac protection induced by ischaemic 
preconditioning (66).  
 
1.2.6 The effect of remote ischaemic preconditioning on coronary physiology  
RIPC has been shown to augment coronary flow and endothelial function. The coronary 
endothelium is primarily responsible for regulating vascular tone and coronary flow and 
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endothelial dysfunction associated with coronary artery disease (67). RIPC increased 
peak diastolic coronary flow velocity in the LAD as assessed by echocardiography in 
patients attending cardiac rehabilitation (68). Similarly, in patients with heart failure and 
in healthy volunteers, there was an increase in coronary flow reserve (CFR) with RIPC 
as assessed by flow in the distal left anterior descending artery by echocardiography 
(69). Additionally, RIPC reduced coronary vasoconstriction in response to acetylcholine 
(70), a marker of endothelial dysfunction (71).  
The importance of the coronary microcirculation in patients with coronary artery 
disease including those undergoing PCI is discussed in chapter 3. 
 
1.3 Remote ischaemic preconditioning in percutaneous coronary intervention 
 
PCI can cause myocardial injury, measured as increased serum troponin after the 
procedure (7), and this predicts future cardiovascular events and the need for 
revascularization (9,10,72). RIPC prior to PCI has reduced post PCI troponin levels in 
most studies, and there was a suggestion of improved clinical outcomes in some studies. 
Randomised trials investigating the effect of RIPC and RIPerC on cardiac outcomes 
when delivered prior to PCI are included in Table 1.2. 
 
1.3.1 Remote ischaemic perconditioning during ST elevation myocardial infarction  
The results of the randomised controlled trials of RIPerC in the setting of STEMI 
suggest a cardioprotective role with a reduction in infarct size and increase in 
myocardial salvage (73) (Table 1.2). 
RIPerC increased myocardial salvage index, reduced infarct size, reduced cardiac 
biomarker levels and has been associated with more rapid resolution of ST elevation in 
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the setting of STEMI treated with primary PCI (32,74-77). RIPerC also reduced major 
adverse cardiac and cerebrovascular events (MACCE) and was associated with lowered 
all-cause mortality during long term follow up in one study (78). In the setting of 
thrombolysis, RIPerC has also been shown to be associated with reduced infarct-related 
biomarker levels in patients with STEMI (79). Intermittent limb ischaemia commenced 
at the time of primary PCI (remote postconditioning) has been associated with reduced 
levels of myocardial injury biomarkers and reduced myocardial oedema on cardiac MRI 
(80).  
Whether the effect of RIPerC on surrogate markers of myocardial protection will 
translate to clinical benefits may be answered by the ongoing CONDI-2 and ERIC-PPCI 
studies (81). These large, randomised multicentre studies will assess the effect of 
RIPerC on clinical outcomes after STEMI. 
 
1.3.2 Remote ischaemic preconditioning during elective percutaneous coronary 
intervention 
The results of RIPC in elective PCI have been predominantly favourable, with some 
exceptions (Table 1.2). RIPC has been associated with reduced post PCI troponin 
(14,17,21) and a reduction in MACCE, predominantly due to a reduction in acute 
coronary syndromes, during long term follow up (13). In those studies where there was 
no benefit of RIPC (16,25), PCI was performed immediately after RIPC, suggesting that 
there is an optimal interval (1-2 h) between the end of RIPC and PCI. An optimal 
window of benefit was also suggested by the CRISP study (13).  
One of the studies demonstrating no benefit of RIPC was a study of 95 patients 
undergoing elective PCI (25). Methodological differences compared to studies 
demonstrating a benefit of RIPC, such as sphygmomanometer inflation for only 3 min 
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intervals instead of 5 min and delivery of treatment immediately prior to PCI instead of 
1-2 h before, are noteworthy. Other studies have demonstrated a dose-response 
relationship is evident with RIPC (24) and 3 min of limb ischaemia may be insufficient 
for cardiac preconditioning. Contrary to this, a separate study found benefit with only 
one cycle of arm ischaemia delivered immediately prior to elective PCI (82). In this 
study, a single 5 min inflation of a sphygmomanometer on the upper limb, with 1 min of 
reperfusion before commencement of PCI was associated with a significantly lower post 
PCI troponin level than control. This study is differs from other studies which suggest a 
dose effect and an optimal delivery time between RIPC and PCI of 1-2 h. 
Systematic reviews and meta-analyses support the findings of a reduction in post PCI 
myocardial infarction with RIPC (83,84). However, there is difficulty in synthesising 
the data due to the heterogeneous nature of the individual studies and patient subgroups. 
Whether specific subgroups, such as patients with diabetes need separate consideration 
is unclear. In a study of diabetic patients, there was no benefit of RIPC demonstrated 
despite a seemingly adequate ‘dose’ and interval between RIPC and PCI, raising the 
possibility of reduced effectiveness in diabetic patients (85). 
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Table 1.2: Randomised studies involving remote ischaemic preconditioning in 
primary percutaneous coronary intervention and elective percutaneous coronary 
intervention 
Study Design Primary 
outcome 
Results 
Studies in primary PCI 
Eitel 2015 
(75) 
n=696, STEMI; 
RIPerC
a
 + IPostC vs  
IPostC alone vs 
control, on admission 
to hospital. 
Myocardial 
salvage index 
(CMRI). 
Higher myocardial salvage 
index with RIPerC + 
IPostC. No effect of IPostC 
alone. 
Botker 
2010(74) 
Sloth 2014 
(78)  
n=333, STEMI; 
RIPerC
b
 vs control, 
during transport to 
hospital. 
Myocardial 
salvage index 
(SPECT). 
Higher myocardial salvage 
index, reduced MACCE at 
3.8 yr.  
    
Munk 2010 
(86) 
n=242, STEMI; 
RIPerC
b
 vs control, 
during transport to 
hospital. 
LVEF and infarct 
size (SPECT). 
Increased LVEF, smaller 
infarct size for anterior 
infarcts. 
White 2015 
(76) 
n=197, STEMI; 
RIPerC
b
 vs control, 
on admission to 
hospital. 
Infarct size 
(CMRI). 
Smaller infarct size and 
lower troponin.  
Prunier 2014 
(77) 
n=151, STEMI; 
RIPerC
 a
 vs RIPerC + 
IPostC vs control, on 
arrival to 
catheterisation 
laboratory. 
CK-MB level. Lower CK-MB in both 
treatment groups.  
Rentoukas 
2010 (32) 
n=96, STEMI; 
RIPerC (3 x 4 min 
ST segment 
resolution, 
More frequent ST segment 
resolution lower troponin 
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cycles, 20 mmHg 
above systolic 
pressure to arm), vs 
RIPerC + morphine 
infusion vs control, 
10 min before 
coronary balloon 
inflation. 
troponin level. in both treatment groups. 
Positive studies in elective PCI 
Miyoshi 
2017 (87), 
Ejiri 2018 
(88) 
n=391; RIPC
 a
 vs 
intravenous 
nicorandil vs control, 
at least 1 h before 
PCI. 
Periprocedural 
myocardial 
infarction. 
Periprocedural myocardial 
infarction lower with RIPC 
but did not reach 
significance. Significantly 
lower in subgroup with 
complex PCI. 
    
    
Hoole 2009 
(14), Davies 
2013 (13) 
n=242; RIPC
 a
 vs 
control, 
1h before PCI. 
Troponin 24 h. Lower post PCI troponin 
and less chest pain and ST 
segment change during 
balloon inflation. Reduced 
MACCE at 6 months and 6 
yr. 
Luo 2013 
(17) 
n=205; RIPC
 a
 vs 
control, 
<2 h before PCI. 
Troponin 16 h 
and type 4a MI at 
16 h. 
Reduced troponin and type 
4a MI.    
Liu 2014 
(89) 
n=200; RIPC
 a
 vs 
control,  
18-24 h before PCI. 
Not specified.  Lower troponin and 
creatine kinase, less chest 
pain and ST segment 
change during PCI. Lower 
MACCE at 6 months. 
Zhou 2017 
(90) 
n=184; RIPC
b
 vs 
control, 1 h before 
Not specified. Lower troponin and 
creatine kinase 1 day after 
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PCI. PCI in RIPC group. 
Ahmad 2013 
(21) 
n=149; RIPC
 a
 vs 
control, immediately 
before PCI. 
Troponin level at 
16 h. 
Lower post PCI troponin. 
Zografos 
2014 (82) 
n=96; RIPC (1 x 5 
min cycle, 200 
mmHg to arm) vs 
control, immediately 
prior to PCI. 
Change from pre 
PCI troponin at 
24 h. 
Lower post PCI troponin.  
Ghaemian 
2012 (91) 
n=80; RIPC (2 x 5 
min cycles, above 
systolic blood 
pressure to thigh) vs 
control, 1 h prior to 
PCI. 
Troponin at 12 
and 24 h. 
Smaller increase in 
troponin with PCI.  
 
 
Negative studies in elective PCI 
Xu 2014 
(85) 
n=200 diabetic 
patients; RIPC
 a
 vs 
control, <2 h prior to 
PCI. 
Not specified.  No effect on 16 h troponin. 
Prasad 2013 
(25) 
n=95; RIPC (3 x 3 
min cycles, 200 
mmHg to arm) vs 
sham (10 mmHg), 
immediately prior to 
PCI. 
Post PCI 
troponin.  
No effect on troponin 
levels. 
Iliodromitis 
2006 (16) 
n=41; RIPC
 a
 (both 
arms) vs control, 
immediately prior to 
PCI. 
Not specified.  Increased troponin and 
creatinine kinase-MB with 
RIPC.  
 
 
Chapter 1 
 
19 
 
All treatment effects refer to effect of RIPerC or RIPC unless otherwise stated. 
a
 3 x 5 min cycles, 200 mmHg to arm.  
b
 4 x 5 min cycles, 200 mmHg to arm. 
AUC, area under the curve; CK-MB, creatine kinase MB fraction; IPostC, ischaemic postconditioning; 
LVEF, left ventricular ejection fraction; MACCE, major adverse cardiovascular and cerebrovascular 
events; MI, myocardial infarction; CMRI, cardiac magnetic resonance imaging; PCI, percutaneous 
coronary intervention; RIPC, remote ischaemic preconditioning; RIPerC, remote ischaemic 
perconditioning; SPECT, single photon emission computed tomography, STEMI- ST elevation 
myocardial infarction.  
 
1.4 Remote ischaemic preconditioning in coronary artery bypass grafting surgery  
 
Despite improvements in surgical and anaesthetic techniques, IR injury is still a 
significant concern in patients undergoing CABG. Myocardial injury is reflected by an 
increase in serum troponin levels postoperatively, which is very commonly observed 
after CABG (8). Elevated postoperative troponin is associated with a worse prognosis 
(11,92). Randomized controlled trials of at least 100 patients (50 patients in RIPC and 
control arms) investigating RIPC prior to on-pump CABG are included in Table 1.3.  
As is demonstrated in Table 1.3, the results of early studies suggested that RIPC 
reduced myocardial injury and MACCE when delivered prior to CABG and this was 
supported by early meta-analyses (84,93). There also appeared to be secondary 
beneficial effects of RIPC in the perioperative setting such as a reduction in 
postoperative atrial fibrillation, acute kidney injury and reduction in length of intensive 
care stay (94). However several larger studies, including the two most recent multi-
centre studies (ERICCA and RIPHeart) have failed to show clinical benefit or any 
definite reduction in postoperative cardiac biomarker levels as a result of RIPC 
(22,23,95). It is however important to note that in the ERICCA (23) and RIPHeart (22) 
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studies a significant proportion of patients underwent concomitant valve surgery which 
is associated with myocardial injury unrelated to IR.  
Table 1.3 details the anaesthetic agents used in the clinical studies. Propofol is known to 
be a scavenger of free radicals (96), and has been proposed to interfere with the 
protective effects of RIPC (97).  However, any interaction between propofol and RIPC 
is inconsistent, with some studies demonstrating a benefit of RIPC in patients 
undergoing CABG under propofol anaesthesia. Conversely, it has also been proposed 
that volatile anaesthetic agents, which are known preconditioning agents, may mask or 
attenuate the effect of RIPC (84,93,98).  
Whether the duration of RIPC or anaesthetic agents used are relevant to the 
discrepancies in clinical outcomes after CABG is unclear. At this time, RIPC cannot be 
advocated for use in on pump CABG surgery. In the absence of studies in patients 
receiving off pump surgery no specific recommendation can be made for these patients.  
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Table 1.3: Randomised studies involving remote ischaemic preconditioning in 
coronary artery bypass grafting surgery 
Study Design Anaesthetic 
regimen 
Primary 
outcome 
Results 
Positive studies 
Thielmann 
2013 (19) 
n=329, on-pump 
CABG; RIPC
a
  vs 
control.  
Not 
standardize
d, propofol 
in 79 
patients. 
Postoperative 
troponin (AUC 
in first 72 h). 
Reduced troponin, 
all-cause mortality 
and MAACE (4 
yr). No effect in 
sub-group 
receiving propofol. 
 
Candilio 
2015 (94) 
n=180, on-pump 
CABG ± valve 
surgery; RIPC (2 x 
5 min cycles, 200 
mmHg to arm and 
leg) vs control, after 
induction of 
anaesthesia and 
prior to surgical 
incision. 
All patients 
received 
propofol. 
Postoperative 
troponin (AUC 
in first 72 h). 
Reduced troponin. 
 
Ali 2010 
(99) 
n=100, on-pump 
CABG; RIPC
a
 vs 
control.  
Not 
standardize
d. 
Postoperative 
CK-MB.   
Reduced CK-MB.  
Negative studies 
Hausenloy 
2015 (23) 
n=1612, on-pump 
CABG ± valve 
surgery; RIPC
b
 vs 
sham.  
90% 
received 
propofol. 
Cardiovascular 
death, MI, 
coronary 
revascularisati
on and stroke 
at 12 months. 
No difference in 
combined primary 
or individual 
clinical endpoints. 
Lower 
postoperative 
troponin in patients 
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with complete 
data. 
Meybohm 
2015 (22), 
Meybohm 
2018 (100) 
n=1403, on-pump 
CABG ±/or valve 
surgery; RIPC
b
 vs 
RIPC to dummy 
arm.  
All received 
propofol. 
Death, MI, 
stroke or acute 
renal failure up 
to 14 days 
postoperatively
. 
No difference in 
combined primary 
or individual 
clinical endpoints. 
No difference at 1 
yr follow up. 
Hong 2013 
(95) 
n=1280, on-pump 
(62.7%) and off-
pump (37.3%) 
CABG ±/or valve 
surgery; RIPC
b
 + 
remote ischaemic 
postconditioning vs 
control.  
All received 
propofol. 
Major clinical 
adverse events. 
No difference. 
 
Rahman 
2010 (98) 
n=162, on-pump 
CABG; RIPC
a
 vs 
RIPC to dummy 
arm. 
Most 
patients 
received 
enflurane 
and 
sevoflurane.  
Postoperative 
troponin (AUC 
in first 48 h). 
No difference.  
 
All treatment effects refer to effect of RIPC unless otherwise stated. 
a
 3 x 5 min cycles, 200 mmHg to arm, delivered after induction of anaesthesia and prior to surgical 
incision. 
b
 4 x 5 min cycles, 200 mmHg to arm, delivered after induction of anaesthesia and prior to surgical 
incision. 
AF, atrial fibrillation; AUC, area under the curve; CABG, coronary artery bypass grafting surgery; CK-
MB, creatine kinase MB isoenzyme; GI, gastrointestinal; ICU, intensive care unit; MACCE, major 
adverse cardiovascular and cerebrovascular events; RIPC, remote ischaemic preconditioning;  
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1.5 Summary 
 
RIPC remains a potential treatment modality for the reduction of myocardial injury in 
defined settings. It is supported by extensive mechanistic data in animals and variable 
data in humans. Mechanistic studies indicate that there are differences between RIPC, 
local ischaemic preconditioning, and postconditioning which should be considered in 
the design of future clinical studies. Differences in the delivery of RIPC such as the 
interval between the end of RIPC and the onset of myocardial IR injury may relate to 
the release of soluble mediators and their downstream effects on target tissues and 
should also be considered in future study design. While there appears an effect of the 
number of cycles of RIPC and the interval between delivery and PCI on the 
cardioprotection conferred, the optimal treatment protocol has yet to be determined.  
Given the results of recent high quality randomised trials, RIPC cannot be advocated for 
use in the setting of on-pump CABG. The results of RIPC during the setting of PCI are 
promising, both elective and primary, but require further investigation before 
incorporation into routine clinical practice, which is also suggested in the 2014 
ESC/EACTS guidelines on myocardial revascularization (5). Clarification of the 
benefits of RIPC prior to PCI delivered to specific patient groups, particularly in 
patients with diabetes, and in those receiving optimal medical therapy including dual 
antiplatelet therapy and statins in larger multicentre studies are clearly needed.   
There are multiple clinical trials ongoing or recently completed, assessing the utility of 
RIPC in the management of not only coronary artery disease, but also other disease 
processes such as vascular disease, stroke, contrast induced nephropathy and non-
cardiac surgery. The results of these studies may further clarify which patient 
populations may benefit from this simple, low-cost, non-invasive intervention. 
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Given the benefits of RIPC in the setting of coronary artery stenting, the focus of the 
studies presented in this thesis is the investigation of the effects of RIPC on factors that 
contribute significantly to patient prognosis during PCI. The coronary microcirculation 
predicts the prognosis of patients undergoing both elective and primary PCI. Chapter 3 
describes the effects of RIPC on invasively measured markers of microcirculatory 
function. Chapters 4 and 5 describe the effect of RIPC on platelet activation. Although 
previously performed studies have described an attenuation of platelet activation in 
response to platelet agonists, the studies presented in this thesis investigated the effect 
of RIPC on expression of a larger range of markers of platelet activation in response to 
a range of platelet agonists. Additionally, given the importance of dual antiplatelet 
therapy (DAPT) at the time of PCI, the interaction between antiplatelet medications and 
the platelet effects of RIPC were also explored. Finally, chapter 6 describes the effect of 
RIPC on plasma miRNA profile. As miRNA have been shown to contribute to RIPC-
mediated cardiac protection, the effect of RIPC on plasma miRNA in patients with 
suspected CAD was explored. Given the modulation of protein transcription, miRNAs 
could potentially play a part in the long standing effects of RIPC seen in some studies. 
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Chapter 2: Methods 
 
2.1 Remote ischaemic preconditioning 
 
RIPC or sham treatment was delivered to patients in order to investigate for 
mechanisms by which conditioning may provide benefit to patients undergoing PCI. 
RIPC was delivered by inflation of a sphygmomanometer (Welch Allyn, Skaneateles 
Falls, New York, USA) on the left upper limb to 200 mmHg or 50 mmHg greater than 
systolic blood pressure (whichever was greater) for 5 min, followed by deflation for 5 
min. This cycle was performed a total of 3 times as previously published with the total 
protocol lasting 30 min (14,17,89). Patients allocated to sham treatment had the 
sphygmomanometer inflated to 10 mmHg but otherwise the protocol was identical to 
the RIPC protocol. To ensure that the sphygmomanometer pressure was adequate to 
occlude the brachial artery, the radial pulse was examined in each patient ensuring that 
it was impalpable during RIPC and unaffected during sham treatment. Effective 
ischaemia was established in a pilot study (section 2.1.2) before commencing the 
randomised study. 
 
2.1.1 Patient population 
Patients who were referred for invasive coronary angiography at Concord Repatriation 
General Hospital, Sydney, Australia, were invited to participate in the study. All 
patients were suspected of having CAD based on symptoms or the results of non-
invasive investigations. Exclusion criteria included the need for emergent coronary 
angiography, contra-indication to inflation of a sphygmomanometer on the left arm (e.g. 
arterio-venous fistula for haemodialysis, peripheral vascular disease involving the upper 
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limbs) and existing neuropathy or myopathy which may predispose to nerve or muscle 
injury from upper limb ischaemia.  
All patients received an information sheet detailing the background, requirements and 
potential risks involved with participation in the study. Informed consent was obtained 
from each patient prior to commencement of the study protocol. Patients were recruited 
for inclusion into one of two study cohorts. The cardiac catheterisation group received 
RIPC or sham treatment during their cardiac catheterisation procedure, while on the 
catheterisation laboratory table. The non-invasive group received RIPC or sham 
treatment prior to their cardiac catheterisation procedure.  
Unless otherwise stated, patients were randomised in a 1:1 fashion to RIPC or sham 
through a closed envelope system. Patients were blinded to treatment allocation. The 
operator performing the cardiac catheterisation and coronary physiology measurements 
in the cardiac catheterisation group and the investigators processing the blood samples 
in the non-invasive group were also blinded to patient treatment allocation.  
Ethics approval was granted by the Sydney Local Health District Human Research 
Ethics Committee, Sydney, Australia (CH62/6/2014-016). This study was registered 
with the Australia and New Zealand Clinical Trials Registry 
(ACTRN12616000486426). 
 
2.1.2 Blood lactate with remote ischaemic preconditioning 
To ensure that the RIPC protocol was effectively inducing ischaemia to the treated 
upper limb a pilot study was performed. Consecutive patients underwent RIPC or sham 
treatment and had venous blood collected immediately before and after their treatment 
from the ipsilateral cubital fossa, into tubes containing lithium heparin (77 IU) (BD, 
Franklin Lakes, New Jersey, USA). Whole blood lactate was measured in these samples 
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were within 20 min of collection(RapidLab 1260 blood gas analyser, Siemens, Munich, 
Germany). 
In 10 patients who received RIPC, there was a significant increase in blood lactate (1.4 
± 0.6 mmol/L before RIPC vs 1.7 ± 0.6 mmol/L after RIPC, P=0.004) while there was 
no effect on blood lactate in 6 patients who received sham treatment (1.4 (1.1-1.6) 
mmol/L before sham vs 1.5 (1.2-1.7) mmol/L after sham, P=0.50) (Figure 2.1) 
confirming effective ischaemia after the RIPC protocol. 
 
  
Figure 2.1 Blood lactate concentration pre and post remote ischaemic 
preconditioning or sham treatment 
Blood lactate concentration was significantly higher post RIPC than pre RIPC. There was no effect of 
sham treatment on blood lactate. RIPC, n=10; sham, n=6. P values compare measurements from patients 
pre and post RIPC/sham treatment using the paired t test for parametrically distributed data or the 
Wilcoxon signed rank test for non-parametrically distributed data. 
RIPC, remote ischaemic preconditioning; 
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2.2 Coronary physiology measurements 
 
Coronary physiology studies were performed in patients from the cardiac catheterisation 
cohort during their procedure. Established techniques were used to calculate the 
fractional flow reserve (FFR), CFR and index of microcirculatory resistance (IMR) 
(101-106). The FFR is a measurement used to help determine the haemodynamic 
significance of an epicardial coronary lesion and to help guide revascularisation 
(107,108). The IMR assesses the resistance of the microcirculation and has been shown 
to correlate well with true microcirculatory resistance, and to be minimally affected by 
haemodynamic changes in the patient (105,109). While the FFR assesses the epicardial 
coronary artery and the IMR assesses the coronary microcirculation, the CFR is a ratio 
of maximal hyperaemic flow to resting flow and thus assesses flow across both the 
epicardial coronary artery and the microcirculation. The CFR therefore is unable to 
discriminate between pathology in the epicardial coronary artery or the microcirculation 
(110). 
 
2.2.1 Measurement of the fractional flow reserve 
To perform cardiac catheterisation, a 6F radial or femoral arterial sheath was inserted 
and coronary angiography was performed by standard techniques. Unfractionated 
heparin was administered at a dose of 70 U/kg. Patients were included in the cardiac 
catheterisation cohort if after coronary angiography the decision was made to 
interrogate a lesion in a major epicardial coronary artery with measurement of the FFR.  
A 4F femoral venous sheath was inserted for administration of intravenous (IV) 
adenosine. In order to perform the coronary physiology study, a 6F guiding catheter 
without side holes was used to engage either the left main coronary artery or the right 
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coronary artery. A pressure-temperature sensor guidewire (Certus; St Jude Medical, St 
Paul, Minnesota, USA) was used in conjunction with the associated analysis console 
(RadiAnalyzer Xpress; St Jude Medical, St Paul, Minnesota, USA). The wire was 
advanced to the tip of the guiding catheter for pressure equalisation before being 
advanced to the distal segment of the target artery ensuring that the sensor position was 
at least 30 mm distal to the lesion in question. Intracoronary glyceryl trinitrate was 
administered (100 μg). The mean proximal/aortic pressure and mean distal pressure 
were recorded at rest. 
Hyperaemia was induced with an IV infusion of adenosine (140 μg/kg/min) via the 
femoral venous sheath. The mean aortic and distal pressures during hyperaemia were 
also recorded and as previously described, the fractional flow reserve was calculated 
during hyperaemia by (101,102):  
 
FFR = Pd/Pa  
Where Pd is mean distal coronary pressure and Pa is mean aortic pressure, both measured during 
hyperaemia. 
 
2.2.2 Thermodilution to calculate the coronary flow reserve 
In addition to recording the pressure measurements to calculate FFR, the pressure-
temperature sensor wire was also used to measure the transit time (Tmn) which is 
inversely proportional to flow. With the pressure-temperature sensor wire in the same 
position, the Tmn was measured by producing thermodilution curves in triplicate by 
brisk injection of 3 mL of room temperature saline down the coronary artery as 
previously described (103,104). An average of the three measurements was recorded as 
the resting transit time (TmnR). This procedure was repeated during IV adenosine 
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infusion to record the hyperaemic transit time (TmnH). The coronary flow reserve was 
calculated by (103,104): 
 
CFR = TmnR / TmnH 
Where TmnR is the transit time during rest and TmnH is the transit time during hyperaemia. 
 
2.2.3 Calculation of the index of microcirculatory resistance 
True microcirculatory resistance (TMR) can be calculated with a pressure-temperature 
sensor wire with the formula below: 
 
TMR = Pa x TmnH x [(Pd – Pw)/(Pa – Pw)] 
Where Pa is the mean aortic pressure during hyperaemia, TmnH is the transit time during hyperaemia, Pd is 
the mean distal coronary pressure during hyperaemia and Pw is the mean distal coronary pressure during 
proximal occlusive balloon inflation. 
 
TMR is independent of disease in the epicardial coronary artery as the wedge pressure 
(Pw) accounts for flow in collateral arteries (111). The wedge pressure requires coronary 
balloon inflation, which is not convenient to measure if it is uncertain whether the 
patient is undergoing PCI. Additionally, balloon inflation may cause local ischaemic 
preconditioning confounding studies of RIPC. 
The IMR correlates well with true microcirculatory resistance but overestimates the 
degree of resistance in the microcirculation when there is haemodynamically significant 
disease in the epicardial coronary artery due to increasing collateral flow (105,111). The 
IMR was calculated by two methods. In patients where there was no haemodynamically 
significant epicardial coronary artery disease (FFR >0.80), the apparent IMR (IMRapp) 
was calculated by (105): 
Chapter 2 
 
31 
 
IMRapp = Pd x TmnH 
Where Pd is the mean distal coronary pressure during hyperaemia and TmnH is the transit time during 
hyperaemia. 
 
In all patients, regardless of the FFR, the calculated IMR (IMRcalc) was calculated by 
the formula derived by Yong et al. (106) negating the need to measure Pw: 
 
IMRcalc = Pa x TmnH x ((1.34 x Pd/Pa) – 0.32) 
Where Pa is the mean aortic pressure during hyperaemia, TmnH is the transit time during hyperaemia and 
Pd is the mean distal coronary pressure during hyperaemia. 
 
The TMR was not calculated during this study as not all patients underwent coronary 
balloon inflation for PCI. Coronary balloon inflation solely to measure Pw could not be 
justified due to the associated coronary endothelial injury, increasing the risk procedure 
related complications.  
 
2.3 Quantitative coronary angiography  
 
Coronary angiography was performed on each epicardial coronary artery in at least two 
orthogonal views at a frame rate of 15/s (Artis, Siemens, Munich, Germany). Two 
dimensional quantitative coronary angiography (QCA) was performed after the 
procedure with commercially available software (Artis, Siemens) to determine the 
diameter stenosis, lesion length and reference vessel diameter, as previously described 
(112). Pixel size calibration was performed using the contrast filled, non-tapered part of 
the guiding catheter. Measurements were performed during end diastole based on the 
electrocardiogram (ECG) in views which demonstrated the lesion well with the least 
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amount of foreshortening. The automatically detected lumen edge was adjusted if 
necessary. Patients with a diameter stenosis >50% in at least one epicardial coronary 
artery were deemed to have significant CAD. Additionally, patients with prior PCI or 
CABG were also deemed to have significant CAD. 
 
2.3.1 Three dimensional quantitative coronary angiography 
Three dimensional QCA was performed post-procedure with 3D reconstruction 
software on a Leonardo workstation (IC3D, Siemens) as previously described (112). 
Pixel size calibration was performed using the contrast filled, non-tapered part of the 
guiding catheter. Two orthogonal angiographic views of the coronary artery were used 
for three dimensional QCA reconstructions in both the end diastolic and end systolic 
frames based on the ECG. The lesion, proximal arterial segment and distal arterial 
segment were manually identified in each angiographic projection and a three 
dimensional reconstruction of the arterial segment of interest was produced by the 
software. The minimum luminal area and diameter were recorded based on the three 
dimensional reconstruction allowing compliance and distensibility to be calculated at 
the site of the lesion as follows (113-115): 
 
Compliance = (AS – AD)/AD 
Distensibility = 1000 x [(AS – AD)/AD]/ΔP  
Where AS is the minimum lumen area at end-systole, AD is the minimum lumen area at end-diastole and 
ΔP is the difference between systolic and diastolic intracoronary pressure. 
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2.4 Blood sampling 
 
Blood was collected from study participants via a 20G cannula inserted into a right 
cubital fossa vein (contralateral to arm subjected to RIPC or sham treatment) as 
previously described (116). The first 3 mL of blood was discarded to avoid collection of 
activated platelets. Blood was drawn slowly through the cannula, without a tourniquet 
or haemostatic valve, at a rate of 0.5 mL/s into a syringe and gently transferred into 
tubes containing 3.2% (v/v) buffered sodium citrate (BD, Franklin Lakes, New Jersey, 
USA), 15 μg/mL hirudin (Roche, Basel, Switzerland) and K2EDTA (BD, Franklin 
Lakes, New Jersey, USA). Blood collection was performed before and after RIPC or 
sham treatment and transported carefully at room temperature for processing within 20 
min of collection. 
 
2.5 Storage of patient plasma  
 
Patient blood collected before and after RIPC/sham into tubes containing sodium citrate 
and K2EDTA were centrifuged for plasma storage. Blood was centrifuged at 2500 g for 
15 min at room temperature with the resultant plasma from the K2EDTA containing 
blood tubes aliquoted for storage. The plasma from the sodium citrate containing tubes 
was centrifuged again at 2500 g for 15 min at room temperature and aliquoted for 
storage. Plasma was stored at -80 °C for later analysis. Unless otherwise specified, 
analysis of stored plasma was performed on plasma aliquots which had not previously 
been thawed. 
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2.6 Platelet activation 
 
Platelet activation plays an important role in the pathophysiology of complications of 
CAD. This importance is reflected by the emphasis placed on antiplatelet therapy in 
CAD clinical management guidelines (3,4). Platelets contain intracellular granules, the 
contents of which are released by fusion with the surface membrane upon activation, 
exposing antigens on the platelet surface which can be detected by flow cytometry 
(117,118). Glycoprotein IIb-IIIa (GPIIb-IIIa) is a platelet surface receptor which upon 
activation, changes conformation exposing a fibrinogen binding site, allowing cross-
linking between platelets and aggregation to occur (118). Conformationally activate 
GPIIb-IIIa was detected on the platelet surface with the monoclonal antibody PAC-1 
utilising flow cytometry techniques (117,119).  
Upon activation, a subpopulation known as procoagulant platelets develops, which have 
an emerging role in cardiovascular disease and pathological thrombosis (120-122). 
Platelet uptake of a trivalent arsenical 4-[N-(S-
glutathionylacetyl)amino]phenylarsonous acid (GSAO), cell death marker, can allow 
identification of these platelets. Platelets which take up GSAO and express P-selectin  
(GSAO
+
/CD62P
+
) were defined as procoagulant platelets by flow cytometry (120) and 
have been shown to be increased in patients with CAD (123). Platelets may also form 
aggregates with leukocytes upon activation and these aggregates may also have 
important roles in thrombosis (124). 
 
2.6.1 Surface markers of platelet activation 
Platelet CD62P expression (signifying α-granule release), CD63 expression (signifying 
dense granule and lysosome release) and PAC-1 binding (signifying GPIIb-IIIa active 
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conformational change) were quantified as markers of platelet activation (119,125). 
Quantification of these markers was performed using whole blood by flow cytometry as 
previously described (116,126). 
Citrated blood was added to reaction mixes of Dulbecco’s modified phosphate buffered 
saline (DPBS, Invitrogen, Carlsbad, California, USA) with and without agonists ADP (5 
μM, final concentration) (Helena Laboratories, Mt Waverley, Victoria, Australia), 
protease-activated receptor-1 (PAR-1) agonist (SFLLRN, 20 μM) (AUSPEP, 
Tullamarine, Victoria, Australia), thrombin (2 U/mL) (Sigma-Aldrich, St Louis, 
Missouri, USA) ± collagen (10 μg/mL) (Takeda, Osaka, Osaka Prefecture, Japan). H-
Gly-Pro-Arg-Pro-OH (173 μg/mL) (Calbiochem, Merck Group, Frankfurter, Darmstadt, 
Germany) was added to thrombin containing reaction mixes to prevent platelet 
aggregation. Reaction mixes (50 μL) were added to fluorescence-activated cell sorting 
(FACS) tubes (Falcon, Tewksbury, Massachusetts, USA) containing isotype control 
IgG (MOPC-21) or IgM (G155-228) and antibodies to CD61 (VI-PL2), CD62P (AK-4), 
CD63 (H5C6) or conformationally active GPIIb-IIIa (PAC-1). These were incubated at 
room temperature for 20 min then fixed with 1 mL of 0.16% (v/v) paraformaldehyde 
(ProSciTech, Kirwan, Queensland, Australia) saline solution before immediate analysis 
by flow cytometry. All antibodies were sourced from BD Bioscience (Franklin Lakes, 
New Jersey, USA). 
Flow cytometry was performed on a FACSCalibur (BD, Franklin Lakes, New Jersey, 
USA) with 10,000 platelet-gated events acquired for each analysis. Platelet events were 
selected based on forward and side scatter. The isotype control was used to determine 
positive events on the basis of a 0.5% background expression (Figure 2.2). Levels of 
CD62P and CD63 expression and PAC-1 binding were then quantified in a similar 
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manner as previously published with results expressed as a percentage of total platelets 
(116,126). Data were analysed with FlowJo (FlowJo, LLC, Ashland, Oregon, USA). 
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a) 
 
b) 
 
c) 
 
d) 
 
Figure 2.2 Selection of platelets and determination of positive events by flow 
cytometry 
Representative example of analysis of flow cytometry data with FlowJo software. Platelets were selected 
by their light scatter characteristics (forward and side scatter) (a). The platelet population was confirmed 
to be CD61 positive (b). PAC-1 positive events were determined based on 0.5% background expression 
using the isotype control (c). The PAC-1 positive events were calculated as a proportion of the total 
platelet events (d). 
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2.6.2 The stability of platelet activation markers over time 
Platelet activation experiments as described in 2.6.1 were performed on pre and post 
RIPC/sham blood samples approximately 60 min apart. After delivery of the pre 
RIPC/sham samples, approximately 60 min was required to walk back to the patient, 
deliver RIPC/sham and transport post samples from the cardiac catheterisation 
laboratory to the platelet laboratory.  
To determine the effect of delay in analysing fixed platelet reaction mixtures by flow 
cytometry, venous blood was collected from the cubital fossa of healthy volunteers into 
citrate tubes, without a tourniquet. Platelet activation experiments were performed as 
described in 2.6.1 with some alterations. Blood from citrate tubes was added to reaction 
mixes of DPBS with and without agonists ADP (2.5 μM and 5 μM) or collagen (5 
μg/mL). Reaction mixes (50 μL) were added to FACS tubes containing isotype control 
IgG or IgM, or antibodies to CD61, CD62P, CD63 or PAC-1. These were incubated at 
room temperature for 20 min then fixed with 1 mL of 0.16% paraformaldehyde saline 
solution. The samples were analysed by flow cytometry with a FACSCalibur, as 
described in section 2.6.1, immediately after fixation and then at 30 min, 60 min, 90 
min and 120 min after fixation. The samples were stored at room temperature, in the 
dark, between flow cytometry analyses.  
Variations in the measurements of platelet activation caused by delay in analysis after 
addition of the platelet fixative was observed (Figure 2.3). Therefore platelet samples 
were analysed immediately after fixation during the randomised study. 
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a)
 
 
 
 
 
b)
 
 
 
 
 
c) 
 
 
 
 
 
d)
 
 
 
 
 
Figure 2.3 Stability of platelet activation markers on flow cytometry analysis with 
delay after fixation 
Healthy volunteer platelet CD62P expression, CD63 expression and PAC-1 binding under basal/ 
unstimulated conditions (a), 2.5 μM ADP (b), 5 μM ADP (c) and 5 μg/mL collagen (d). Time intervals on 
x-axis denote time after platelet reaction mixture fixation with 0.16% paraformaldehyde saline solution. 
CD62P and PAC-1, n=2; CD63, n=1. Symbols and bars represent mean ± SD.  
ADP, adenosine diphosphate; 
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2.6.3 The effect of fixative concentration on platelet activation marker measurement 
Given the apparent lack of efficacy of 0.16% paraformaldehyde saline solution in 
stabilising platelet activation marker expression as demonstrated by Figure 2.3, a 
comparison with a 1% (v/v) paraformaldehyde saline was performed. Venous blood was 
collected from the cubital fossa of heathy volunteers into citrate tubes, without a 
tourniquet. Whole blood was added to reaction mixes of DPBS with and without 
agonists ADP (0.1 μM and 5 μM). Reaction mixes (50 μL) were added to FACS tubes 
containing isotype control IgG or IgM, or antibodies to CD61, CD62P, CD63 or PAC-1 
in duplicate. These were incubated at room temperature for 20 min then fixed with 
either 1 mL of 0.16% paraformaldehyde saline solution or 1 mL of 1% 
paraformaldehyde saline solution. The samples were analysed by flow cytometry with a 
FACSCalibur, as described in section 2.6.1, immediately after fixation, 30 min, 60 min, 
90 min and 120 min after fixation. The samples were stored at room temperature, in the 
dark, between flow cytometry analyses.  
The effect of time delay from fixation to analysis by flow cytometry was not corrected 
by the higher concentration of paraformaldehyde saline and thus 0.16% 
paraformaldehyde saline was used to fix the platelet samples (Figure 2.4). The platelets 
were analysed by flow cytometry immediately after fixation as described in 2.6.1, and 
always within 30 minutes of activation. 
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a) 
 
 
 
 
 
b) 
 
 
 
 
 
c) 
 
 
 
 
 
Figure 2.4 Stability of platelet activation markers on flow cytometry analysis with 
delay after fixation and two concentrations of paraformaldehyde saline 
Healthy volunteer platelet CD62P expression, CD63 expression and PAC-1 binding under basal/ 
unstimulated conditions (a), 0.1 μM ADP (b), 5 μM ADP (c). Time intervals on x-axis denote time after 
platelet reaction mixture fixation with 0.16% or 1% paraformaldehyde saline solution. n=2. Symbols and 
bars represent mean ± SD. Red and black symbols represent data from samples fixed with 0.16% and 1% 
paraformaldehyde saline respectively.  
ADP, adenosine diphosphate;  
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2.6.4 Platelet aggregometry 
Impedance aggregometry was performed in whole blood collected before and after 
RIPC/sham into hirudin tubes. Aggregometry was performed with a Multiplate
TM
 
analyser (Roche) as per the manufacturer’s instructions. ADP (6.67 μM) and 
arachidonic acid (1 mM) (Helena Laboratories, Mt Waverley, Victoria, Australia) were 
used as agonists. The Multiplate analyser reaction cuvettes have two pairs of electrodes 
which act as an internal quality control mechanism and allow the measurements to be 
performed in duplicate. 
 
2.6.5 Platelet-leukocyte aggregates 
The reaction mixtures of citrated whole blood with DPBS without agonists and with 5 
μM ADP, 20 μM SFLLRN, 2 U/mL Thrombin, with H-Gly-Pro-Arg-Pro-OH (5 
mg/mL) added to the thrombin reaction mix, were used to assess platelet-leukocyte 
aggregates (PLA). Reaction mixes (200 μL) were added to FACS tubes containing 
isotype control IgG (MOPC-21) and antibodies to CD45 (2D1) or CD42b (HIP1). All 
antibodies were sourced from BD Bioscience (Franklin Lakes, New Jersey, USA). The 
samples were then left to incubate for 20 min at room temperature before being fixed 
with a combination of paraformaldehyde, Hank’s buffered salt solution and water. After 
a further 10 min, water (840 μL) was added to restabilise the osmotic balance and lyse 
the erythrocytes. The samples were analysed by flow cytometry (FACSCalibur) with 
1000 monocyte gated events, based on light scatter characteristics and CD45 
expression, acquired for each analysis. The isotype control was used to determine 
positive events based on 0.5% background expression. The proportion of monocyte and 
granulocyte events, based on light scatter characteristics and the leukocyte marker 
CD45, which expressed the platelet marker CD42b were quantified with FlowJo. Figure 
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2.5 shows flow cytometry histograms demonstrating increased PAC-1 binding, CD62P 
expression, CD63 expression and PLA formation after stimulation with platelet 
agonists. 
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a) 
 
b) 
 
c) 
 
d) 
 
Figure 2.5 Flow cytometry histograms demonstrating platelet activation by agonist 
stimulation 
Representative examples of platelet activation as demonstrated by flow cytometry in a patient with 
coronary artery disease demonstrating increased PAC-1 binding (a), CD62P expression (b), CD63 
expression (c) and platelet-granulocyte aggregate formation (d) in response to thrombin and collagen (a,b 
and c) and SFLLRN (d). In each histogram platelet binding of the isotype control (red) and binding of 
PAC-1(a), CD62P antibody (b), CD63 antibody (c) or CD42b antibody (d) under unstimulated (blue) or 
stimulated conditions (orange) is displayed. Increased positive events in stimulated sample demonstrated 
by shift of curve to the right indicating increased numbers of events with greater fluorescence intensity 
relative to the isotype control.    
SFLLRN, PAR-1 agonist; 
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2.6.6 Procoagulant platelets 
Procoagulant platelets were quantified in whole blood with incubation and staining 
steps performed in a sterile 96-well polypropylene plate. Citrated whole blood was 
diluted with Hank’s balanced salt solution (HBSS, pH adjusted to 7.35, Life 
Technologies, Carlsbad, California, USA), Gly-Pro-Arg-Pro amide (2.5 mM) (Sigma-
Aldrich, St Louis, Missouri, USA) and calcium (2.5 mM), with and without agonists (as 
in section 2.6.1). Reactions were stopped after 10 min of incubation at room 
temperature by a 20- fold dilution with HBSS. Aliquots of agonist or non-stimulated 
blood were labelled for 15 min with antibodies to CD62P (Psel.KO2.3) (eBioscience, 
Waltham, Massachusetts, USA), CD41a (HIP8) (BD Biosciences, Franklin Lakes, New 
Jersey, USA), CD45 (HI30) (StemCell Technologies, Vancouver, British Colombia, 
Canada) and with GSAO conjugated to AlexaFluor 647. Samples were then fixed with 
two volumes of PAMFix (Platelet Solutions Ltd, Nottingham, United Kingdom). 
Samples were then transferred to FACS tubes and washed once with 10 volumes of 
HBSS with 0.35% (v/v) human serum albumin (HSA) (CSL, Melbourne, Victoria, 
Australia). The cells were then pelleted (1,500 g for 8 min) and then re-suspended in 1 
mL of HBSS/HSA before being stored at room temperature in the dark for 1 h prior to 
analysis. Flow cytometry was performed on a BD FACS Canto II or BD Fortessa (BD, 
Franklin Lakes, New Jersey, USA) with 10,000 platelet events acquired for each 
analysis. Procoagulant platelets were defined as being CD62P and GSAO positive 
(CD62P+/GSAO+) and represented as a percentage of total platelet events. Data were 
analysed with FlowJo.  
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2.7 MicroRNA extraction from plasma 
 
In chapter 6, microRNA was extracted from plasma to assess for the effects of RIPC. 
Methods relevant to this work are described below.  
  
2.7.1 Determination of degree of haemolysis in plasma  
Specific miRNA species are abundant in erythrocytes and hence, haemolysis during 
plasma preparation can have a significant impact on the miRNA profile (127,128). In 
particular, the levels of miRNA-16 and miRNA-451 are elevated in plasma samples 
with significant degrees of haemolysis. In order to assess for the degree of haemolysis, 
once plasma samples were thawed, 100 μL was pipetted into a 96-well plate and 
assessed by spectrophotometry on an EnSpire Multimode Plate Reader (Perkin Elmer, 
Waltham, Massachusetts, USA). The optical density at 414 nm, which is the absorbance 
peak of free haemoglobin, was used to determine the degree of haemolysis with 
A414<0.2 interpreted as an insignificant amount of haemolysis, as described by 
Kirschner et al (127). 
A comparison of stored citrated plasma which was centrifuged twice and stored EDTA 
plasma which was centrifuged once, from a patient with coronary artery disease, 
demonstrated a lower optical density at 414 nm indicating that there was less 
haemolysis in double-centrifuged plasma samples (Figure 2.6). Therefore twice-
centrifuged citrated plasma was used for isolation of miRNA from randomised patient 
samples. 
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Figure 2.6 Comparison of the degree of haemolysis in single-centrifuged and 
double-centrifuged plasma from the same patient 
Plasma in EDTA (centrifuged once) and in citrate (centrifuged twice) from the same patient was stored at 
-80 °C. After thawing absorption spectra between 350 nm and 640 nm were determined. The OD at 
414nm was used to determine the degree of haemolysis. 
 
2.7.2 Comparison of microRNA extraction kits and method optimisation   
In order to determine which commercially available miRNA extraction kit was most 
suitable to isolate miRNA from patient plasma, several extraction kits were compared 
(Table 2.1). All kits extract miRNA from plasma based on differential binding to silica 
or glass-fibre columns and elution of miRNA from the column using water or an elution 
buffer. Kits differed in amount of plasma used for extraction and elution volumes. All 
experiments were carried out with RNase-free equipment in areas of the laboratory 
dedicated to RNA-based work.  
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2.7.2.1 Comparison of miRNeasy, mirVana and Isolate II kits 
The miRNeasy serum/plasma kit (Qiagen, Hilden, Germany), mirVana PARIS miRNA 
isolation kit (Thermofisher, Waltham, Massachusetts, USA) and Isolate II miRNA kit 
(Bioline, Taunton, Massachusetts, USA) were used to extract miRNA from plasma 
prepared from a healthy volunteer as described in section 2.6, as per the manufacturers 
guidelines. All extractions were performed in duplicate. The plasma was stored at -80 
°C in RNase free tubes and was not thawed until analysis.  
The miRNeasy kit involves phenol/guanidine-based lysis of samples followed by silica 
membrane based miRNA extraction. The mirVana kit involves an acid-phenol 
chloroform solution followed by glass-fibre filter based extraction with both miRNA 
and ‘large’ RNA extracted separately on different columns. Conversely, the Isolate II 
kit uses a high affinity RNA resin to extract RNA from the sample without phenol or 
chloroform. This kit also allows extraction of ‘large’ RNA from the sample followed by 
miRNA extraction using separate columns. A phenol-free method was also assessed as 
concerns have been raised about phenol contamination being responsible for variable 
yields and quality of the various different extraction methods (129). Differences in 
starting plasma volume and final elution volume are listed in Table 2.1.  The isolated 
small RNA species were analysed and quantified using a Bioanalyzer (Agilent, Santa 
Clara, California, USA), with 1 μL of sample loaded onto a small RNA chip, as per the 
manufacturer’s instructions.  
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Table 2.1 Comparison of the input plasma volume and final elution volumes of the 
miRNeasy, mirVana and Isolate II kits  
Kit Plasma volume (μL) Final elution volume (μL) 
miRNeasy 200 14 
mirVana* 450  100 
Isolate II 100 20 
 
* Up to 625 μL permitted. 
miRNA, micro ribonucleic acid; 
 
Quantification of miRNA concentration by Bioanalyzer analysis indicated large 
differences between duplicate samples (Figure 2.7 and Table 2.2). It also suggested the 
greatest concentration of miRNA in Isolate II samples despite requiring the smallest 
input plasma volume (Figure 2.7 and Table 2.2). Interestingly, the Isolate II large RNA 
samples also seemed to have relatively large amounts of small miRNA. However, the 
concentrations obtained in these isolations were significantly lower than described in 
the literature. The yield of miRNA from frozen human plasma has been reported to be 
greater than 105 ng/100 μL input plasma (130). Additionally, there were no discernible 
peaks in the electropherogram from any of the samples, suggesting very low 
concentrations of miRNA, raising concerns regarding the accuracy of the miRNA 
quantification. The manufacturer recommended range for small RNA detection in 
samples analysed using a Bioanalyzer with a small RNA chip was 1-20 ng/μL, 
significantly higher than most of the concentrations that were achieved with any of the 
three kits trialled. This suggested that these concentrations most likely were not an 
accurate reflection of the true quantity of miRNA in the samples.  
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a) 
  
b) 
 
 
Figure 2.7 Comparison of miRNeasy, mirVana and Isolate II kits with Bioanalyzer  
Bioanalyzer software output after microfluidics electrophoresis of miRNA samples run with a small RNA 
chip to determine miRNA concentration (a). As per the manufacturer’s instructions, the gel-dye mix, 
small RNA conditioning solution, small RNA marker, ladder and 1 μL of each miRNA sample was 
loaded into the appropriate wells of the small RNA chip before analysis. Electropherogram of 
standard/ladder with arrow indicating expected location of miRNA peak (b). 
miRNA, micro ribonucleic acid; RNA, ribonucleic acid;    
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Table 2.2 Comparison of microRNA concentrations of extractions with miRNeasy, 
mirVana and Isolate II kits  
Kit/sample miRNA concentration  
(pg/μL) 
Total miRNA per input 
plasma volume (pg/100 
μL)* 
miRNeasy-1 0.8 5.6 
miRNeasy-2 5.2 36.4 
mirVana miRNA-1 17.4 386.7 
mirVana miRNA-2 9.8 217.8 
mirVana large-1 11.1 246.7 
mirVana large-2 3.8 84.4 
Isolate II miRNA-1 60.1 1202.0 
Isolate II miRNA-2 70.5 1410.0 
Isolate II large-1 98.1 1962.0 
Isolate II large-2 126.8 2536.0 
 
Concentrations based on Bioanalyzer analysis with a small RNA chip. Plasma from the same heathy 
subject was isolated in duplicate using the indicated extraction kits (“-1” and “-2” respectively).  For 
mirVana and Isolate II kits the quantity for both the ‘large’ and miRNA isolations are shown.  
* Calculated by multiplying concentration by elution volume and dividing by input plasma volume (x 100 
μL).  
miRNA, micro ribonucleic acid; 
 
Given the low miRNA concentrations, potential methods to increase the miRNA yield 
were explored, with the Isolate II kit used for extraction as this kit appeared to provide 
the greatest and most consistent miRNA yield without the use of phenol containing 
reagents.  
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2.7.2.2 Assessment of microRNA from extracellular vesicle-enriched plasma 
Extracellular vesicles are known to be carriers of miRNA in the circulation (48). In an 
attempt to increase the yield of miRNA or determine whether extracellular vesicles 
were a better source of miRNA to investigate, isolating miRNA from the microparticle 
fraction of plasma was compared to miRNA isolated from whole plasma. Frozen plasma 
(500 μL), which had not been previously thawed, from a patient with significant CAD, 
was thawed and centrifuged at 164,000 g for 60 min (Beckman Coulter TLA-110 rotor) 
to concentrate extracellular vesicles (131). The bottom fraction (100 μL) containing the 
extracellular vesicles, and whole plasma from the same patient, were processed with the 
Isolate II kit, in duplicate, to extract miRNA. The resultant miRNA was stored at -80 °C 
until analysed with a Bioanalyzer.  
Each miRNA extraction from microparticle concentrated plasma was derived from 500 
μL of whole plasma compared with 100 μL of plasma with the Isolate II kit. Despite 
this, as is demonstrated in Table 2.3, miRNA extraction from microparticle-enriched 
plasma did not result in a consistent increase in miRNA yield.   
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Table 2.3 Comparison of microRNA concentrations of extractions from whole 
plasma and microparticle concentrated plasma 
Kit/sample miRNA concentration 
(pg/μL) 
Total miRNA per 100 μL 
plasma volume (pg) 
Isolate II miRNA-1 17.3 346 
Isolate II miRNA-2 32.5 650 
Isolate II miRNA-1 (M) 28.9 115.6 
Isolate II miRNA-2 (M) 7.3 29.2 
Isolate II large-1 37 740 
Isolate II large-2 23.6 472 
Isolate II large-1 (M) 2.2 8.8 
Isolate II large-2 (M) 2.5 10 
 
Concentrations based on Bioanalyzer analysis with small RNA chip. 
* Calculated by multiplying concentration by elution volume and dividing by total plasma volume (x 100 
μL). 100 μL of whole or microparticle-enriched plasma (derived from 500 μL of whole plasma) was 
loaded onto the Isolate II kit.  
M, microparticle-enriched plasma; miRNA, micro ribonucleic acid; 
 
This result was not completely unexpected as most miRNA in the circulation is found 
independent of microvesicles (132,133). There were significant differences between 
duplicate samples. All concentrations were below the recommended range for the 
Bioanalyzer and this may have led to error in quantification.  
 
2.7.2.3 Assessment of microRNA extracted from lipoprotein fraction of plasma and 
efficacy of concentration with SpeedVac  
Lipoprotein particles such as high density lipoprotein are also known to be carries of 
miRNA in the circulation (134). Hence, a comparison of miRNA extracted from the 
lipoprotein fraction of plasma and from whole plasma was performed. Plasma (850 μL) 
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from the same patient described in section 2.7.2.2 was thawed and subjected to density 
ultracentrifugation to isolate total plasma lipoproteins. Potassium bromide was added to 
the plasma to adjust the density to 1.21 g/mL and the sample was centrifuged at 100,000 
rpm (Optima TLX Ultracentrifuge, TLA-110 rotor, Beckman Coulter, Brea, California, 
USA) for 16 h at 4 °C. Following centrifugation, total lipoproteins (>1.21 g/mL) were 
concentrated at the top of the solution and were visible as a white band. The lipoprotein 
fraction was removed, saline was added to a total volume of 100 µL and miRNA was 
extracted using the Isolate II kit. MicroRNA was also extracted from 100 µL of whole 
plasma from the same patient for comparison. 
As all previous Bioanalyzer results indicated very low RNA concentrations, which 
hampered accurate determination of the miRNA quantity, the miRNA samples were 
concentrated using a SpeedVac (Savant, Thermofisher). The SpeedVac is a centrifuge 
which applies a negative pressure to the samples to promote evaporation of water. The 
samples, as described in section 2.7.2.2 (microparticle-associated miRNA) were also 
concentrated with a SpeedVac. The samples were placed in the SpeedVac until 
approximately half the volume had evaporated. 
The results of analysis of the samples with a Bioanalyzer are displayed in Table 2.4. 
While concentration by SpeedVac of the lipoprotein fraction of plasma appeared to 
provide the greatest concentration of miRNA, it was also below the recommended range 
for the Bioanalyzer. This miRNA was derived from a larger volume of plasma (850 µL) 
than the samples extracted from whole plasma (100 µL). The 8.5 fold greater volume of 
plasma did not translate to a measurable quantity of miRNA. 
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Table 2.4 Comparison of microRNA concentrations of extractions from whole 
plasma and lipoprotein fraction of plasma and the effect of concentration by 
SpeedVac 
Kit/sample miRNA concentration 
before SpeedVac (pg/μL) 
miRNA concentration 
after SpeedVac (pg/ μL) 
Isolate II miRNA-1 17.3 5.2 
Isolate II large-2 23.6 25.3 
Isolate II miRNA-1 (M) 28.9 36.7 
Isolate II large-2 (M) 2.5 40.2 
Isolate II miRNA-3 - 3.9 
Isolate II large-3 - 74.1 
Isolate II miRNA-3 (L) - 127.2 
Isolate II large-3 (L) - 107.3 
 
Concentrations based on Bioanalyzer analysis with small RNA chip. Samples 1 and 2 were prepared as 
described in section 2.7.2.2 and reported in Table 2.3. Sample 3 was prepared in parallel from whole 
plasma and the lipoprotein fraction. Samples were centrifuged in a SpeedVac until the volume had 
reduced by approximately 50% to increase the concentration of miRNA. 
 L, lipoprotein fraction of plasma; M, microparticle-enriched; miRNA, micro ribonucleic acid; 
 
2.7.2.4 Combining microRNA and large RNA output from Isolate II extraction kit  
As it appeared that there was a significant amount of miRNA in the Isolate II large 
RNA column (sections 2.7.2.1, 2.7.2.2 and 2.7.2.3), pooling the miRNA and large RNA 
isolate II kit outputs, followed by SpeedVac based concentration, was tested. 
MicroRNA and large RNA Isolate II outputs from the plasma of a patient with 
significant CAD were pooled and an aliquot was stored for analysis with a Bioanalyzer. 
The remaining sample was concentrated with a SpeedVac, aiming for a reduction in 
volume by half. After 25 min in the SpeedVac, one sample (A) had almost completely 
evaporated while the other sample (B) volume had decreased by approximately 50%, 
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indicating variable evaporation using this method. Sample A had 5 μL water added 
(total volume 10 μL) and the total volume of sample B was 25 μL after SpeedVac 
centrifugation. The results of Bioanalyzer analysis of these samples are displayed in 
Table 2.5. The results demonstrated discrepant concentrations between the duplicate 
samples (between A and B) prior to SpeedVac concentration and inconsistent apparent 
increases in miRNA concentration after evaporation.  
Additionally, the concentration of miRNA was still below the recommended range of 
the Bioanalyzer and given the un-predictable rate of evaporation of samples during 
centrifugation in the SpeedVac, it was decided that the method of pooling of the 
miRNA and large RNA outputs from the Isolate II kit and using the SpeedVac was 
inappropriate to use with randomised cohort miRNA samples. During these experiments 
it also became apparent that due to a lack of a protein precipitation step in the protocol, 
the Isolate II isolation columns had the potential to become occluded, resulting in loss 
of miRNA. As this issue could not be resolved, the use of Isolate II columns to isolate 
miRNA from patient plasma samples was abandoned as was the use of the Bioanalyzer 
to assess miRNA concentration. 
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Table 2.5 MicroRNA concentrations after combining outputs of Isolate II kit and 
the effect of concentration by SpeedVac 
Kit/sample miRNA concentration 
before SpeedVac (pg/μL) 
miRNA concentration 
after SpeedVac (pg/ μL) 
Isolate II-A 12.3 164.6 
Isolate II-B 147.4 79.4 
 
Concentrations based on Bioanalyzer analysis with small RNA chip. Samples A and B were duplicate 
extractions from the same plasma with miRNA and large RNA outputs of the Isolate II kit pooled prior to 
analysis. Samples were centrifuged in a SpeedVac until the volume had reduced by approximately 50% to 
increase the concentration of miRNA. 
miRNA, micro ribonucleic acid; 
 
2.7.2.5 Comparison of NucleoSpin and mirVana Phenol Free microRNA extraction kits 
and analysis for microRNA-16 by reverse transcription and quantitative polymerase 
chain reaction 
Given the inconsistencies described in earlier sections, the clogging of the Isolate II 
columns and difficulty increasing and quantifying the concentration of the miRNA 
extracted from plasma, the approach was changed to adopt a published method based on 
consistent volumes of miRNA rather than absolute quantities (127). Additionally, two 
additional commercially available phenol-free miRNA extraction kits were trialled. 
Instead of analysis with a Bioanalyzer, specific quantitative polymerase chain reactions 
(qPCR) for miRNA-16 were used to assess isolation and relative quantity of miRNA. 
MicroRNA-16 is a stable and abundant species in plasma and is commonly used for 
normalisation (135,136). 
Plasma from a patient with significant CAD underwent miRNA extraction with the 
NucleoSpin miRNA Plasma kit (Macherey-Nagel, Duren, Germany) and the mirVana 
Phenol Free miRNA kit (Thermofisher) in triplicate and duplicate extractions 
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respectively, as per the manufacturer’s instructions. Mussel glycogen (Roche) was 
added as a carrier protein as previously described, to increase miRNA yield 
(127,130,137). As the NucleoSpin and mirVana Phenol Free kits differed in the final 
elution volume (Table 2.6), the miRNA isolated by the mirVana kit was precipitated 
and finally diluted in a volume of water to match the sample volume produced by the 
NucleoSpin kit (20 μL).  
Precipitation was performed as previously described (127). The mirVana miRNA 
samples (100 μL) were mixed with 0.1 volumes of 3 M sodium acetate (pH 5.2), 2.5 ng 
mussel glycogen and 2.5 volumes ice cold 100% ethanol (Sigma-Aldrich). This mixture 
was incubated overnight at -80 °C. After thawing, the sample was centrifuged at 17000 
g for 20 min at 4 °C. The pellet was washed with 1 mL 80% (v/v) ice cold ethanol and 
re- centrifuged at 17000 g for 10 min at 4 °C. The supernatant was carefully removed 
and the pellet air dried at room temperature for 10 min before being resuspended in 
RNase free water (20 μL).  
 
Table 2.6 Comparison of the input plasma volume and final elution volumes of the 
NucleoSpin and mirVana Phenol Free kits  
Kit Plasma volume (μL) Final elution volume (μL) 
NucleoSpin 300 20-30 
mirVana Phenol Free 450 100 
 
Volume of plasma loaded onto and final volume for elution of miRNA from each kit as recommended by 
the manufacturer. 
miRNA, micro ribonucleic acid; 
 
After sample preparation,  a reverse transcription (RT) reaction was performed as 
described previously (127). In short, 0.5 μL RNA was mixed with 0.5 nM dNTPs, 16.5 
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U MultiScribe reverse transcriptase, 0.5 μL 10x RT buffer, 1.2 U RNAse inhibitor, 1 μL 
miRNA-16 primer (5x) in a total volume of 5ul. The RT reagents were sourced from 
Applied Biosystems (Thermofisher). The RT reaction was performed in a Multigene 
thermal cycler (Labnet International, Edison, New Jersey, USA) with reaction 
conditions of 16 °C for 30 min, then 42 °C for 30 min then 85 °C for 5 min. After the 
RT reaction, 5 μL of water was added and samples were either frozen or used for qPCR 
analysis. 
To perform the qPCR, 2.25 μL of complementary deoxyribonucleic acid (cDNA) was 
added to 1x KAPA fast probe universal mix, 1x Rox low and 0.25 μL miRNA-16 probe 
(20x) in a total volume of 10 μL. The qPCR reagents were sourced from Kapa 
Biosystems (Wilmington, Massachusetts, USA). The qPCR reactions were performed in 
duplicate on a Viia 7 system (Thermofisher) under the following reaction conditions: 95 
°C for 20 sec followed by 40 cycles of 95 °C for 1 sec and 60 °C for 20 sec. The 
amplification curves and number of PCR cycles required for fluorescence to reach a 
threshold value (Ct values) were determined by using PCR analysis software 
(QuantStudio, Applied Biosystems, Foster City, California, USA). The threshold was 
automatically determined by the software and the reported Ct values are the mean of the 
duplicate qPCR reactions. 
Figure 2.8 demonstrates the Ct values, indicating comparable miR-16 content of the 
samples prepared with the NucleoSpin and mirVana Phenol Free kits, with lower Ct 
values indicating a greater concentration of the species in the sample. The results 
indicated a similar yield of miRNA-16 with both extraction kits, despite the mirVana kit 
having a greater input plasma volume. Therefore the NucleoSpin kit was used to isolate 
plasma miRNA from the plasma stored from the randomised patient cohort. The 
NucleoSpin kit also included a protein precipitation step, which was deemed likely to 
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reduce clogging of the isolation columns by plasma proteins. Additionally, as all RNA 
is isolated with one column in the NucleoSpin kit, as opposed to a miRNA and ‘large’ 
RNA isolation, the reduced number of steps was anticipated to result in reduced 
variability between samples. 
 
 
Figure 2.8 Quantitative polymerase chain reaction for microRNA-16 of samples 
prepared with NucleoSpin and mirVana Phenol Free kits 
Values represent the mean Ct value of duplicate reactions for each sample, with lower values indicating 
greater a greater concentration of miRNA-16 in the sample. Quantitative PCR was performed as 
described in section 2.7.2.5. Bars represent range. 
miRNA, micro ribonucleic acid; PF, phenol free; 
 
2.7.2.6 Summary and conclusions regarding microRNA extraction 
The experiments performed to compare various commercially available miRNA 
extraction kits and methods to optimise miRNA recovery revealed inconsistencies in 
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isolations and that achieving the recommended concentration for analysis with the 
Bioanalyzer was difficult. Several methods to increase the concentration of miRNA 
were tested with all methods resulting in a concentration below the recommended range 
for Bioanalyzer analysis. It was therefore decided to follow a reported protocol for 
investigation of plasma miRNAs that uses minimal handling steps, rather than based on 
miRNA yield. The NucleoSpin isolation kit was deemed most suitable and specific RT 
and qPCR reactions for miRNA-16, an abundant species in plasma which is commonly 
used as a reference species, indicated successful isolation of miRNA with comparable 
miRNA-16 levels between samples indicating consistency in miRNA isolation. 
MicroRNA isolation using this kit with subsequent determination of miRNA-16 levels 
was therefore chosen to investigate changes in plasma miRNA levels with RIPC in 
chapter 6. 
 
2.8 Storage of platelet lysates 
 
To study the effect of RIPC on intracellular platelet pathways, platelet pellets were 
stored from patients who were treated with RIPC. In particular, phosphorylation of 
Vasodilator Stimulated Phosphoprotein (VASP), cyclic Adenosine Monophosphate 
(cAMP) and cyclic Guanosine Monophosphate (cGMP) were to be studied as these 
factors play a role in pathways mediating platelet activation. Blood collected in sodium 
citrate containing tubes was centrifuged at 200 g for 10 min at room temperature. The 
resultant platelet rich plasma (PRP) (2 x 500 μL) was either centrifuged immediately at 
2500 g for 15 min at room temperature in a 15 mL centrifuge tube (Greiner, 
Kremsmünster, Austria) to study platelet lysates under basal conditions or stimulated 
with SFLLRN (20 μM) for 20 min at room temperature prior to centrifugation. The 
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platelet count of the PRP was measured (Sysmex, Roche). The plasma supernatant was 
discarded and the platelet pellet was resuspended in 1 mL of ice-cold DPBS before 
being centrifuged at 2600 g for 10 min at 4 °C. The supernatant was discarded and the 
platelet pellet was washed with another 1 mL of ice-cold DPBS before being 
centrifuged again. The platelet pellets were then further handled in one of two manners:  
 The supernatant was discarded and 100 μL of a mix of 1 mL Mammalian Protein 
Extraction Reagent (Thermofisher), 40 μL Complete Protease Inhibitor Mix 
(Roche) and 50 uL PhosSTOP Phosphatase Inhibitors (Roche), before being 
stored at -80 °C. 
 A second platelet pellet was washed a third time with 1 mL of ice-cold DPBS 
before being centrifuged at 2600 g for 10 min at 4 °C. The supernatant was 
discarded and resuspended in 1 mL (if PRP platelet count <200 x 10
9
/L) or 1.5 
mL (if PRP platelet count >200 x 10
9
/L) of cell lysis buffer (cAMP/cGMP 
ELISA kit, R&D Systems, Minneapolis, Minnesota, USA). The suspension was 
then frozen at -80 °C, then thawed with gentle mixing. The sample was then re-
frozen and thawed as previously before being centrifuged at 600 g for 10 min at 
4 °C to remove cellular debris. The supernatant was stored at -80 °C either 
undiluted or diluted with cell lysis buffer aiming for a cell count of 1 x 10
7
/mL, 
as per the manufacturer’s instructions and to maintain consistency in protein 
mass across patients samples, with the dilution factor calculated based on the 
platelet count of the PRP. 
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2.9 Statistical analysis 
 
The primary analysis in the majority of the studies presented is the difference between a 
specific measurement pre and post RIPC to determine the effect of conditioning on that 
particular marker. Similar analyses of pre and post sham were performed to ensure that 
the effect demonstrated was specific to RIPC.  
 
In the following chapters, data distribution was assessed with the D’Agostino and 
Pearson normality test. Categorical variables are presented as frequency and percentage 
while continuous variables are expressed as mean ± SD for parametrically distributed 
data and median (IQR) for non-parametrically distributed data. Categorical data were 
compared using 𝜒2 tests or Fisher’s exact test as appropriate while comparisons between 
continuous variables were performed using paired or unpaired t tests as appropriate for 
parametrically distributed data, and Wilcoxon signed rank or Mann-Whitney U tests as 
appropriate for non-parametric data. Where performed, correlations between variables 
was assessed by Pearson’s correlation or Spearman rank correlation for parametric and 
non-parametric data respectively.  
The percentage change in a particular marker or measurement in response to RIPC or 
sham was calculated by: 
 
Percentage change = ((post – pre)/pre) x 100 
Where post and pre are the specific measurements post or pre RIPC/sham respectively. A negative value 
indicates a decrease with RIPC/sham while a positive value indicates an increase with RIPC/sham. 
 
The percentage change between RIPC and sham groups was compared with the Mann-
Whitney U test in analyses where the paired comparison demonstrated an effect of 
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RIPC. This was performed to assess the robustness of the results. Specific statistical 
methods relevant to each study are described in the respective chapters.
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Chapter 3: The effect of remote ischaemic preconditioning on coronary 
physiology 
 
3.1 Introduction 
 
As discussed in chapter 1, most studies of RIPC in the setting of PCI have demonstrated 
protection against procedure related myocardial injury or a reduction in myocardial 
infarct size (138). While the main focus of treatment of patients with CAD is often the 
epicardial atherosclerotic disease, the coronary microcirculation confers an important 
prognostic influence. The coronary flow reserve (CFR) and the index of 
microcirculatory resistance (IMR) have been shown to predict outcome in patients with 
epicardial coronary artery disease (CAD) and in patients without obvious obstructive 
coronary lesions (139-144). In the setting of elective or primary PCI, patients with a 
lower IMR have a superior prognosis (143,144). As discussed in section 1.2.6, there is 
some evidence that RIPC may augment coronary microcirculatory function. Given the 
importance of coronary physiology markers and the microcirculation in predicting the 
prognosis of patients with CAD, including those undergoing PCI, it was hypothesised 
that RIPC may confer a beneficial effect on microcirculatory function. In order to 
determine the effect of RIPC on coronary physiology, a randomised, blinded, placebo 
controlled trial to investigate the effect of RIPC on invasively measured markers of 
microcirculatory function was conducted.  
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3.2 Methods 
 
3.2.1 Coronary physiology measurements and remote ischaemic preconditioning 
Clinically stable patients, who were referred for non-urgent coronary angiography at 
Concord Hospital, Sydney, Australia, with symptoms or non-invasive investigations 
suggestive of significant CAD, were invited to participate as described in chapter 2. 
Coronary physiology measurements, coronary angiography and RIPC were performed 
as described in chapter 2. Methods specific to this chapter not described elsewhere are 
described below. 
Patients were approached prior to their planned procedure and provided with written 
and verbal information about the study before informed consent was obtained. Coronary 
angiography was performed, as planned, and patients were only included if they 
required FFR assessment of an angiographically equivocal lesion in a major epicardial 
coronary artery based on clinical grounds. The need for FFR was determined by the 
interventional cardiologist performing the procedure. The decision to only include 
patients who required FFR measurement on clinical grounds was to justify the 
additional risk associated with coronary artery wiring. Consecutive patients who met 
these inclusion criteria were included in the study. 
Patients with prior myocardial infarction in the target artery territory were excluded as 
were patients with coronary anatomy which would impact on accurate coronary 
physiology assessment, such as left or right coronary ostial disease leading to guide 
pressure ‘damping’. Patients in atrial fibrillation were also excluded as irregularity of 
the cardiac cycle could affect thermodilution measurements. Finally, patients with 
severe asthma were not invited to participate as adenosine, required for the coronary 
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physiology study, can exacerbate airways disease. Data regarding patient demographics, 
co-morbidities, medications and pre-procedure investigations were collected.  
Participants were randomised to either RIPC or sham treatment by way of a closed 
envelope system. RIPC/sham was delivered as described in section 2.1 by an assistant 
who did not communicate with the operator. Patients and the investigator performing 
the cardiac catheterisation procedure were blinded to the treatment allocation, with 
randomisation performed by the assistant. The patients were warned of possible 
discomfort from sphygmomanometer inflation but were asked not to express discomfort 
unless it was intolerable. All patients complied with this request. To maintain blinding 
of the operator, the sphygmomanometer was obscured from view and music was played 
throughout the laboratory to mask the sound of sphygmomanometer inflation.  
Coronary physiology measurements, including IMRcalc, IMR, CFR and FFR, were 
recorded pre and post RIPC or sham ensuring that the pressure-temperature sensor 
position remained constant. Two and three dimensional QCA was performed off-line in 
two orthogonal views in patients where there was adequate image quality to allow 
analysis. 
 
3.2.2 Assessment of circulating regulators of microcirculatory function 
In order to study whether RIPC-mediated changes in microcirculatory function were 
associated with changes in circulating factors previously reported to affect vascular 
function, blood was collected from the femoral venous sheath after each coronary 
physiology study. After the first 3 mL was discarded, blood was drawn slowly into 
syringes at a rate of 0.5 mL/sec and transferred to tubes containing K2EDTA. Plasma 
was prepared and stored as described in section 2.6 by centrifugation at 2500 g for 15 
min. 
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The stored plasma was analysed with the following commercially available kits as per 
the manufacturer’s instructions: Total Nitric Oxide and Nitrate/Nitrite (all from R&D 
Systems), 6-keto-PGF1α (Abcam, Cambridge, United Kingdom) and Adrenomedullin 
(MyBioSource). Nitric oxide, adrenomedullin and prostacyclin (metabolised to 6-keto-
PGF1α) are factors that contribute to regulation of the human microcirculation (145). 
Nitric oxide is metabolised to nitrite and nitrate. Adrenomedullin is a peptide hormone 
which plays a role in the regulation of vascular tone by regulating vasodilation in a 
cAMP and cAMP-independent manner (146). Adrenomedullin has been shown to be 
involved in RIPC mediated protection against IR injury (147). Hence these factors were 
measured in the plasma to explore the mechanism behind RIPC induced changes in 
coronary microcirculatory function. 
 
3.2.3 Statistical analysis 
Categorical variables are presented as frequency and percentage while continuous 
variables are expressed as mean ± SD for parametrically distributed data and median 
(IQR) for non-parametrically distributed data. Categorical data were compared using 𝜒2 
tests or Fisher’s exact test as appropriate. Comparisons between continuous variables 
were performed using paired or unpaired t tests as appropriate for parametrically 
distributed data, and Wilcoxon signed rank or Mann-Whitney U tests as appropriate for 
non-parametric data. Correlations between variables were assessed by Pearson r 
correlation or Spearman rank correlation for parametrically and non-parametrically 
distributed data respectively.  
Pre treatment and post-treatment measurements of markers of microcirculatory function 
were compared. The primary analysis was change in the index of microcirculatory 
resistance with RIPC. Based on the first 4 patients who received RIPC as part of the 
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randomised study, an absolute decrease in IMRcalc with RIPC was expected to be 5.5 ± 
7.0. With a power of 80% and a two-sided α value of 0.05, it was estimated that 15 
patients would need to be studied for paired comparison to detect a change in IMRcalc 
with RIPC. Therefore 30 patients, randomised in a 1:1 manner to RIPC or sham 
treatment, were recruited. The secondary analyses included changes in IMR, CFR, TmnR, 
TmnH and FFR. The percentage change (section 2.9) with RIPC was compared with the 
percentage change with sham using the Mann-Whitney U test in measurements where 
the paired comparison demonstrated an effect of RIPC. 
All analyses were performed with the use of SPSS version 22 (IBM, Armonk, New 
York, USA) or GraphPad, Prism (GraphPad Software Inc., La Jolla, California, USA) 
software. A two-tailed probability value < 0.05 was considered statistically significant. 
 
3.3 Results 
 
A total of 65 patients underwent coronary angiography as part of screening for inclusion 
into the study. Figure 3.1 summarises patient recruitment and randomisation. Thirty 
four patients were excluded after coronary angiography as there was no clinical 
indication for FFR measurement. One additional patient was excluded as coronary 
wiring precipitated significant coronary spasm (which was successfully treated with 
appropriate vasodilators and withdrawal of the wire). Thirty patients underwent 
randomization and the full study protocol. There were no complications of RIPC or 
sham treatment. 
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3.3.1 Baseline clinical characteristics 
Of the 30 patients who underwent randomisation to either RIPC or sham treatment, the 
mean age was 63.1 ± 10.0 yr and 26 (87%) were male. Paired coronary physiology 
measurements were performed before and after the allocated treatment in all patients. 
There were 15 patients randomised to RIPC and 15 patients randomised to sham 
treatment. The baseline characteristics, lesion characteristics and medications, of the 
RIPC and sham groups are displayed in Table 3.1. Although there were some numeric 
differences between the groups, the differences did not meet statistical significant for 
any of the characteristics, acknowledging the relatively small numbers. 
Twenty two (73%) of the lesions assessed were in the left anterior descending artery, 12 
in the RIPC cohort and 10 in the sham cohort (P=0.41). The mean pre treatment 
(RIPC/sham) FFR in the RIPC and sham cohorts were not significantly different (0.83 ± 
0.06 vs 0.82 ± 0.08, P=0.76). There were 3 (20%) and 6 (40%) pre treatment FFR 
measurements ≤0.80 in the RIPC and sham groups respectively (P=0.43).  
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Figure 3.1 Patient recruitment and randomisation – Coronary physiology cohort 
Patients with suspected CAD, referred for cardiac catheterisation, were approached prior to their planned 
procedure. After informed consent was obtained, patients underwent cardiac catheterisation as planned 
and randomised to RIPC or sham treatment if there was a clinical indication for FFR. In 34 patients, there 
was no coronary artery lesion with a diameter stenosis between 40-70% by visual assessment and hence 
FFR was not indicated. A coronary physiology study was performed before and after RIPC/sham while 
on the catheterisation table. Venous blood was collected after each coronary physiology study, after the 
cessation of the adenosine intravenous infusion. After the study protocol, the procedure proceeded as 
clinically indicated. 
CAD, coronary artery disease; FFR, fractional flow reserve; RIPC, remote ischaemic preconditioning; 
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Table 3.1 Baseline characteristics of randomised coronary physiology cohort 
Characteristic RIPC 
(n=15) 
Sham 
(n=15) 
P value 
Age - years 64.5 ± 8.8 61.7 ± 11.2 0.47 
Male – no. (%) 13 (87) 13 (87) 1.00 
Clinically stable – no. (%) 14 (93) 14 (93) 1.00 
Prior myocardial infarction – no. (%) 1 (7) 4 (27) 0.33 
Prior PCI – no. (%) 2 (13) 6 (40) 0.22 
Prior CABG- no. (%) 0 (0) 0 (0) - 
Heart failure – no. (%) 0 (0) 1 (7) 1.00 
Prior stroke – no. (%) 1 (7) 2 (13) 1.00 
Peripheral vascular disease – no. (%) 0 (0) 2 (13) 0.48 
Hypertension – no. (%) 11 (73) 10 (67) 0.69 
Diabetes – no. (%) 7 (47) 3 (20) 0.25 
Dyslipidaemia – no. (%) 13 (87) 9 (60) 0.22 
Current smoking – no. (%) 1 (7) 3 (20) 0.60 
Normal left ventricular contractility – no. (%) 14 (93) 14 (93) 1.00 
Left ventricular hypertrophy – no. (%) 2 (13) 1 (7) 1.00 
Medications    
Aspirin – no. (%) 14 (93) 15 (100) 0.31 
P2Y12 antagonist – no. (%) 12 (80) 10 (67) 0.41 
Warfarin/ NOAC – no. (%) 0 (0) 0 (0) - 
Statin – no. (%) 14 (93) 14 (93) 1.00 
Beta blocker – no. (%) 5 (33) 8 (53) 0.27 
ACEi or ARB – no. (%) 11 (73) 7 (47) 0.14 
Nitrate – no. (%) 1 (7) 1 (7) 1.00 
Coronary assessment    
LAD assessed – no. (%) 12 (80) 10 (67) 0.41 
Lesion diameter stenosis - %* 38.7 ± 10.0 39.5 ± 6.4 0.78 
Vessel reference diameter – mm* 2.9 ± 0.5 2.6 ± 0.5 0.05 
Lesion length – mm* 9.4 ± 4.3 10.1 ± 4.2 0.65 
Parameters during admission    
Systolic blood pressure – mmHg 128.5 ± 12.8 136.1 ± 12.3 0.11 
Heart rate – beats/min 68.4 ± 11.0 67.9 ± 10.5 0.89 
Haemoglobin concentration – g/L 138.1 ± 19.9 130.9 ± 15.2 0.28 
eGFR - mL/min/1.73m
2
 83.1 ± 11.1 84.9 ± 13.4 0.68 
 
P values compare characteristics from RIPC and sham treatment groups using unpaired t tests for 
continuous data. Categorical data were compared using 𝜒2 tests or Fisher’s exact test as appropriate.  
* Average value from quantitative coronary angiographic assessment of 2 views of each lesion per 
patient. 
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary 
artery bypass grafting; eGFR, estimated glomerular filtration rate; NOAC, novel oral anticoagulant; PCI, 
percutaneous coronary intervention;  
Chapter 3 
 
73 
 
3.3.2 The effect of remote ischaemic preconditioning on the index of microcirculatory 
resistance 
An example of the coronary physiology data obtained from one patient is presented in 
the Figure 3.2. This patient was randomised to receive RIPC on the catheterisation 
laboratory table during the procedure. Figure 3.2a displays the coronary physiology 
indices pre RIPC and Figure 3.2b displays the same indices post RIPC. In this case, 
RIPC was associated with a decrease in IMR and an increase in CFR. 
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a) 
 
b) 
 
Figure 3.2 An example of coronary physiology measurements from one patient 
randomised to remote ischaemic preconditioning 
Coronary physiology measurements obtained from one patient who was randomised to RIPC. The data in 
(a) was obtained pre RIPC and the data in (b) was obtained post RIPC. There was a reduction in IMR 
(calculated) and TmnH with RIPC, while the CFR increased. The green and red pressure traces were 
recorded from the pressure sensor on the coronary wire and tip of the guiding catheter respectively. The 
yellow line (top of each figure) represents the ratio of distal to proximal pressure. The figures in the 
rectangular boxes represent the transit times with the average displayed to the left of the triplicate 
recordings. The measurements in the left half of each figure were recorded in the resting state whereas the 
measurements in the right half were taken during hyperaemia induced by administration of intravenous 
adenosine. IMR (calculated) = Pa x TmnH x (1.34 x Pd/Pa – 0.32), calculated during hyperaemia. 
CFR, coronary flow reserve; IMR, index of microcirculatory resistance; RIPC, Remote ischaemic 
preconditioning; TmnH, hyperaemic transit time;  
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Considering the entire randomised cohort, RIPC resulted in a significant reduction in 
IMRcalc and a significant reduction in IMR in patients with a pre treatment FFR >0.80 
(Table 3.2 and Figure 3.3). There was no significant change in IMRcalc or IMR with 
sham treatment. 
 
Table 3.2 The effect of remote ischaemic preconditioning and sham on coronary 
physiology measurements 
Marker RIPC (n=15) Sham (n=15) 
 Pre Post P† Pre Post P † 
IMRcalc 22.6 
(17.9-25.6) 
17.5 
(14.5-21.3) 
0.007 16.0 
(10.8-20.5) 
16.8 
(10.8-21.2) 
0.85 
IMR* 24.3  
(18.5-26.1) 
17.7  
(13.2-21.7) 
0.005 16.1 
(9.3-22.8) 
11.4 
(10.6-24.7) 
0.83 
CFR 2.6 ± 0.9 3.8 ± 1.7 0.001 3.1 ± 1.5  3.1 ± 1.6 0.97 
TmnH (s) 0.33 
(0.26-0.40) 
0.25 
(0.20-0.30) 
0.01 0.27 
(0.23-0.41) 
0.31 
(0.16-0.39) 
0.64 
TmnR (s) 0.95 ± 0.43  1.03 ± 0.55 0.29 0.88 ± 0.51 0.82 ± 0.47 0.19 
FFR 0.83 ± 0.06 0.83 ± 0.07 0.99 0.82 ± 0.08  0.81 ± 0.09 0.052 
 
P values compare measurements from patients pre and post RIPC/sham treatment using the paired t test 
for parametrically distributed data or the Wilcoxon signed rank test for non-parametrically distributed 
data.  
* Patients with pre treatment FFR >0.80: RIPC, n=12; Sham, n=9. 
FFR, fractional flow reserve; CFR, coronary flow reserve; IMRcalc, calculated index of microcirculatory 
resistance; IMR, index of microcirculatory resistance; RIPC, remote ischaemic preconditioning; TmnR, 
transit time at rest; TmnH, transit time during hyperaemia; 
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a) IMRcalc 
 
 
 
b) IMR 
 
 
 
Figure 3.3 The effect of remote ischaemic preconditioning on the index of 
microcirculatory resistance 
Effect of RIPC (left panels) or sham (right panels) on IMRcalc (a) and IMR in patients with an FFR>0.8 
(b). IMRcalc: RIPC, n=15; Sham, n=15. IMR: RIPC, n=12; Sham, n=9. P values compare measurements 
from patients pre and post RIPC/sham treatment using the paired t test for parametrically distributed data 
or the Wilcoxon signed rank test for non-parametrically distributed data. 
IMRcalc, calculated index of microcirculatory resistance; IMR, index of microcirculatory resistance; FFR, 
fractional flow reserve; RIPC, remote ischaemic preconditioning; 
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There was one patient in each of the RIPC and sham groups that exhibited a very large 
reduction in IMRcalc and IMR with their respective treatments. When this patient was 
removed, the RIPC-mediated decrease in IMRcalc and IMR remained significant (Figure 
3.4).  
 
a) 
 
b) 
 
Figure 3.4 The effect of remote ischaemic preconditioning on the index of 
microcirculatory resistance – outlier removed 
Effect of RIPC on IMRcalc (a) and IMR (b) with the patient exhibiting a large drop in IMRcalc and IMR 
removed. IMRcalc, n=14; IMR, n=11; P values compare measurements from patients pre and post 
RIPC/sham treatment using the paired t test for parametrically distributed data or the Wilcoxon signed 
rank test for non-parametrically distributed data. 
IMRcalc, calculated index of microcirculatory resistance; IMR, index of microcirculatory resistance; RIPC, 
remote ischaemic preconditioning; 
 
There was a larger percentage reduction in IMRcalc with RIPC than sham (-12.6% (-41.5 
- -1.5) vs +2.8% (-19.7 - +27.1), P=0.09) but this did not reach statistical significance. A 
similar result was seen in the percentage change in IMR (-17.7% (-46.7 - -2.5) vs 2.9% 
(-28.4 - +2.9), P=0.11). 
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3.3.3 The effect of remote ischaemic preconditioning on coronary flow reserve 
In the 15 patients randomised to RIPC, there was a significant increase in CFR as 
demonstrated in Figure 3.5 and Table 3.2. There was no effect of sham treatment on 
CFR. There was a significant increase in CFR in the subgroup of patients treated with 
RIPC who had an FFR>0.8 (2.8 ± 0.9 vs 4.1 ± 1.8, P=0.002, n=12).   
 
  
Figure 3.5 The effect of remote ischaemic preconditioning on coronary flow 
reserve 
Effect of RIPC (left panel) or sham (right panel) on CFR. RIPC, n=15; Sham, n=15. P values compare 
measurements from patients pre and post RIPC/sham treatment using the paired t test for parametrically 
distributed data or the Wilcoxon signed rank test for non-parametrically distributed data. 
CFR, coronary flow reserve; RIPC, remote ischaemic preconditioning; 
 
There was a statistically significant greater percentage increase in CFR with RIPC than 
sham (+41.2% (+20.0 - +61.7) vs (-7.8% (-19.1 - +10.3), P<0.001). 
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3.3.4 The effect of remote ischaemic preconditioning on other coronary physiology 
measurements 
The changes in IMRcalc, IMR and CFR with RIPC were associated with a significant 
decrease in TmnH signifying an increase in hyperaemic coronary flow (Figure 3.6). 
Conversely, there was no change in TmnR with RIPC, suggesting no change in resting 
coronary flow (Figure 3.6). 
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a) 
 
 
 
b) 
 
 
 
 
Figure 3.6 The effect of remote ischaemic preconditioning on transit time 
Effect of RIPC (left panels) or sham (right panels) on TmnH (a) and TmnR (b). Lower values indicate an 
increase in coronary flow. RIPC, n=15; Sham, n=15. P values compare measurements from patients pre 
and post RIPC/sham treatment using the paired t test for parametrically distributed data or the Wilcoxon 
signed rank test for non-parametrically distributed data. 
TmnH, transit time during hyperaemia; TmnR, transit time during rest; RIPC, remote ischaemic 
preconditioning;  
 
Considering the other components of the IMRcalc formula, there was no effect of RIPC 
on Pd or Pa during hyperaemia or rest (Figure 3.7). The trans-lesion pressure gradient (Pa 
– Pd) did not change with RIPC either during hyperaemia (13 mmHg (10-14) vs 13 
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mmHg (11-19), P=0.37) or at rest (6 ± 4 mmHg vs 6 ± 4 mmHg, P=0.85). Associated 
with this, there was no effect of RIPC on FFR (Table 3.2). 
 
a) 
 
 
 
b) 
 
 
 
 
Figure 3.7 The effect of remote ischaemic preconditioning on distal and proximal 
mean coronary pressures 
Effect of RIPC on Pd (a) and Pa (b) measured during hyperaemia (left panels) or rest (right panels). n=15; 
P values compare measurements from patients pre and post RIPC using the paired t test for parametrically 
distributed data or the Wilcoxon signed rank test for non-parametrically distributed data. 
Pa, mean aortic (proximal coronary) pressure; Pd, mean distal coronary pressure; RIPC, remote ischaemic 
preconditioning; 
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With regards to the pulse pressure (systolic – diastolic pressure), RIPC resulted in no 
difference in the distal coronary pulse pressure or proximal coronary pulse pressure, 
either during hyperaemia or at rest (Figure 3.8). 
 
a) 
 
 
 
b) 
 
 
 
Figure 3.8 The effect of remote ischaemic preconditioning on distal and proximal 
pulse pressures 
Effect of RIPC on the distal (a) and proximal (b) coronary pulse pressure measured during hyperaemia 
(left panels) or rest (right panels). n=15; P values compare measurements from patients pre and post RIPC 
using the paired t test for parametrically distributed data or the Wilcoxon signed rank test for non-
parametrically distributed data. 
RIPC, remote ischaemic preconditioning; 
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3.3.5 The effect of remote ischaemic preconditioning on lesion characteristics as 
assessed by three dimensional quantitative coronary angiography 
There were adequate angiogram images both pre and post RIPC to perform three 
dimensional QCA in 10 patients. An example of a three dimensional reconstruction of a 
coronary artery lesion during end diastole is displayed in Figure 3.9. 
 
 
Figure 3.9 Example of a three dimensional quantitative coronary angiogram 
reconstruction of a coronary artery lesion 
An example of a three dimensional reconstruction of a coronary artery lesion at end diastole. The IC3D 
software provides measurements including the lumen area and diameter at the site of the lesion, cross-
sectional area stenosis (CS) and length of the lesion (L). 
 
Given the change in hyperaemic coronary flow with no change in trans-lesional 
pressure gradient or FFR, a change in the lesion characteristics which may give rise to a 
reduction in resistance at the site of the lesion was sought. The compliance and 
Chapter 3 
 
84 
 
distensibility at the site of the lesion was calculated with lesion measurements taken at 
end-diastole and end-systole before and after RIPC. There was no change in compliance 
(0.35 ± 0.34 vs 0.18 ± 0.27, P=0.27, n=10) or distensibility (7.49 ± 7.06 mmHg
-1
 vs 
2.64 ± 4.43 mmHg
-1
, P=0.14, n=10) as a result of RIPC. Indeed, contrary to the 
expected changes in these parameters, there was a trend towards a reduction in 
compliance and distensibility with RIPC. 
 
3.3.6 The effect of remote ischaemic preconditioning on circulating regulators of 
microcirculatory function 
To investigate potential mediators of the reduction in microcirculatory resistance and 
increase in coronary flow reserve, the levels of known regulators of the microcirculation 
were measured in stored plasma. There was no change in plasma nitrite with either 
RIPC or sham (Figure 3.10a). There was a significant reduction in plasma nitrate with 
RIPC (22.8 μmol/L (14.5-25.2) vs 21.9 μmol/L (13.7-24.3), P=0.006, n=13), however, 
this was also the case with sham treatment (23.0 ± 16.5 μmol/L vs 21.6 ± 15.5 μmol/L, 
P=0.009, n=10)   (Figure 3.10b). 
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a) 
 
 
 
b) 
 
 
 
Figure 3.10 The effect of remote ischaemic preconditioning on plasma nitrite and 
nitrate 
Plasma nitrite (a) and nitrate (b) concentrations in stored plasma pre and post RIPC (left panels) and sham 
(right panels) measured with a commercially available ELISA kit as per manufacturer guidelines. RIPC, 
n=13; Sham, n=10; P values compare measurements from patients pre and post RIPC/sham treatment 
using the paired t test for parametrically distributed data or the Wilcoxon signed rank test for non-
parametrically distributed data. 
ELISA, enzyme-linked immunosorbent assay; RIPC, remote ischaemic preconditioning; 
 
Measurement of other factors, which are known to induce a vasodilatory response in the 
microcirculation, in stored plasma samples demonstrated a significant decrease in in 6-
keto-PGF1α with RIPC (845.9 pg/mL (298.4-1374.0) vs 576.9 pg/mL (254.5-1282.0), 
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P=0.02, n=11) with no effect of sham treatment (Figure 3.11). Plasma adrenomedullin 
levels were unchanged by either RIPC or sham treatment (Figure 3.12). 
 
  
Figure 3.11 The effect of remote ischaemic preconditioning on plasma 6-keto-
PGF1α 
Plasma 6-keto-PGF1α concentrations in stored plasma pre and post RIPC (left panel) or sham (right 
panel) measured with a commercially available ELISA kit as per manufacturer guidelines. RIPC, n=11; 
Sham, n=10; P values compare measurements from patients pre and post RIPC or sham treatment using 
the paired t test for parametrically distributed data or the Wilcoxon signed rank test for non-
parametrically distributed data. 
ELISA, enzyme-linked immunosorbent assay; RIPC, remote ischaemic preconditioning; 
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Figure 3.12 The effect of remote ischaemic preconditioning on plasma 
adrenomedullin 
Plasma adrenomedullin concentrations in stored plasma pre and post RIPC (left panel) or sham (right 
panel) measured with a commercially available ELISA kit as per manufacturer guidelines. RIPC, n=13; 
Sham, n=7; P values compare measurements from patients pre and post RIPC or sham treatment using the 
paired t test for parametrically distributed data or the Wilcoxon signed rank test for non-parametrically 
distributed data. 
ELISA, enzyme-linked immunosorbent assay; RIPC, remote ischaemic preconditioning; 
 
3.4 Discussion 
 
RIPC has been shown to confer cardioprotection to patients undergoing elective and 
primary PCI with reductions in post PCI troponin and infarct size (14,74,76) yet the 
mechanism remains unknown (148).  This study has demonstrated that RIPC acutely 
improves coronary microcirculatory function as assessed by validated coronary 
pressure/temperature sensor wire based techniques. In this cohort of patients with 
coronary artery disease, RIPC was associated with a significant reduction in 
microcirculatory resistance as measured by the IMR and an increase in coronary flow 
reserve, both contributed to by a reduction in hyperaemic transit time indicating an 
increase in coronary flow. 
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The coronary microcirculation is recognised as an important determinant of prognosis in 
patients with CAD. Multiple studies have shown the utility of the CFR to predict 
cardiac events and may be of greater importance than the degree of disease in the 
epicardial coronary arteries in determining prognosis (140,142,149-151). The IMR 
predicts post PCI myocardial infarction after elective PCI and the occurrence of death 
and heart failure hospitalisation after primary PCI (143,144). Given the importance of 
these markers of microcirculatory function in predicting prognosis in patients with 
CAD, including those undergoing PCI, and the benefits of RIPC in patients undergoing 
PCI, a randomised blinded placebo controlled trial was conducted to determine the 
effect of RIPC on the IMR and CFR. RIPC led to a rapid reduction in the index of 
microcirculatory resistance and an increase in coronary flow reserve with no effect of 
sham treatment. This suggests that beneficial effects on the coronary microcirculation 
contribute to RIPC mediated cardioprotection during PCI. These results were supported 
by the percentage change analysis between RIPC and sham groups. However, the 
difference in percentage change in IMRcalc and IMR did not reach statistical significance 
likely due to the study being underpowered to demonstrate a difference with these 
measures. 
The results of this study raise the possibility that RIPC may be beneficial in other 
clinical settings where microcirculatory dysfunction is important such as microvascular 
angina, congestive heart failure and aortic stenosis (152,153).   
There is data supporting the role of the coronary microcirculation as a target of RIPC 
mediated cardioprotection (154). In a study by Kono et al (69), 10 healthy volunteers 
and 10 patients with heart failure who received RIPC twice per day for 1 week 
demonstrated an increase in CFR as assessed by echocardiographic spectral Doppler 
analysis of flow in the distal left anterior descending artery. Additionally, RIPC has 
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been shown to attenuate vasoconstriction after acetylcholine administration, which is a 
marker of endothelial dysfunction (70). The endothelium is an important component of 
the microcirculation and plays a central role in the regulation of flow and resistance 
(145). 
However, there is conflicting evidence regarding the effects of RIPC on the coronary 
microcirculation. Studies of RIPC in the setting of primary PCI, despite demonstrating 
reduction in myocardial injury, have reported no changes in surrogate markers of 
microcirculatory function such as the TIMI frame count and the appearance of 
microvascular obstruction on magnetic resonance imaging (74,76). Additionally, a 
study by Hoole et al found that RIPC had no effect on coronary microvascular 
resistance in 11 patients assessed by a Doppler/pressure wire based technique requiring 
coronary balloon inflation during cardiac catheterisation (15). The null result in this 
study may have been due to local preconditioning, or distal embolisation, induced by 
the coronary balloon inflation. There was a small numerical increase in the 
microcirculatory resistance after coronary balloon inflation in patients who did not 
undergo RIPC in this study, but the study may have been underpowered to detect a 
statistically significant difference.  
In the present study, there was no change in TmnR, suggesting that RIPC does not affect 
resting coronary flow. However there was an increase in hyperaemic flow, indicated by 
a reduction in TmnH, in the absence of change in distal or proximal coronary pressures or 
a change in FFR. This increase in hyperaemic flow supports the interpretation that RIPC 
reduces coronary microcirculatory resistance. The increase in coronary flow in the 
absence of a change in trans-lesional gradient is interesting as an increase in the 
gradient might have been expected. A possible explanation for this is the modest cohort 
size, possibly leading to the study being underpowered to detect a change in gradient. 
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Alternatively, it was hypothesised that there may have been a change in the lesion 
characteristics, leading to a reduction in resistance to flow at the site of the lesion. 
Hence the angiograms were reconstructed with three dimensional QCA to calculate the 
compliance and distensibility of the vessel at the site of the lesion, which may have 
been expected to increase with RIPC. A comparison of measurements before and after 
RIPC did not demonstrate any significant change in either of these measurements. This 
result should be interpreted in the context of the modest cohort size and also the fact 
that the angiogram images, which were used to perform the three dimensional 
reconstructions, were taken during resting conditions. The changes in flow were 
observed during hyperaemia and changes in lesion characteristics during hyperaemia 
may not be reflected in angiogram images obtained at rest. 
Considering the mechanism behind the rapid enhancement of microcirculatory function 
caused by RIPC, given evidence in the literature for circulating mediators, factors 
known to control the human microcirculation were studied in stored plasma taken 
before and after RIPC/sham. Adenosine and nitric oxide (metabolised to nitrite and 
nitrate) contribute to the coronary microcirculatory tone, and as they have been 
implicated in RIPC mediated cardiac protection (31,34,42,155), are candidate mediators 
of the effects of RIPC on microcirculatory resistance and flow that were observed. 
However, given the high doses of adenosine and intracoronary glyceryl trinitrate that 
were given at the time of each coronary physiology study to achieve hyperaemia, it is 
unlikely that these mediators are primarily responsible for the effects that were 
identified. The lack of change in plasma nitrite levels, the major metabolite of nitric 
oxide, with RIPC supports this conclusion with respect to nitric oxide. Although the 
measured level of nitrate in plasma was reduced after RIPC, there was a similar effect 
with sham treatment and hence this result is likely to be an artefact.  
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Prostacyclin is known to lead to vasodilation in the coronary vasculature, with 6-keto-
PGF1α a stable metabolite (156,157). We hypothesised an increase in prostacyclin may 
contribute to the effect of RIPC, however there was a reduction in plasma6-keto-PGF1α 
with RIPC without a change with sham. This result suggests reduced prostacyclin the in 
the circulation which is unexpected given the increase in coronary flow demonstrated. 
Adrenomedullin is another hormone that is known to enhance microcirculatory function 
and has been identified as a potential mediator of RIPC induced protection in an animal 
model of IR injury (147,158). Adrenomedullin augments vascular tone, vasodilation and 
endothelial function through the regulating of cAMP, cGMP and intracellular calcium 
mobilisation (159). Contrary to  animal data suggesting an upregulation of 
adrenomedullin in response to RIPC (147), there was no change in plasma 
adrenomedullin levels with RIPC in the present study suggesting that this hormone is 
not contributing to the changes in microcirculatory function that were observed. 
A range of other candidate mediators remain unexplored in this study. Other mediators 
and pathways implicated in cardiac preconditioning include bradykinin, potassium ATP 
channels and calcium activated potassium channels of the BK type (24,66,160). As 
potassium ATP channels are involved in RIPC mediated protection against IR injury 
associated endothelial dysfunction (24), they may play a role in the improved 
microcirculatory function observed and warrant future investigation.   
There are some limitations with the present study. Due to the relatively small numbers, 
it was not possible to investigate for clinical characteristics that predict an improvement 
in coronary microcirculatory function in response to RIPC. Additionally, due to the 
modest numbers, despite randomisation, there were some minor differences in the 
baseline characteristics of the study cohorts. There were numerically more patients with 
diabetes mellitus in the RIPC cohort. However, there is a suggestion of reduced efficacy 
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of RIPC in patients with diabetes (85,161) and hence, this difference between the 
cohorts, if anything, may have biased the study towards a null result. These minor 
differences along with the relatively small cohort size may have also led to differences 
in the pre treatment levels of IMRcalc, IMR and CFR, as well as plasma factors such as 
6-keto-PGF1α. The lesion reference vessel diameter was also numerically larger in the 
RIPC group than the sham group. In a subgroup analysis, matched for vessel reference 
diameter, the effect of RIPC on IMR and CFR were still apparent (data not shown).  
These minor difference in pre treatment measures are unlikely to have influence the 
overall results as the primary analysis was a paired comparison of coronary physiology 
measurements or plasma marker taken before and after RIPC/sham, however it is not 
possible to exclude that this confounded the results. 
It is difficult to comment on the durability of the RIPC effect and to be certain that the 
maximal effect on microcirculatory resistance and flow reserve has been identified. 
Performing a third coronary physiology study at a later time point was ethically difficult 
to justify given the invasive nature of the measurements. Due to the administration of 
glyceryl trinitrate, additional assessments of endothelial function, such as response to 
acetylcholine administration, could not be performed in this study. Finally, as this was a 
mechanistic study with only small numbers of patients undergoing PCI, clinical 
outcomes and the correlation of microcirculatory change with change to post PCI 
troponin were not assessed. The results of this study indicate the need for a study 
correlating change in coronary microcirculatory status and clinical outcomes with RIPC. 
 
 
 
 
Chapter 3 
 
93 
 
3.5 Conclusions 
 
Remote ischaemic preconditioning rapidly decreases the index of microcirculatory 
resistance and increases the coronary flow reserve, suggesting an enhancement of 
microcirculatory function. This suggests that RIPC confers cardioprotection during PCI 
as a result of an improvement in coronary microcirculatory function. The application of 
RIPC to augment the coronary microcirculation in other clinical settings demonstrating 
microcirculatory dysfunction also warrants investigation. 
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Chapter 4: The effect of remote ischaemic preconditioning on 
traditional markers of platelet activation 
 
4.1 Introduction 
 
As discussed in chapter 1, RIPC at the time of primary and elective PCI has been shown 
to be associated with reduced myocardial injury and reduced thrombotic events during 
follow up (13,14,74,78). Platelets play an important pathological role in the occlusion of 
the coronary artery lumen, obstructing coronary blood flow and leading to acute 
coronary syndromes (ACS) with associated morbidity and mortality. Hence, inhibition 
of platelet activity is an important treatment strategy (3,4,162). Upon this basis, a study 
was conducted to explore the effects of RIPC on platelet activity, in a population being 
investigated and treated for potential CAD. 
As summarised in section 1.2.4, RIPC has been shown to reduce platelet activity as 
determined by flow cytometry based analysis of surface markers of activation. In the 
previously performed studies, with the exception of the study by Lanza et al. (57), 
participants were either taking aspirin (most studies) or no antiplatelet medications, and 
few have investigated the effects of RIPC in patients taking P2Y12 inhibitors. The effect 
of RIPC on the activation of GPIIb-IIIa has not previously been investigated. 
Additionally, the effects of RIPC after exposure of platelets to agonists other than ADP, 
such as thrombin and collagen, which are particularly relevant at the site of coronary 
atherosclerotic plaques, has not been investigated. Given the proposed benefits of RIPC 
in the setting of elective and primary PCI, where DAPT is commonly used, establishing 
the effects of RIPC on platelet activation in the presence of DAPT is important and has 
not been established.  
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The aims of the studies presented in this chapter were to investigate the effect of RIPC 
on specific pathways of platelet activation under basal conditions and in response to 
ADP, SFLLRN (thrombin receptor PAR-1 agonist), thrombin and a combination of 
thrombin and collagen. Given the contextual importance of antiplatelet therapy in the 
clinical studies demonstrating a benefit of RIPC, the present studies investigated the 
effects of RIPC in patients recruited from the cardiac catheterisation laboratory, with 
suspected CAD, taking contemporary antiplatelet therapy, with a significant number of 
patients on DAPT. As the aim of this study was to investigate resting and soluble 
agonist-mediated effects on platelet activation, all platelet studies were performed on 
samples taken prior to cardiac catheterisation so that there was no confounding by the 
procedure itself.  
 
4.2 Methods 
 
4.2.1 Remote ischaemic preconditioning and markers of platelet activation 
Patients referred by their physician for non-urgent coronary angiography at Concord 
Hospital, Sydney, Australia, with symptoms or non-invasive investigations suggestive 
of significant CAD, were invited to participate as described in chapter 2. Patients were 
randomised in a 1:1 ratio to receive RIPC or sham treatment prior to their planned 
procedure as described in section 2.1 (randomised platelet cohort). Venous blood was 
collected before and immediately after the allocated treatment as described in section 
2.4. The blood samples were processed within 20 min of collection. Patients and 
investigators processing the blood samples were blinded to patient treatment allocation. 
The study design is summarised in Figure 4.1. This cohort was separate from the cohort 
described in chapter 3. 
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An additional cohort of patients presenting for coronary angiography were recruited to 
investigate the changes in intracellular phosphorylated-VASP, cAMP and cGMP 
(intracellular platelet cohort). These patients all received RIPC with blood collected 
before and after treatment as in the randomised cohort. 
 
 
Figure 4.1 Patient recruitment and randomisation – Randomised platelet cohort 
Patients with suspected CAD, referred for cardiac catheterisation, were approached prior to their planned 
procedure. After informed consent was obtained, patients were randomised to RIPC or sham treatment 
with blood collected before and after the allocated treatment. All blood samples were collected prior to 
cardiac catheterisation. 
CAD, coronary artery disease; RIPC, remote ischaemic preconditioning; 
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4.2.2 Assessment of platelet activation 
Unless otherwise stated, the assessment of platelet activation was performed in whole 
blood collected into tubes containing either sodium citrate or hirudin. Blood samples 
collected before and after RIPC/sham were processed in the same manner.  
 
4.2.2.1 Surface markers 
As described in detail in section 2.5.1, platelet CD62P expression, CD63 expression and 
PAC-1 binding (conformationally active GPIIb-IIIa) were quantified in whole blood 
collected with sodium citrate as the anticoagulant (119,125). The expression of these 
markers was quantified by flow cytometry as previously described (116,126). In brief, 
whole blood was added to reaction mixes of DPBS with and without agonists ADP 
(final concentration, 5 μM), protease-activated receptor-1 (PAR-1) agonist (SFLLRN, 
20 μM), thrombin (2 U/mL) ± collagen (10 μg/mL). H-Gly-Pro-Arg-Pro-OH (173 
μg/mL) was added to thrombin containing reaction mixes to minimise fibrinogen 
aggregation and fibrin polymerisation. Reaction mixes were immediately added to 
FACS tubes containing isotype control antibodies and antibodies to CD61, CD62P, 
CD63 or PAC-1. After incubation at room temperature for 20 min, the samples were 
fixed with 0.16 % paraformaldehyde in saline before immediate analysis by flow 
cytometry on a BD FACSCalibur with 10,000 platelet gated events, based on light 
scatter characteristics, acquired for each analysis. The isotype control was used to 
determine positive events on the basis of a 0.5% background expression. Levels of 
CD62P and CD63 expression and PAC-1 binding were then quantified as a percentage 
of total platelets.  
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4.2.2.2 Platelet aggregometry 
Platelet aggregometry was performed with blood collected into hirudin containing tubes 
with a Multiplate analyser. ADP (6.67 μM) and arachidonic acid (1 mM) were used as 
agonists for aggregometry and results are presented as a mean of the duplicate 
measurements expressed as area under the curve (AUC).  
 
4.2.2.3 Assessment of platelet-leukocyte aggregates 
As described in section 2.5.5, the reaction mixtures of whole blood containing 5 μM 
ADP, 20 μM SFLLRN, 2 U/mL Thrombin, with H-Gly-Pro-Arg-Pro-OH (173 μg/mL) 
added to the thrombin reaction mix, were used to assess PLAs. These were added to 
FACS tubes containing an isotype control antibody and antibodies to CD45 and CD42b. 
After incubation at room temperature for 20 min, the samples were fixed with a 
combination of paraformaldehyde, Hank’s buffered salt solution and water. After a 
further 10 min, water was added to stabilise the osmotic balance and lyse the 
erythrocytes. The samples were analysed by flow cytometry with 1000 monocyte gated 
events, based on light scatter characteristics and CD45 expression, acquired for each 
analysis. The isotype control was used to determine positive events based on 0.5% 
background expression. The proportion of monocyte and granulocyte events, based on 
light scatter characteristics and the leukocyte marker CD45, which expressed the 
platelet marker CD42b were quantified. The percentage of platelet-leukocyte aggregates 
was expressed as a percentage of total events.  
 
4.2.3 Assessment of circulating regulators of platelet function 
Stored plasma from the randomised platelet cohort was used to assess the effect of 
RIPC on circulating regulators of platelet function. The plasma was analysed with the 
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following commercially available kits as per the manufacturers’ instructions: cAMP 
Parameter Assay, cGMP Parameter Assay and Total Nitric Oxide and Nitrate/Nitrite 
(R&D Systems), Prostacyclin (MyBioSource, San Diego, California, USA), and 6-keto-
PGF1α (Abcam, Cambridge, United Kingdom). The ELISA plates were analysed with 
an EnSpire Multimode Plate Reader (Perkin Elmer, Waltham, Massachusetts, USA) 
with the concentration of each sample determined from a standard curve derived 
according to the manufacturer’s guidelines. 
 
4.2.4 Intracellular VASP and phosphorylated-VASP assessment 
The intracellular regulatory protein VASP, is known to inhibit GPIIb-IIIa activation in 
its phosphorylated form (163,164). Platelet pellet lysates stored with a mixture of 
Mammalian Protein Extraction Reagent, protease inhibitor mix and PhosSTOP, 
prepared from PRP collected before and after RIPC/sham as described in section 2.8, 
were used to assess intracellular VASP and phosphorylated-VASP.  Lysates prepared 
from platelets under basal conditions and after SFLLRN stimulation were analysed in 
the same manner. The bicinchoninic acid (BCA) protein assay (Thermofisher) was used 
to measure protein concentrations in the platelet lysates with this data used to load equal 
quantities of protein onto 4–12% bis–Tris gels (Thermofisher). The iBlot transfer 
apparatus (Thermofisher) was used to transfer proteins to nitrocellulose membranes. 
The membranes were blocked by incubation in Tris-buffered saline containing 0.1% 
(v/v) Tween-20 and 4% (w/v) bovine serum albumin for 60 min. Membranes were 
probed with antibodies against VASP (Cell Signalling Technology, Danvers, 
Massachusetts, USA) or phosphorylated-VASP (Cell Signalling Technology) overnight 
at 4 °C, followed by anti-rabbit horseradish peroxidase-conjugated secondary antibodies 
(Jackson ImmunoResearch, West Grove, Pennsylvania, USA) for 1 h. Blots were 
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visualised using enhanced chemiluminescence reagents and the Gel Doc XR + CCD 
imaging system (BioRad, Hercules, California, USA). Images were acquired before 
signal saturation occurred. Densitometric quantitation and estimation of apparent 
molecular mass of bands were performed using the ImageLab v4.1 software (BioRad).  
 
4.2.5 Intracellular cAMP and cGMP assessment 
Platelet pellet lysates prepared from blood collected before and after RIPC were stored 
with a cell lysis buffer from the cAMP and cGMP Parameter Assay Kits (R&D 
Systems) as described in section 2.8. These platelet lysates were used to assess changes 
in cAMP and cGMP with RIPC treatment. The platelet lysates were analysed with 
cAMP and cGMP ELISA kits as per the manufacturers’ instructions. The samples were 
diluted aiming for a platelet count of 1 x 10
7
/mL as recommended by the manufacturer. 
The optical absorbance of each well in the ELISA plates was assessed with an EnSpire 
Multimode Plate Reader (Perkin Elmer, Waltham, Massachusetts, USA) with the 
concentration of each sample determined from a standard curve. 
 
4.2.6 Statistical analysis 
Categorical variables are presented as frequency and percentage while continuous 
variables are expressed as mean ± SD for parametrically distributed data and median 
(IQR) for non-parametrically distributed data. Data distribution was assessed with the 
D’Agostino and Pearson normality test.  Categorical data were compared using 𝜒2 tests 
or Fisher’s exact test as appropriate. Comparisons between continuous variables were 
performed using paired or unpaired t tests as appropriate for parametrically distributed 
data, and Wilcoxon signed rank or Mann-Whitney U tests as appropriate for non-
parametric data. Correlations between variables were assessed by Pearson’s correlation 
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or Spearman rank correlation for parametric and non-parametric data respectively. 
Ratios of post-treatment to pre treatment parameters were assessed with a one sample t 
test. The pre- and post-treatment expression of markers of platelet activation were 
compared in patients randomised to RIPC or sham treatment. The percentage change 
(section 2.9) in the RIPC cohort was compared with the percentage change with sham 
using the Mann-Whitney U test in analyses where the paired comparison demonstrated 
an effect of RIPC. 
Based on preliminary data collected from 10 patients who underwent the RIPC study 
protocol in a non-randomised fashion prior to commencement of the randomised study, 
an absolute reduction in PAC-1 binding after agonist stimulation of 7.4% ± 9.8% (mean 
± SD) was expected with RIPC. With a power of 80% and a two-sided α value of 0.05, 
it was estimated that 27 patients would need to be studied for paired comparison. 
Hence, in the randomised platelet cohort, 60 patients were recruited and randomised in a 
1:1 fashion to receive either RIPC or sham treatment.  
 
4.3 Results 
 
There were 60 patients recruited into the randomised platelet cohort with 31 randomised 
to the RIPC group and 29 to the sham group. The intracellular platelet cohort consisted 
of another 18 patients who were all treated with RIPC to study mechanistic aspects of 
intracellular signalling pathways. There were no complications of RIPC. All patients 
tolerated RIPC well with no patients requesting cessation of the treatment protocol.   
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4.3.1 Baseline clinical characteristics 
The randomised cohort had a mean age of 63.3 ± 13.2 yr and consisted of 51 (85%) 
male patients. The cohort had 52 (87%) patients who were clinically stable, 43 (72%) 
were on dual antiplatelet therapy with aspirin and a P2Y12 inhibitor (DAPT), 6 (10%) 
were on intravenous heparin and 48 (80%) were found to have significant coronary 
artery disease based on their coronary angiogram. This was determined by the presence 
of at least 50% stenosis in a major epicardial coronary artery based on 2 dimensional 
QCA.  There was no significant difference between the RIPC and sham groups in terms 
of baseline characteristics and medications (Table 4.1). There was a trend towards lower 
haemoglobin concentration in the sham group but this is unlikely to have affected the 
results given the primary analysis was a paired comparison of platelet activation 
markers before and after treatment within each group.  
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Table 4.1 Baseline characteristics of randomised platelet cohort 
Characteristic RIPC 
(n=31) 
Sham 
(n=29) 
P value 
Age - years 64.0 ± 6.9 62.6 ± 17.8 0.70 
Male – no. (%) 28 (90) 23 (79) 0.23 
Clinically stable – no. (%) 27 (87) 25 (86) 0.92 
Significant CAD – no. (%) 25 (81) 23 (79) 0.90 
Prior myocardial infarction – no. (%) 8 (26) 8 (28) 0.88 
Prior PCI – no. (%) 7 (23) 8 (28) 0.66 
Prior CABG- no. (%) 1 (3) 1 (3) 0.96 
Heart failure – no. (%) 2 (7) 2 (7) 0.95 
Prior stroke – no. (%) 1 (3) 3 (10) 0.27 
Peripheral vascular disease – no. (%) 2 (7) 2 (7) 0.95 
Hypertension – no. (%) 20 (65) 21 (72) 0.51 
Diabetes – no. (%) 11 (36) 11 (38) 0.84 
Dyslipidaemia – no. (%) 20 (65) 22 (76) 0.34 
Current smoking – no. (%) 5 (16) 7 (24) 0.44 
Medications*     
Aspirin – no. (%) 30 (97) 27 (93) 0.51 
P2Y12 antagonist – no. (%) 21 (68) 23 (79) 0.31 
Clopidogrel – no. (%) 14 (45) 18 (62) 0.19 
Ticagrelor – no. (%) 6 (19) 4 (14) 0.56 
Prasugrel – no. (%) 1 (3) 1 (3) 0.96 
Dual antiplatelet therapy – no. (%) 21 (68) 22 (76) 0.49 
Warfarin/ NOAC – no. (%) 0 (0) 0 (0) - 
Heparin – no. (%) 3 (10) 3 (10) 0.93 
Statin – no. (%) 22 (71) 25 (86) 0.15 
Beta blocker – no. (%) 17 (55) 16 (55) 0.98 
ACEi or ARB – no. (%) 19 (61) 18 (62) 0.95 
Nitrate – no. (%) 7 (23) 5 (17) 0.61 
Parameters during admission    
Systolic blood pressure – mmHg 141.5 ± 21.2 142.3 ± 21.1 0.89 
Heart rate – beats/min 67.9 ± 10.4 71.7 ± 8.3 0.13 
Haemoglobin concentration – g/L 141.9 ± 14.7 133.5 ± 18.0 0.052 
Platelet count – 109/L 223.6 ± 58.7 229.5 ± 71.2 0.73 
eGFR - mL/min/1.73m
2
 81.5 ± 10.8 76.2 ± 15.4 0.13 
 
P values compare characteristics from RIPC and sham treatment groups using unpaired t tests for 
continuous data. Categorical data were compared using 𝜒2 tests or Fisher’s exact test as appropriate. 
* The number of patients on dual antiplatelet therapy, aspirin monotherapy, P2Y12 monotherapy and no 
antiplatelet therapy in the RIPC and sham groups were 21, 9, 0, 1 and 22, 5, 1, 1 respectively.  
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary 
artery bypass grafting; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; NOAC, 
novel oral anticoagulant; PCI, percutaneous coronary intervention;  
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4.3.2 Patients undergoing coronary angiography demonstrate substantial platelet 
activation despite antiplatelet therapy  
Examining the baseline (pre RIPC/sham) data in the whole randomised cohort (n=60), it 
was evident that there was substantial residual platelet activation in response to all 
agonists despite the administration of DAPT (Figure 4.2). Patients receiving DAPT 
(n=43, 31 clopidogrel, 10 ticagrelor, 2 prasugrel) had significantly less PAC-1 binding 
to unstimulated circulating platelets (basal), and less PAC-1 binding in response to 
stimulation with ADP and SFLLRN, compared to patients receiving aspirin alone 
(n=14). However, there were similarly high levels of PAC-1 binding in response to 
thrombin alone and to thrombin and collagen in patients on DAPT and in patients on 
aspirin alone, indicating significant levels of GPIIb-IIIa activation (Figure 4.2a). 
Similarly, DAPT therapy was also associated with reduced CD62P and CD63 
expression after stimulation with ADP, however CD62P and CD63 expression after 
thrombin and thrombin and collagen appeared to be  unaffected by the administration of 
DAPT (Figure 4.2b and 4.2c). Analysis of the pre RIPC/sham platelet aggregometry 
results demonstrated that patients on DAPT had significantly lower levels of platelet 
aggregation after stimulation with ADP. A similar trend was seen in response to 
arachidonic acid, but this did not reach significance (Figure 4.3).    
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a) 
 
b) 
 
c) 
 
 
Figure 4.2 Platelet activation in response to agonist stimulation, stratified by 
antiplatelet therapy 
Data from pre RIPC/sham platelet analysis. Comparison of platelet activation markers, PAC-1 binding 
(a), CD62P expression (b) and CD63 expression (c), without agonist stimulation (basal) and with agonist 
stimulation in patients on aspirin monotherapy or DAPT. Aspirin monotherapy, n=14; DAPT, n=43; 
Symbol and bars represent mean ± SD. P values compare measurements from patients on aspirin or 
DAPT using the unpaired t test for parametrically distributed data or the Mann-Whitney U test for non-
parametrically distributed data. 
ADP, adenosine diphosphate; DAPT, dual antiplatelet therapy; T+C, thrombin and collagen; SFLLRN, 
PAR-1 agonist;  
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Figure 4.3 Platelet aggregometry in response to agonist stimulation, stratified by 
antiplatelet therapy 
Data from pre RIPC/sham platelet analysis. Comparison of platelet aggregometry in response to ADP or 
AA in patients on aspirin monotherapy or DAPT. Aspirin monotherapy, n=14; DAPT, n=43; Symbol and 
bars represent mean ± SD. P values compare measurements from patients on aspirin or DAPT using the 
unpaired t test for parametrically distributed data or the Mann-Whitney U test for non-parametrically 
distributed data. 
AA, arachidonic acid; ADP, adenosine diphosphate; DAPT, dual antiplatelet therapy;  
 
4.3.3 The effect of remote ischaemic preconditioning on resting and agonist-induced 
binding of PAC-1 and expression of CD62P and CD63 
The results of the flow cytometry analyses of paired blood samples collected from the 
RIPC-and sham-treated groups are displayed in Table 4.2.  
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Table 4.2 The effect of remote ischaemic preconditioning and sham treatment on 
surface platelet activation markers in response to agonists 
Marker* RIPC (n=31) Sham (n=29) 
 Pre Post P Pre Post P 
Basal 
PAC-1  0.6 (0.3-1.4)  0.6 (0.4-1.1) 0.56 0.6 (0.4-1.2) 0.8 (0.3-1.9) 0.38 
CD62P  3.9 (3.4-7.7) 5.0 (3.6-7.4) 0.22 5.9 (3.4-8.2) 5.6 (3.9-8.6) 0.63 
CD63  2.0 (1.1-2.8) 1.7 (1.3-3.2) 0.29 2.7 (1.3-3.6) 2.4 (1.5-3.6) 0.90 
5 μM ADP 
PAC-1 49.1  
(31.5-74.6) 
45.8 
(22.8-69.8) 
0.14 49.1 ± 23.1 49.9 ± 20.7 0.67 
CD62P  51.8 
(28.8-71.6) 
53.2  
(35.9-74.1) 
0.26 56.6 ± 22.9 55.9 ± 24.0 0.59 
CD63  3.5  
(1.6-8.5) 
4.7  
(2.3-10.8) 
0.01 6.2  
(3.2-8.8) 
5.2  
(2.2-10.8) 
0.80 
20 μM SFLLRN 
PAC-1  50.4  
(31.3-73.2) 
49.3  
(23.0-67.7) 
0.002 49.1 ± 22.5  47.5 ± 21.7 0.38 
CD62P  93.7 
(87.5-95.9) 
94.2 
(87.9-95.6) 
0.22 93.9 
(91.3-95.3) 
94.2 
(89.5-95.1) 
0.65 
CD63  65.4  
(50.9-70.8) 
67.1 
(50.1-72.8) 
0.14 65.8 
(55.0-69.2) 
  66.4 
(59.7-71.9) 
0.11 
2 U/mL thrombin 
PAC-1  78.7 
(70.3-89.7) 
83.5 
(63.8-90.2) 
0.92 82.2 
(76.2-88.2) 
86.0 
(72.1-89.7) 
0.81 
CD62P  94.6 
(91.8-96.7) 
95.5 
(92.0-96.5) 
0.36 95.0 
(90.5-96.0) 
94.6  
(92.0-96.4) 
0.16 
CD63  77.8 
(66.1-82.8) 
74.7 
(63.5-83.7) 
0.61 77.2  
(70.6-83.1) 
78.1 
(74.3-83.6) 
0.26 
2 U/mL thrombin and 10 μg/mL collagen 
PAC-1  79.5 ± 11.9 68.9 ± 22.5 <0.001 82.9  
(68.6-87.0) 
85.5 
(65.9-87.9) 
0.80 
CD62P  94.0 
(89.5-96.1) 
93.7 
(91.2-95.6) 
0.88 94.1 
(87.5-95.3) 
92.4 
(89.1-95.4) 
0.32 
CD63  75.8 
(63.6-80.7) 
74.7 
(52.3-79.9) 
0.35 74.4 
(66.4-79.1) 
73.1 
(64.0-82.6) 
0.98 
 
P values compare measurements from patients pre and post RIPC/sham treatment using the paired t test or 
the Wilcoxon signed rank test for parametrically and non-parametrically distributed continuous data 
respectively.  
* Values represent percentage (%) PAC-1 binding or percentage CD62P and CD63 expression. 
ADP, adenosine diphosphate; RIPC, Remote ischaemic preconditioning; SFLLRN, PAR-1 agonist;  
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4.3.3.1 PAC-1 
RIPC treatment had no significant effect on the percentage of unstimulated platelets 
expressing the conformationally active form of GPIIb-IIIa (PAC-1 binding). There was 
also no effect of RIPC on PAC-1 binding in response to ADP. However, RIPC did 
decrease GPIIb-IIIa active conformational change in response to stimulation with 
SFLLRN (50.4% (31.3-73.2) vs 49.3% (23.0-67.7), P=0.002) and after stimulation with 
thrombin and collagen (79.5 ± 11.9% vs 68.9 ± 22.5%, P<0.001). In contrast, there was 
no effect of sham treatment on PAC-1 binding in unstimulated conditions or in response 
to agonists (Figure 4.4). Interestingly, despite the attenuation of GPIIb-IIIa activation in 
response to SFLLRN and thrombin and collagen, RIPC had no effect on PAC-1 binding 
induced by thrombin alone.  
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a) 
 
 
 
b) 
 
 
 
c) 
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d)
 
 
 
e) 
 
 
 
 
Figure 4.4 The effect of remote ischaemic preconditioning on glycoprotein IIb-IIIa 
conformational activation  
Effect of RIPC (left panels) or sham (right panels) on PAC-1 binding without stimulation (basal) (a) and 
in response to ADP (b), SFLLRN (c), thrombin (d) and thrombin and collagen (e). RIPC, n=31 patients; 
Sham, n=29 patients; P values compare measurements from patients pre and post RIPC/sham treatment 
using the paired t test for parametrically distributed data or the Wilcoxon signed rank test for non-
parametrically distributed data. 
ADP, adenosine di-phosphate; RIPC, remote ischaemic preconditioning; T+C, thrombin and collagen; 
SFLLRN, PAR-1 agonist; 
 
Chapter 4 
 
111 
 
There was a significantly greater percentage reduction in PAC-1 binding in response to 
thrombin and collagen with RIPC than sham (-7.1% (-27.6 - +1.9) vs +0.5% (-3.9 - 
+4.8), P=0.009). Similarly there was a greater percentage reduction in PAC-1 binding in 
response to SFLLRN with RIPC than sham (-6.6% (-18.1 - +1.0) vs -0.1% (-18.1 - 
+14.1), P=0.07) but this did not reach statistical significance. 
The attenuation of GPIIb-IIIa activation by RIPC was also observed in the subgroup of 
patients receiving DAPT (n=21). In these patients there was a significant reduction in 
PAC-1 binding in response to SFLLRN (43.0 ± 20.9% vs 38.1 ± 21.6%, P=0.008) and 
thrombin and collagen (78.8 ± 10.9% vs 67.8 ± 24.1%, P=0.005) by RIPC (Figure 4.5).  
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Figure 4.5 The effect of remote ischaemic preconditioning on glycoprotein IIb-IIIa 
conformational activation in patients on dual antiplatelet therapy 
The effect of RIPC on platelet PAC-1 binding under basal conditions and in response to stimulation with 
ADP, SFLLRN, thrombin, and thrombin and collagen in patients on dual antiplatelet therapy. n=21. P 
values compare measurements from patients pre and post RIPC treatment using the paired t test for 
parametrically distributed data or the Wilcoxon signed rank test for non-parametrically distributed data. 
ADP, adenosine diphosphate; DAPT, dual antiplatelet therapy; RIPC, remote ischaemic preconditioning; 
T+C, thrombin and collagen; SFLLRN, PAR-1 agonist;  
 
In the 8 patients on aspirin monotherapy, RIPC was also associated with a significant 
reduction in PAC-1 binding after stimulation with thrombin and collagen (80.7 ± 15.5% 
vs 69.5 ± 19.7%, P=0.048) and a trend towards a decrease after stimulation with 
SFLLRN (66.9 ± 18.6% vs 64.0 ± 21.0%, P=0.08).  
Coronary angiography demonstrated >50% luminal stenosis in at least one epicardial 
coronary artery in 25 (81%) patients in the RIPC cohort. In these patients with 
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significant CAD, there was an attenuation of GPIIb-IIIa activation in response to 
SFLLRN and thrombin and collagen (Figure 4.6). In the remaining 6 patients treated 
with RIPC, there was a trend towards reduced PAC-1 binding in response to SFLLRN 
(71.8% (23.5-83.8) vs 66.2 (15.0-82.2), P=0.09) and thrombin and collagen (87.0% 
(78.2-90.2) vs 81.7% (61.8-87.6), P=0.16). 
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Figure 4.6 The effect of remote ischaemic preconditioning on glycoprotein IIb-IIIa 
conformational activation in patients with significant coronary artery disease 
The effect of RIPC on platelet PAC-1 binding under basal conditions and in response to stimulation with 
ADP, SFLLRN, thrombin, and thrombin and collagen in patients with significant coronary disease 
demonstrated by coronary angiography. n=25. P values compare measurements from patients pre and post 
RIPC treatment using the paired t test for parametrically distributed data or the Wilcoxon signed rank test 
for non-parametrically distributed data. 
ADP, adenosine diphosphate; RIPC, remote ischaemic preconditioning; T+C, thrombin and collagen; 
SFLLRN, PAR-1 agonist;  
 
4.3.3.2 CD62P 
There was no effect of either RIPC or sham treatment on CD62P expression in 
unstimulated samples or in response to platelet agonists (Figure 4.7) indicating 
selectivity for GPIIb-IIIa activation. 
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d) 
 
 
 
e) 
 
 
 
 
Figure 4.7 The effect of remote ischaemic preconditioning on CD62P expression 
Effect of RIPC (left panels) or sham (right panels) on CD62P expression without stimulation (basal) (a) 
and in response to ADP (b), SFLLRN (c), thrombin (d) and thrombin and collagen (e). RIPC, n=31; 
Sham, n=29; P values compare measurements from patients pre and post RIPC/sham treatment using the 
paired t test for parametrically distributed data or the Wilcoxon signed rank test for non-parametrically 
distributed data. 
ADP, adenosine di-phosphate; RIPC, remote ischaemic preconditioning; T+C, thrombin and collagen; 
SFLLRN, PAR-1 agonist; 
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4.3.3.3 CD63 
Interestingly there was a small but statistically significant increase in CD63 expression 
in response to ADP after RIPC (Figure 4.8b). There was no other effect of either RIPC 
or sham on CD63 expression either in the unstimulated samples or in response to other 
agonists (Figure 4.8). 
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a) 
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d) 
 
 
 
e) 
 
 
 
 
Figure 4.8 The effect of remote ischaemic preconditioning on CD63 expression 
Effect of RIPC (left panels) or sham (right panels) on CD63 expression without stimulation (basal) (a) 
and in response to ADP (b), SFLLRN (c), thrombin (d) and thrombin and collagen (e). RIPC, n=31; 
Sham, n=29; P values compare measurements from patients pre and post RIPC/sham treatment using the 
paired t test for parametrically distributed data or the Wilcoxon signed rank test for non-parametrically 
distributed data. 
ADP, adenosine di-phosphate; RIPC, remote ischaemic preconditioning; T+C, thrombin and collagen; 
SFLLRN, PAR-1 agonist; 
 
There was a greater percentage increase in CD63 expression in response to ADP with 
RIPC than sham (+14.4% (-10.5 - +54.0) vs -14.1% (-29.7 - +42.2), P=0.07) but this did 
not reach statistical significance. 
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4.3.5 The effect of remote ischaemic preconditioning on platelet aggregation 
Impedance aggregometry demonstrated no effect of RIPC on platelet aggregation in 
response to ADP (52.7 ± 30.5 U vs 52.5 ± 28.9 U, P=0.90) or arachidonic acid (15.5 
(9.5-38.3) U vs 18.5 (11.5-30.0) U, P=0.78) (Figure 4.9).  
 
a) ADP 
 
 
 
b) Arachidonic acid 
 
 
 
 
Figure 4.9 The effect of remote ischaemic preconditioning on platelet aggregation 
Effect of RIPC (left panels) or sham (right panels) on platelet aggregation, as assessed by impedance 
aggregometry, in response to a) ADP or b) arachidonic acid. RIPC, n=30; Sham, n=28. P values compare 
measurements from patients pre and post RIPC/sham treatment using the paired t test for parametrically 
distributed data or the Wilcoxon signed rank test for non-parametrically distributed data. 
ADP, adenosine di-phosphate; RIPC, remote ischaemic preconditioning. 
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4.3.6 The effect of remote ischaemic preconditioning on platelet-leukocyte aggregates 
PLA were measured in 40 patients from the randomised cohort (20 RIPC, 20 sham). 
The baseline characteristics of the patients who had PLA assessed did not differ 
significantly from those who did not. The results of PLA measurement is summarised in 
Figure 4.10. There was a significant increase in platelet-granulocyte aggregates in 
response to SFLLRN stimulation with RIPC (62.2 ± 21.6% vs 68.2 ± 19.4%, P=0.008). 
There was also a significant increase in platelet-monocyte aggregates under basal 
unstimulated conditions with RIPC (6.9% (5.1-9.1) vs 8.7% (7.4-10.5), P=0.006). RIPC 
was associated with a small but statistically significant decrease in platelet-monocyte 
aggregates in response to thrombin stimulation (96.0% (93.1-97.9) vs 95.0% (88.9-
96.0), P=0.007). 
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a) 
 
  
 
b)   
 
  
 
 
Figure 4.10 The effect of remote ischaemic preconditioning on platelet-leukocyte 
aggregate formation 
Effect of RIPC (left panels) or sham (right panels) on platelet-granulocyte aggregates (a) and platelet-
monocyte aggregates (b) formation under basal conditions or in response to stimulation with ADP, 
SFLLRN or thrombin. RIPC, n=20; Sham, n=20; P values compare measurements from patients pre and 
post RIPC/sham treatment using the paired t test for parametrically distributed data or the Wilcoxon 
signed rank test for non-parametrically distributed data. 
ADP, adenosine diphosphate; RIPC, remote ischaemic preconditioning; SFLLRN, PAR-1 agonist;  
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4.3.7 The effect of remote ischaemic preconditioning on circulating regulators of 
platelet function 
Platelet activity is modulated by multiple factors in the circulation, which lead to 
downstream modulation of intracellular pathways, resulting in changes in the receptor 
profile on the platelet surface. Despite their predominant intracellular role in 
intracellular signalling, the circulating levels of cAMP and cGMP were measured by 
ELISA. There was no effect of RIPC on circulating levels of cAMP or cGMP as 
assessed by ELISA analysis of the stored plasma (Figure 4.11).  
 
a) 
 
b) 
 
 
Figure 4.11 The effect of remote ischaemic preconditioning on plasma cAMP and 
cGMP 
Plasma cAMP (a) and cGMP (b) concentrations pre and post RIPC measured with commercially available 
ELISA kits as per manufacturer guidelines. n=20. P values compare measurements from patients pre and 
post RIPC treatment using the paired t test for parametrically distributed data or the Wilcoxon signed rank 
test for non-parametrically distributed data. 
cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; ELSIA, enzyme-
linked immunosorbent assay; RIPC, remote ischaemic preconditioning; 
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Nitric oxide is an important suppressor of platelet activation. Nitric oxide is metabolised 
to nitrite, which is then metabolised to nitrate. Given the short half-life of nitric oxide, 
the levels of the metabolites nitrite and nitrate were assessed to evaluate for changes in 
response to RIPC. RIPC was associated with a reduction in plasma nitrite concentration 
(2.1 ± 0.3 μmol/L vs 2.0 ± 0.3 μmol/L, P=0.01, n=20) while there was no change in 
patients randomised to sham (Figure 4.12). Analysis of stored plasma demonstrated a 
significant reduction in plasma nitrate concentration with RIPC (21.0 μmol/L (17.9-
30.5) vs 19.8 μmol/L (15.9-27.5), P=0.001, n=20). There was also a reduction in the 
measured plasma nitrate concentration in patients randomised to sham treatment (17.1 ± 
6.0 μmol/L vs 16.2 ± 5.8 μmol/L, P=0.006, n=11).  There was no correlation between 
the change in plasma nitrite concentration with RIPC and the change in PAC-1 binding 
in response to SFLLRN. However, there was a moderate association between the 
change in plasma nitrite with RIPC and the change in PAC-1 binding in response to 
thrombin and collagen with RIPC, which approached statistical significance (Figure 
4.13). 
 
 
 
  
Chapter 4 
 
125 
 
a) 
 
 
 
b) 
 
 
 
 
Figure 4.12 The effect of remote ischaemic preconditioning on plasma nitrate and 
nitrite concentrations  
Plasma nitrite (a) and nitrate (b) concentrations in stored plasma pre and post RIPC and sham measured 
with a commercially available ELISA kit as per manufacturer guidelines. RIPC, n=20; Sham, n=11; P 
values compare measurements from patients pre and post RIPC/sham treatment using the paired t test for 
parametrically distributed data or the Wilcoxon signed rank test for non-parametrically distributed data. 
ELSIA, enzyme-linked immunosorbent assay; RIPC, remote ischaemic preconditioning; 
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a) 
 
b) 
 
 
Figure 4.13 Correlation between change in plasma nitrite and change in PAC-1 
binding with remote ischaemic preconditioning 
Correlation between changes in plasma nitrite with RIPC and changes in PAC-1 binding in response to 
SFLLRN (a) and thrombin and collagen (b) measured by ELISA and flow cytometry respectively. Values 
determined by calculating the difference in post and pre values and representing the difference as a 
percentage of the pre value. A negative value suggests a reduction with RIPC. n=20. Correlations 
between variables were assessed by Pearson’s correlation or Spearman rank correlation for parametrically 
and non-parametrically distributed data respectively. 
ELSIA, enzyme-linked immunosorbent assay; RIPC, remote ischaemic preconditioning; T+C, thrombin 
and collagen; SFLLRN, PAR-1 agonist; 
 
 
The prostaglandin, prostacyclin, is another inhibitor of platelet activation. Prostacyclin 
is metabolised to 6-keto-PGF1α. To assess whether the prostacyclin pathway was 
involved in the observed attenuation of platelet activation by RIPC, prostacyclin and 6-
keto-PGF1α levels were measured in stored plasma. There was no change in plasma 
prostacyclin or 6-keto-PGF1α concentrations with RIPC (Figure 4.14). 
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a) 
 
b) 
 
  
Figure 4.14 Plasma prostacyclin and 6-keto-PGF1α concentrations with remote 
ischaemic preconditioning 
Plasma prostacyclin (a) and 6-keto-PGF1α (b) concentrations before and after RIPC measured with 
commercially available ELISA kits as per manufacturer guidelines. Prostacyclin, n=10; 6-keto-PGF1α, 
n=20; P values compare measurements from patients pre and post RIPC treatment using the paired t test 
for parametrically distributed data or the Wilcoxon signed rank test for non-parametrically distributed 
data. 
ELISA, enzyme-linked immunosorbent assay; RIPC, remote ischaemic preconditioning; 
 
4.3.8 The effect of remote ischaemic preconditioning on platelet intracellular VASP and 
phosphorylated-VASP 
In order to explore the possibility that RIPC was associated with an increase in VASP 
phosphorylation in platelets, the effect of RIPC was carefully determined in a separate 
group of 18 patients undergoing coronary angiography. The baseline characteristics of 
this second patient cohort are shown in Table 4.3. The cohort consisted of 
predominantly male patients (94%), with significant CAD demonstrated in 13 (72%) of 
patients. The number of patients on DAPT was 6 (33%) with all of these patients on 
aspirin and clopidogrel. 
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Table 4.3 Baseline characteristics of intracellular platelet cohort 
Characteristic RIPC treated 
(n=18) 
Age - years 64.5 ± 9.9 
Male – no. (%) 17 (94) 
Clinically stable – no. (%) 18 (100) 
Significant CAD – no. (%) 13 (72) 
Prior myocardial infarction – no. (%) 3 (17) 
Prior PCI – no. (%) 2 (11) 
Prior CABG- no. (%) 3 (17) 
Heart failure – no. (%) 0 (0) 
Prior stroke – no. (%) 4 (22) 
Peripheral vascular disease – no. (%) 1 (6) 
Hypertension – no. (%) 10 (56) 
Diabetes – no. (%) 8 (44) 
Dyslipidaemia – no. (%) 14 (78) 
Current smoking – no. (%) 3 (17) 
Medications   
Aspirin – no. (%) 17 (94) 
P2Y12 antagonist – no. (%) 6 (33) 
Clopidogrel – no. (%) 6 (33) 
Ticagrelor – no. (%) 0 (0) 
Prasugrel – no. (%) 0 (0) 
Dual antiplatelet therapy – no. (%) 6 (33) 
Warfarin/ NOAC – no. (%) 0 (0) 
Heparin – no. (%) 0 (0) 
Statin – no. (%) 14 (78) 
Beta blocker – no. (%) 6 (33) 
ACEi or ARB – no. (%) 7 (39) 
Nitrate – no. (%) 2 (11) 
Parameters during admission  
Systolic blood pressure – mmHg 143.9 ± 22.2 
Heart rate – beats/min 70.5 ± 11.2 
Haemoglobin concentration – g/L 141.7 ± 16.1 
Platelet count – 109/L 232.1 ± 79.9 
eGFR - mL/min/1.73m
2
 84.7 ± 13.3 
 
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary 
artery bypass grafting; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; NOAC, 
novel oral anticoagulant; PCI, percutaneous coronary intervention;  
 
From the 18 patients who had blood collected before and after RIPC and had platelet 
lysate samples stored, there were 15 paired lysates stored under basal unstimulated 
conditions and 5 pairs of lysates stored after stimulation with SFLLRN. A 
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representative western blot of the platelet lysates stored under basal conditions is shown 
in Figure 4.15. The pixel volume after interrogation of each sample with a 
phosphorylated-VASP antibody was corrected for total VASP and GAPDH. A post 
RIPC: pre RIPC ratio was calculated with values >1 indicating an increase in 
phosphorylated-VASP with RIPC and values <1 suggesting a reduction with RIPC. The 
corrected and uncorrected post RIPC: pre RIPC phosphorylated-VASP ratios for all the 
patients are displayed in Table 4.4. The mean phosphorylated-VASP post:pre ratio, 
corrected for total VASP and GAPDH,  was 1.0 ± 0.5 (P=0.98) in unstimulated platelet 
lysates and 1.1 ± 0.5 (P=0.65) in SFLLRN stimulated platelet lysates.  
  
 
Figure 4.15 Western blot of platelet lysates before and after remote ischaemic 
preconditioning 
Representative western blot of stored platelet lysates pre and post RIPC under unstimulated conditions 
and of a positive control sample (platelets stimulated with prostaglandin E1, only loaded onto the p-
VASP blot). Each blot probed with antibodies to VASP, p-VASP and GAPDH. The predicted molecular 
weight of VASP and p-VASP is 46 kDa and the predicted molecular weight of GAPDH is 37 kDa. n=5.  
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; p-VASP, phosphorylated vasodilator stimulated 
phosphoprotein; RIPC, remote ischaemic preconditioning; VASP, vasodilator stimulated phosphoprotein;  
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Table 4.4 Changes in phosphorylated-VASP with remote ischaemic 
preconditioning 
 Basal SFLLRN 
Patient 
number 
Uncorrected Corrected Uncorrected Corrected 
1 0.73 0.66   
2 0.48 0.43   
3 0.56 0.57   
4 1.60 1.90   
5 0.93 1.40   
6 0.59 0.88   
7 0.82 0.78   
8 1.32 1.82   
9 0.33 0.49   
10 1.37 1.08   
11 0.79 0.64   
12 1.86 1.17   
13 1.23 1.20   
14 0.76 0.81 0.50 0.67 
15 1.21 1.22 0.88 0.89 
16   1.10 1.94 
17   0.55 1.10 
18   0.85 0.93 
 
Ratio of phosphorylated-VASP in post RIPC platelet lysates to pre RIPC platelet lysates stored under 
unstimulated (basal) conditions or after SFLLRN stimulation. Ratios without and with correction for total 
VASP and GAPDH presented. A ratio >1 suggests an increase in phosphorylated-VASP with RIPC. 
GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; RIPC, remote ischaemic preconditioning; 
SFLLRN, PAR-1 agonist; VASP, vasodilator stimulated phosphoprotein;  
 
In the intracellular platelet cohort, treatment with RIPC reduced GPIIb-IIIa activation 
(PAC-1 binding) in response to SFLLRN (77.7% (62.2-84.7) vs 63.0% (42.6-79.4), 
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P=0.002) and thrombin and collagen (87.8% (82.1-90.8) vs 84.8% (66.2-91.2), 
P=0.006) as observed in the main study cohort, establishing the robustness of the key 
observation. There was a significant correlation between pre RIPC corrected 
phosphorylated-VASP pixel volumes and PAC-1 binding in response to SFLLRN (r=-
0.80, P=0.0004) and in response to thrombin and collagen (r=-0.64, P=0.01). Similarly 
there was a significant correlation between post RIPC corrected phosphorylated-VASP 
pixel volumes and PAC-1 binding in response to SFLLRN (r=-0.57, P=0.03) and in 
response to thrombin and collagen (r=-0.67, P=0.008). However, there was no 
correlation between changes in PAC-1 binding in response to SFLLRN and thrombin 
and collagen and the phosphorylated-VASP post:pre ratio in unstimulated samples 
(Figure 4.16). 
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a) 
 
b) 
 
 
Figure 4.16 Correlation between change in PAC-1 binding and phosphorylated-
VASP with remote ischaemic preconditioning 
Change in PAC-1 binding determined by calculating the difference in PAC-1 binding post and pre RIPC 
as a percentage of PAC-1 binding pre RIPC, with a negative value representing a reduction with RIPC. 
Phosphorylated-VASP post: pre ratio in unstimulated platelet lysates corrected for total VASP and 
GAPDH with a ratio <1 suggesting a reduction with RIPC. n=15. Correlations between variables were 
assessed by Pearson’s correlation or Spearman rank correlation for parametrically and non-parametrically 
distributed data respectively. 
GAPDH, Glyceraldehyde 3-phosphate dehydrogenase; RIPC, remote ischaemic preconditioning; VASP, 
vasodilator stimulated phosphoprotein; T+C, thrombin and collagen; SFLLRN, PAR-1 agonist; 
 
4.3.9 The effect of remote ischaemic preconditioning on platelet intracellular cAMP and 
cGMP 
The cAMP and cGMP concentrations of 15 pairs of platelet lysates under unstimulated 
conditions and 3 pairs after SFLLRN stimulation was determined by ELISA. The cAMP 
concentrations were below the detection limit on the standard curve in all but one pair. 
There were 11 pairs of unstimulated lysates and one pair of SFLLRN stimulated platelet 
lysates with cGMP concentrations within the range of the standard curve with the 
remaining samples below this range. There was no significant change in cGMP levels in 
the unstimulated platelet lysates with RIPC (5.8 pmol/mL (4.8-10.7) vs 6.6 (4.6-7.7), 
p=0.83, n=11).   
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4.4 Discussion 
 
In this chapter, the effect of RIPC on pathway-specific platelet activation in response to 
defined agonists was investigated in a randomised controlled trial. The results 
demonstrate that RIPC attenuates the induction of GPIIb-IIIa conformational activation 
in response to SFLLRN and in response to combined thrombin and collagen 
stimulation. There were also other unexpected effects on CD63 expression and platelet-
leucocyte aggregate formation.  Importantly, these effects were not seen in sham-treated 
patients indicating that these are RIPC-specific and were supported by the analysis of 
percentage change in these markers with RIPC or sham. 
RIPC attenuated platelet GPIIb-IIIa conformational activation in response to the PAR-1 
agonist, SFLLRN, and in response to combined stimulation with thrombin and collagen, 
potent platelet agonists that are present at the site of atherosclerosis related thrombosis. 
In vivo, reduced exposure of the fibrinogen binding site on platelet surface GPIIb-IIIa 
may reduce platelet aggregation at the site of complicated atherosclerotic coronary 
plaques and may help explain the benefit conferred by RIPC in acute myocardial 
infarction and in reducing peri-procedural events in the context of primary and elective 
PCI (13,14,74,76,165). The effects on GPIIb-IIIa conformational activation appear to be 
specific. As there was no effect on GPIIb-IIIa activation in circulating platelets before 
stimulation, it is likely that the preconditioning influences a pathway which attenuates 
activation by subsequent agonist stimulation rather than directly affecting PAC-1 
binding sites.  
There was no effect of RIPC on CD62P or CD63 expression apart from a small but 
statistically significant increase in CD63 expression in response to ADP after RIPC. 
There was also an increase in platelet-granulocyte aggregates in response to SFLLRN 
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and platelet-monocyte aggregates under unstimulated conditions with a reduction in 
platelet-monocyte aggregates in response to thrombin. These results suggest an increase 
in dense granule or lysosomal release in response to a relatively weak agonist and 
varied effects on PLA formation. The potential clinical significance of these findings is 
unclear but suggests that RIPC may exert complex effects on platelet biology, not all of 
which inhibit platelet activation.  
The observed effects of RIPC on PLA formation are in contrast to prior studies which 
have demonstrated RIPC-induced reduction in platelet-monocyte aggregate formation 
with ADP, exercise or cardiac catheterisation (56,57). Whilst one of these studies 
studied patients undergoing cardiac catheterisation on DAPT (57), there were 
differences in the flow cytometry methods, range of agonists and timing of blood 
collection compared to this present study. In the previous study, blood was collected 
before RIPC, conditioning was then delivered and blood was collected again after the 
cardiac catheterisation procedure was completed whereas in our study blood was 
collected before angiography. Thus the former study may be identifying RIPC related 
decreases in the induction of PLA by the coronary catheterisation procedure. These 
methodological differences may account for the discrepant results. 
There was no observed effect of RIPC on platelet aggregation in response to ADP or 
arachidonic acid, as assessed by platelet impedance aggregometry. This is in keeping 
with another study which investigated the effect of long term RIPC on platelet 
aggregation (166).  
The effects of RIPC on platelet activation have been studied in other patient populations 
and unlike our study, have principally concentrated on the effect of RIPC on procedure-
related platelet activation augmented by ADP stimulation (55,57). This study is unique 
in that pathway-specific and agonist-specific effects of RIPC on platelet activation have 
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been identified and it is the first to investigate the effect of RIPC on GPIIb-IIIa 
conformational activation induced by thrombin-related pathways. Furthermore, the 
inhibitory effects of RIPC on platelet activation have been shown to be additional to the 
inhibitory effects of contemporary DAPT. Although DAPT was effective in inhibiting 
platelet activation in response to ADP compared to aspirin alone, the addition of a 
P2Y12 ADP receptor inhibitor had relatively little inhibitory effect on the activation of 
platelets by thrombin and the potent combination of thrombin and collagen. This is of 
interest as thrombin and collagen are abundant at the site of complicated atherosclerotic 
plaques and are involved in the development of ACS. 
Thrombin is understood to activate platelets via the protease activated receptor (PAR) 
family of G Protein coupled receptors, PAR-1 and PAR-4 being expressed in human 
platelets (167).  Cleavage of the N-terminus of PAR-1 and PAR-4 by serine proteases 
exposes a new terminus which acts as a tethered ligand, and this can be replicated by 
synthetic ligands for each PAR receptor. Activation of PARs activates the β isoforms of 
phospholipase C, in turn activating IP3 and inducing calcium release to cause a cascade 
of effects including activation of Rap1, promoting its binding to talin on the C-terminus 
of GPIIb-IIIa to promote its conformational change (168,169).  In our study, SFLLRN, 
which activates the PAR-1 receptor, effectively activated platelets despite DAPT, but 
did so less effectively than did thrombin, suggesting added effects arising from PAR-4 
activation by thrombin. In a sub-group of 10 patients, the effect of RIPC on PAC-1 
binding in response to a PAR-4 agonist (AYPGFK, 300 μM) was assessed. This 
demonstrated no effect of RIPC (data not shown), highlighting the importance of the 
PAR-1 thrombin activation pathway in the RIPC induced attenuation of GPIIb-IIIa 
activation.  
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SFLLRN-mediated conformational activation of GPIIb-IIIa was inhibited by RIPC 
whereas SFLLRN-mediated expression of CD62P and CD63 were unaffected, 
indicating that alpha and dense granule release are not inhibited by RIPC, whereas 
inside-out signalling regulating GPIIb-IIIa conformational change is specifically 
attenuated. This suggests that downstream effectors of conformational change, rather 
than generalised effects on platelet activation, are targets of RIPC. However, given that 
the power calculation was based upon PAC-1 binding, it is possible that the study was 
underpowered to detect an effect of RIPC on these other markers of platelet activation.  
RIPC also attenuated GPIIb-IIIa conformational change after stimulation with thrombin 
and collagen in combination, but, surprisingly, did not inhibit activation after thrombin 
alone, suggesting that collagen facilitates the inhibitory effects of RIPC. Collagen 
activates platelets through direct interaction with GPVI and the integrin α2β1, and by 
indirect interaction via vWF-mediated binding to GPIb-IX-V complex and GPIIb-IIIa 
(167). Under the ex vivo conditions in this study, without circulatory flow, interaction 
via GPVI and the integrin α2β1 are likely to be involved. After activation, clustering of 
GPVI results in phosphorylation of tyrosine residues in the FcRγ cytoplasmic domain 
causes downstream activation of Syk, which leads to Rap1 activation and initiation of 
inside-out activation of integrin GPIIb-IIIa. Similarly, activation of the integrin α2β1 
promotes activation of Syk. At this stage it can only be speculated that clustering of 
GPVI after exposure to collagen or binding to integrin α2β1 induce novel inhibitors of 
GPIIb-IIIa conformational change that work synergistically with the inhibitory 
pathways induced by RIPC. Whether RIPC also inhibits conformational activation of 
integrin α2β1 and whether these changes are a direct consequence of collagen binding 
will require further investigation.  
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Nitric oxide has important functions in human biology (170). It is known to have 
inhibitory actions on platelet activation with nitrite being the major metabolite and 
cGMP its major intracellular messenger (170-172). In an animal model, nitric oxide and 
nitrite were demonstrated to be mediators of RIPC mediated cardiac protection (42). On 
this basis, it was hypothesised that RIPC mediated modulation of nitric oxide 
metabolism may contribute to the attenuation of platelet activation that was observed. 
Hence, an analysis of stored plasma was undertaken which demonstrated a reduction in 
plasma nitrite with RIPC. There was also a reduction in plasma nitrate with RIPC, but 
this may have been a result of artefact after blood collection and storage as there was 
also a reduction in the patients randomised to sham. There was a moderate association 
between the change in plasma nitrite and reduction in PAC-1 binding, which 
approached statistical significance. Further investigation will be required to characterise 
this in more detail.  
An alternative explanation for the observed reduction in plasma nitrite levels with RIPC 
is consumption during reduction to nitric oxide under hypoxic conditions. This pathway 
of reduction of nitrite to form nitric oxide by molecules such as haemoglobin and 
myoglobin allows maintenance of nitric oxide levels during hypoxia (170). Forearm 
ischaemia during RIPC may have led to promotion of this pathway of nitric oxide 
production, resulting in the reduced levels of systemic nitrite observed during plasma 
analysis. Thus, decreased plasma nitrite may be a surrogate marker for effectiveness of 
remote ischaemia rather than directly biologically responsible for the inhibition of 
GPIIb-IIIa activation  effects. It does remain possible that the modest stimulatory effects 
of RIPC seen on platelet-leukocyte aggregate formation and CD63 release could be 
contributed to by NO consumption during RIPC.  
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Prostacyclin also has important platelet inhibitory actions mediated through cAMP 
(173-176). Prostacyclin is metabolised to 6-keto-PGF1α, which is more stable in the 
circulation.  RIPC in an animal model appeared to upregulate prostacyclin production in 
the heart, demonstrated by an increase in 6-keot-PGF1α (177). In this study however, 
there was no correlation between prostacyclin levels and cardiac protection against 
tachyarrhythmia after IR injury. In this present study, there was no change in plasma 
prostacyclin or 6-keto-PGF1α levels with RIPC. This suggests that either 1) RIPC has 
no effect on these circulating factors and that the prostacyclin pathway is not primarily 
responsible for the attenuation of platelet activation that was observed or 2) that the 
methods utilised were not sensitive enough to detect such a change.  
While there was no significant change in the platelet cohort, there was a small but 
statistically significant reduction in 6-keto-PGF1-alpha in the coronary physiology 
group. While the two cohorts have similar baseline characteristics and were both 
comprised of patients undergoing coronary angiography for investigation of CAD, the 
samples were collected under different conditions. In the coronary physiology cohort, 
blood samples were collected after administration of IV adenosine, other drugs 
administered during the procedure such as heparin, midazolam and fentanyl and after 
the physical stimulus of cardiac catheterisation. In the platelet cohort, the blood samples 
were collected prior to the patient’s procedure. These multiple differences may help 
explain the discrepant results. 
GPIIb-IIIa conformational activation is the result of inside-out signalling through 
several different pathways as discussed above. A well described regulator of GPIIb-IIIa 
conformational activation is the intracellular phosphoprotein VASP. Phosphorylation of 
VASP by cAMP and cGMP dependent kinases results in inhibition of GPIIb-IIIa and is 
the pathway involved in inhibition of platelet activity by substances such as nitric oxide 
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and prostacyclin (164). It was hypothesised that RIPC may mediate its platelet 
inhibitory effects via an increase in VASP phosphorylation. As such, a separate cohort 
of 18 patients were recruited and treated with RIPC to specifically study these 
intracellular pathways. This second cohort of patients also demonstrated a significant 
reduction in GPIIb-IIIa conformational activation in response to SFLLRN and thrombin 
and collagen after RIPC confirming robustness of our primary observation. Western 
blot analysis of platelet lysates demonstrated heterogeneity between patients, with no 
significant effect of RIPC overall after appropriate adjustments for total VASP and 
GAPDH levels. In addition, there was no correlation between changes in 
phosphorylated-VASP and changes in PAC-1 binding in response to either SFLLRN or 
thrombin and collagen. Thus, the effect of RIPC on GPIIb-IIIa activation does not 
appear to be explained by increased VASP phosphorylation. 
To investigate the effect of RIPC on the integral intracellular messengers cAMP and 
cGMP, platelet lysates were also stored for analysis with ELISA. All but one pair of 
platelet lysates had cAMP levels below the lowest concentration on the standard curve 
and thus were interpretable. There were also some pairs of platelet lysate samples which 
had concentrations below the standard cGMP curve. There appeared to be no change in 
cGMP levels with RIPC in the samples with concentrations within the standard curve 
range. Despite following the manufacturer’s instructions, intracellular cAMP levels 
were not detectable with the method used to store platelet lysates. Given the important 
role of cAMP in intracellular platelet signalling, analysis of intracellular cAMP levels 
could provide interesting insights into the effects of RIPC on platelet biology. This is an 
area for potential future investigation but will require adjustment of the current method 
or an alternative method to measure intracellular cAMP. Analysis of stored plasma 
cAMP and cGMP levels demonstrated no change with either RIPC or sham treatment. 
Chapter 4 
 
140 
 
Due to the mechanistic focus of this study, and the small numbers of patients that 
subsequently had PCI, correlation between changes in PAC-1 binding and clinical 
outcomes such as troponin rise post PCI could not be performed. Additionally, due to 
the relatively small patient numbers, clinical characteristics that predict a response to 
RIPC could not be sought.  
 
4.5 Conclusions 
 
RIPC attenuates platelet GPIIb-IIIa conformational activation in response to SFLLRN 
and thrombin and collagen. This response is additional to the effects of contemporary 
antiplatelet therapy in patients with CAD. The greatest effect of RIPC appeared to be in 
response to thrombin and collagen, a combination of agonists against which DAPT 
appears to be relatively ineffective and which are abundant at the site of complicated 
coronary atherosclerotic plaques. Attenuation of pathological platelet activation may 
contribute to the beneficial effects of RIPC at the time of primary and elective PCI. The 
mechanism behind the RIPC mediated attenuation of platelet activation remains 
uncertain.  
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Chapter 5: The effect of remote ischaemic preconditioning on 
procoagulant platelet formation 
 
5.1 Introduction 
 
The significant role of platelets in in both physiological haemostasis and pathological 
thrombosis was discussed in chapter 4. Procoagulant platelets are a subset of platelets 
that provide a surface for assembly of coagulation complexes and are characterised by 
externalisation of phosphatidylserine (PS) (121,122,178-180). They can be found at the 
site of collagen exposure in the vessel wall and are most readily formed ex vivo by 
stimulation with a combination of thrombin and collagen (181). Procoagulant platelets 
have been shown to have low levels of GPIIb-IIIa activation and thus may have a 
greater or more specific role in thrombus formation than in platelet aggregation and 
adhesion (181). Within thrombus, platelets with a procoagulant phenotype appear to 
interact with aggregatory platelets expressing activated GPIIb-IIIa (182). Consequently, 
inhibiting the formation of procoagulant platelets could have additional consequential 
secondary effects via their interaction with other platelets.  
Platelet PS externalisation has been linked to cyclophilin D-dependent inner 
mitochondrial membrane disruption through formation of the mitochondrial 
permeability transition pore (MPTP), leading to membrane depolarisation (178,182). 
Another pivotal step is an increase in cytosolic calcium (183). Cyclosporin A, which 
inhibits cyclophilin D, inhibits PS exposure, mitochondrial membrane depolarisation 
and the increase in cytoplasmic calcium induced by platelet agonists (183). High 
cytoplasmic calcium and mitochondrial membrane depolarisation distinguishes 
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procoagulant platelets from aggregating platelets with active GPIIb-IIIa on their surface 
(184).  
As described in section 2.6.6, a novel flow cytometry assay to detect procoagulant 
platelets has been developed using the uptake of a trivalent arsenical 4-[N-(S-
glutathionylacetyl)amino]phenylarsonous acid (GSAO) and co-staining with CD62P 
(GSAO+/CD62P+ platelets) (120). GSAO is tagged with the fluorophore AlexaFluor 
647 and is retained in the platelet cytoplasm by covalently binding to proteins 
containing closely spaced di-thiol bonds (185). Data using the above method 
demonstrates that compared to healthy controls, patients with CAD have increased 
levels of circulating procoagulant platelets and hyper-reactivity to thrombin, mimicking 
thrombin and collagen stimulation of platelets from healthy volunteers, indicating that 
this platelet population may be relevant to patients with coronary disease (123).  
It was hypothesised that RIPC may confer protective effects against coronary events by 
inhibiting the formation of procoagulant (GSAO
+
/CD62P
+
) platelets. This was 
investigated under unstimulated conditions and in response to platelet agonists in this 
chapter.  
 
5.2 Methods 
 
The data presented in this chapter was collected concurrently with the data presented in 
chapter 4. Hence, the patient population, blood collection methods and delivery of RIPC 
were identical. 
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5.2.1 Patient population    
Patients who were recruited to study the effects of RIPC on platelet activation, 
described in chapter 4, also had procoagulant platelet activity studied. These patients 
were referred for coronary angiography by their treating physician due to a suspicion of 
CAD. Participants provided informed consent and all blood samples were collected 
prior to the cardiac catheterisation procedure. Medication prescription, including the 
administration of antiplatelet therapy, was at the discretion of the patient’s treating 
physician.   
 
5.2.2 Blood collection  
Blood collection was performed as described in chapters 2 and 4.  
 
5.2.3 Remote ischaemic preconditioning 
Remote ischaemic preconditioning and sham treatment was delivered as described in 
chapters 2 and 4. A closed envelope system was used to randomise 60 patients, in a 1: 1 
manner, to receive either RIPC or sham treatment. Patients and investigators processing 
the blood samples were both blinded to patient treatment allocation. The study design is 
described in Figure 4.1. A separate cohort of patients (n=25) had blood samples taken to 
further explore the effect of RIPC on agonist-induced procoagulant platelet formation 
and to investigate changes in platelet mitochondrial membrane potential in response to 
RIPC (exploratory cohort). All of these patients received RIPC with blood collected 
before and after treatment.   
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5.2.4 Assessment of procoagulant platelet formation 
As described in section 2.6.6, procoagulant platelets were quantified in whole blood 
with reactions performed in a sterile 96-well polypropylene plate. Whole blood 
collected into sodium citrate tubes was diluted with HBSS, Gly-Pro-Arg-Pro amide and 
calcium with and without agonists. The agonist panel mirrored the study of surface 
markers of platelet activation (chapter 4), ADP (5 μM), SFLLRN (20 μM), thrombin (2 
U/mL) and thrombin (2 U/mL) + collagen (10 μg/mL). In the exploratory cohort, 
procoagulant platelet formation was assessed additionally with the PAR-4 agonist 
AYPGFK (300 μM) and also with 0.5 U/mL thrombin, 1 U/mL thrombin, 2 U/mL 
thrombin, 5 U/mL thrombin each with and without 10 μg/mL collagen and 10 μg/mL 
collagen alone. A 20- fold dilution with HBSS was used to stop reactions after 10 min at 
room temperature. Agonist or non-stimulated blood were labelled for 15 min with 
antibodies to CD62P, CD41a, CD45 and with GSAO conjugated to AlexaFluor 647 
before being fixed with two volumes of PAMFix. Samples were then transferred to 
FACS tubes and washed with 10 volumes of HBSS/HSA. The cells were then pelleted 
and then re-suspended in 1 mL of HBSS/HSA before being stored at room temperature 
in the dark for 1 h prior to analysis. Flow cytometry was performed on a BD FACS 
Canto II or BD Fortessa with 10,000 platelet events acquired for each analysis. 
Procoagulant platelets were defined by CD62P and GSAO co-positivity 
(CD62P+/GSAO+). Preliminary data with this assay demonstrated that heparin inhibits 
formation of procoagulant platelets in response to thrombin and thrombin + collagen, 
but not TRAP. Consequently patients receiving heparin were excluded from this part of 
the analysis. Additionally, data was excluded when clot was noted during in-vitro 
agonist stimulation (4 patients in thrombin and thrombin + collagen stimulated 
samples). Data were analysed with FlowJo. 
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5.2.5 Platelet mitochondrial membrane potential 
The mitochondrial membrane potential of platelets was quantified in PRP with 
incubation and staining steps performed in a sterile 96-well polypropylene plate. 
Citrated whole blood was centrifuged at 200g for 10 min at room temperature with low 
brake to obtain PRP. Citrated PRP was then diluted with HBSS, Gly-Pro-Arg-Pro amide 
(2.5 mM) and calcium (2.5 mM), with and without agonists. The agonists used were 0.5 
U/mL thrombin, 1 U/mL thrombin and 2 U/mL thrombin, each with and without 10 
μg/mL collagen and 10 μg/mL collagen alone. Reactions were stopped after 10 min of 
incubation at room temperature by a 20- fold dilution with HBSS. Aliquots of agonist- 
or non-stimulated PRP were labelled for 15 min with antibodies to CD41a (HIP8) and 
CD45 (HI30) (BD Biosciences), and with tetramethylrhodamine ethyl ester perchlorate 
(TMRE), a fluorescent potential-sensitive probe for mitochondria (Sigma-Aldrich). 
Samples were then transferred to in 1 mL of HBSS with 0.35% HSA in FACS tubes and 
analysed immediately. Flow cytometry was performed on a BD Fortessa with 10,000 
platelet events acquired for each analysis. Mitochondrial membrane disruption and 
depolarisation was indicated by absence of TMRE signal (TMRE negative, TMRE-). 
Platelets with intact mitochondrial membranes retain TMRE (TMRE+) and were 
defined based on fluorescence. The proportion of TMRE- events was determined by 
100% - TMRE+.  
5.2.6 Statistical analysis 
The statistical analysis was performed as in chapter 4 with the primary outcome being 
pre treatment vs post-treatment expression of procoagulant platelets. TMRE agonist-
response curves were determined with linear regression with differences between the 
curves determined with statistical analysis software (GraphPad, Prism). 
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5.3 Results 
 
5.3.1 Baseline clinical characteristics 
The baseline characteristics of the 60 patients who were recruited to study the effects of 
RIPC on procoagulant platelet activity were described in section 4.3.1 and Table 4.1. 
There were 6 patients, 3 in the RIPC cohort and 3 in the sham cohort, who were on 
intravenous heparin at the time of the study. The data regarding thrombin and thrombin 
+ collagen induced procoagulant platelet formation from these patients were excluded 
from analysis as heparin inhibits thrombin-induced formation of procoagulant platelets. 
 
5.3.2 The effect of remote ischaemic preconditioning on circulating procoagulant 
platelets 
The effect of RIPC or sham treatment on the formation of procoagulant platelets in the 
unstimulated basal sample and in response to platelet agonists is summarised in Table 
5.1.  
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Table 5.1 The effect of remote ischaemic preconditioning and sham treatment on 
procoagulant platelet formation  
Agonist* RIPC Sham 
 Pre Post P Pre Post P 
Basal  2.0 
(1.3-2.4) 
1.3 
(1.1-2.1) 
0.01 2.0 
(1.3-2.9) 
1.9 
(1.1-2.5) 
0.91 
ADP 4.6 ± 2.6 4.2 ± 2.5 0.25 3.7 
(2.5-6.4) 
3.6 
(2.4-5.3) 
0.36 
SFLLRN 9.2  
(7.0-11.7) 
7.4 
(6.0-10.5) 
0.04 10.6 
(8.0-12.8) 
8.7 
(6.9-12.0) 
0.06 
Thrombin 9.8 
(7.9-12.3) 
9.5  
(6.2-13.0) 
0.43 10.2 
(7.1-15.0) 
10.4 
(6.3-14.9) 
0.63 
T+C 14.7 
(11.3-17.0) 
14.2 
(11.1-18.8) 
0.75 16.6 
(12.6-23.4) 
16.7 
(12.4-20.5) 
0.68 
 
P values compare measurements from patients pre and post RIPC/sham treatment using the paired t test 
for parametrically distributed data or the Wilcoxon signed rank test for non-parametrically distributed 
data. 
* Values represent percentage (%) procoagulant platelets. 
Basal, ADP, SFLLRN, Thrombin, T+C: RIPC, n=26, 24, 26, 23 and 23 respectively; Sham, n=27, 26, 28, 
22 and 22 respectively. 
ADP, adenosine diphosphate; RIPC, remote ischaemic preconditioning; T+C, thrombin + collagen; 
SFLLRN, PAR-1 agonist;  
 
There was a significant reduction in the proportion of unstimulated procoagulant 
platelets in the circulation with RIPC, from 2.0% to 1.3% (p=0.01), whereas there was 
no effect of sham treatment (Figure 5.1). This remained significant after repeating the 
analysis excluding the one outlier with a dramatic reduction in procoagulant platelets in 
the RIPC group (1.9 ± 0.8% vs 1.6 ± 0.9%, P=0.03).  
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Figure 5.1 The effect of remote ischaemic preconditioning on circulating 
procoagulant platelets 
Effect of RIPC (left panel) or sham (right panel) on procoagulant platelet formation without stimulation 
(basal). RIPC, n=26; Sham, n=27; P values compare measurements from patients pre and post RIPC/sham 
treatment using the paired t test for parametrically distributed data or the Wilcoxon signed rank test for 
non-parametrically distributed data. 
RIPC, remote ischaemic preconditioning; 
 
There was also a greater percentage reduction in unstimulated procoagulant platelets 
with RIPC than sham (-14.9% (-35.0 - +7.9) vs -5.0% (-20.0 - +12.7), P=0.15) but this 
did not reach statistical significance. 
 
5.3.3 The effect of remote ischaemic preconditioning on procoagulant platelets in 
response to platelet agonists 
Examining the pre RIPC/sham data in the entire cohort, the median level of 
procoagulant platelets increased from 2.0% (1.3-2.8) (n=53) without agonist 
stimulation, to 3.7% (2.3-6.7) (n=50) after ADP, 10.1 (7.5-12.3) (n=54) after SFLLRN, 
10.0%  (7.6-14.7) (n=45) after thrombin, and 15.4% (11.8-19.9) (n=45) after the 
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combination of thrombin and collagen, indicating that there were substantial differences 
in the extent to which procoagulant platelets were generated by the different agonists.   
Under agonist stimulation, there was a small decrease in procoagulant platelet formation 
after SFLLRN stimulation which just reached statistical significance (Figure 5.2).   
There was no effect of RIPC on procoagulant platelet formation in response to any other 
agonists.  
 
a) 
 
 
 
b) 
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c) 
 
 
 
d) 
 
 
 
 
Figure 5.2 The effect of remote ischaemic preconditioning on procoagulant 
platelets in response to agonists 
Effect of RIPC (left panels) or sham (right panels) on procoagulant platelet formation in response to ADP 
(a), SFLLRN (b), thrombin (c) and thrombin + collagen (d). ADP, SFLLRN, Thrombin, T+C: RIPC, 
n=24, 26, 23 and 23 respectively; Sham, n=26, 28, 22 and 22 respectively; P values compare 
measurements from patients pre and post RIPC/sham treatment using the paired t test for parametrically 
distributed data or the Wilcoxon signed rank test for non-parametrically distributed data. 
ADP, adenosine diphosphate; RIPC, remote ischaemic preconditioning; T+C, thrombin + collagen; 
SFLLRN, PAR-1 agonist;  
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Analysis of these results according to the use of antiplatelet agents revealed that in the 
subgroup of patients receiving aspirin monotherapy there was a significant reduction in 
procoagulant platelet formation in response to SFLLRN (11.4 ± 5.2% vs 8.9 ± 2.8%, 
P=0.04) and thrombin (12.9 ± 5.9% vs 8.7 ± 3.2%, P=0.04) with a trend towards a 
reduction in response to thrombin + collagen (19.3 ± 8.7% vs 15.5 ± 5.3%, P=0.052). 
However there was no apparent effect of RIPC on procoagulant platelet formation in 
patients on DAPT (Figure 5.3 and Table 5.2). These reductions were not seen with sham 
treatment.  
a) 
 
b) 
 
 
Figure 5.3 The effect of remote ischaemic preconditioning on procoagulant platelet 
formation in patients on aspirin monotherapy and dual antiplatelet therapy 
Effect of RIPC on procoagulant platelets in unstimulated basal samples or in response to ADP, SFLLRN, 
thrombin and thrombin + collagen in patients on aspirin monotherapy (a) and DAPT (b). Aspirin, n=9; 
DAPT: basal, ADP, SFLLRN, thrombin, T+C, n=16, 14, 16, 13 and 13 respectively; P values compare 
measurements from patients pre and post RIPC treatment using the paired t test for parametrically 
distributed data or the Wilcoxon signed rank test for non-parametrically distributed data. 
ADP, adenosine diphosphate; DAPT, dual antiplatelet therapy; RIPC, remote ischaemic preconditioning; 
T+C, thrombin + collagen; SFLLRN, PAR-1 agonist;  
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Table 5.2 The effect of remote ischaemic preconditioning on procoagulant platelet 
formation in response to agonists, stratified by antiplatelet therapy 
Agonist* Aspirin monotherapy DAPT 
 Pre RIPC Post RIPC P Pre RIPC Post RIPC P 
Basal  2.3  
(1.2-3.2) 
1.5  
(1.0-2.3) 
0.09 1.8 ± 0.7 1.6 ± 0.9 0.13 
ADP 5.8 ± 2.2 5.7 ± 1.8 0.64 3.1  
(1.7-5.5) 
3.1  
(1.2-3.9) 
0.70 
TRAP6 11.4 ± 5.2 8.9 ± 2.8 0.04 8.8  
(6.2-10.7) 
6.9 
(5.7-9.7) 
0.14 
Thrombin 12.9 ± 5.9 8.7 ± 3.2 0.04 9.6  
(7.3-11.6) 
9.5 
(6.2-12.7) 
0.42 
T+C 19.3 ± 8.7 15.5 ± 5.3 0.052 13.2 ± 4.0 14.2 ± 7.2 
 
0.56 
 
P values compare measurements from patients pre and post RIPC using the paired t test for parametrically 
distributed data or the Wilcoxon signed rank test for non-parametrically distributed data. 
* Values represent percentage (%) procoagulant platelets. 
Basal, ADP, TRAP6, Thrombin, T+C: aspirin monotherapy, n=9, 9, 9, 9 and 9 respectively; DAPT, n=16, 
14, 16, 13 and 13 respectively. 
ADP, adenosine diphosphate; DAPT, dual antiplatelet therapy; T+C, thrombin + collagen; TRAP6, 
thrombin related activating peptide 6;  
 
In the subgroup of patients with significant CAD based on QCA of the coronary 
angiogram, there was a significant reduction in procoagulant platelet formation under 
unstimulated circulating conditions (Figure 5.4). There was no effect of sham on the 
formation of procoagulant platelets in response to any of the agonists or in the 6 patients 
treated with RIPC without significant CAD (data not shown). 
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Figure 5.4 The effect of remote ischaemic preconditioning on procoagulant platelet 
formation in patients with significant coronary artery disease 
Effect of RIPC on procoagulant platelets in unstimulated basal samples or in response to ADP, SFLLRN, 
thrombin and thrombin + collagen in patients with significant coronary artery disease as demonstrated by 
coronary angiography. Basal, ADP, SFLLRN, thrombin, T+C, n=18, 17, 18, 16 and 16 respectively; P 
values compare measurements from patients pre and post RIPC treatment using the paired t test for 
parametrically distributed data or the Wilcoxon signed rank test for non-parametrically distributed data. 
ADP, adenosine diphosphate; RIPC, remote ischaemic preconditioning; T+C, thrombin + collagen; 
SFLLRN, PAR-1 agonist;  
 
5.3.4 Correlation between remote ischaemic preconditioning induced reduction in 
circulating procoagulant platelet formation and agonist induced PAC-1 binding 
There was no significant correlation between the change in procoagulant platelets under 
unstimulated conditions with RIPC and the changes in PAC-1 binding with either 
SFLLRN or thrombin + collagen as described in chapter 4 (Figure 5.5). This suggests 
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that RIPC acts differentially on these two pathways of platelet activation in individual 
patients and inhibition of one platelet activation pathway does not predict effect on the 
other. 
 
a)  
 
b) 
 
Figure 5.5 Correlation between change in procoagulant platelets under 
unstimulated conditions and change in PAC-1 binding with remote ischaemic 
preconditioning 
Correlation between changes in procoagulant platelet formation under unstimulated conditions with RIPC 
and changes in PAC-1 binding in response to SFLLRN (a) and thrombin + collagen (b). Values 
determined by calculating the difference in post and pre values and representing the difference as a 
percentage of the pre value. A negative value suggests a reduction with RIPC. n=26. Correlations 
between variables were assessed by Pearson r correlation or Spearman rank correlation for parametrically 
and non-parametrically distributed data respectively. 
RIPC, remote ischaemic preconditioning; T+C, thrombin + collagen; SFLLRN, PAR-1 agonist; 
 
5.3.5 Further exploration into the effect of remote ischaemic preconditioning on 
procoagulant platelet formation in response to agonist stimulation 
Despite the relatively small size of this subgroup in the randomised cohort, there was a 
RIPC-mediated reduction of procoagulant platelet formation in response to SFLLRN 
and thrombin in patients on aspirin monotherapy. To explore the effect of RIPC on 
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agonist induced procoagulant platelet formation further, a separate cohort of patients 
was recruited focusing on patients on aspirin monotherapy. All these patients had blood 
collected before and after RIPC. In total 25 patients were recruited with a mean age of 
66.0 ± 9.5 yr, 23 (92%) were male, 20 (80%) were found to have significant CAD. 
Fifteen (60%) of these patients were on aspirin monotherapy and 9 (36%) were on 
aspirin and clopidogrel. The baseline characteristics of this exploratory cohort are 
displayed in Table 5.3.  
As observed in the randomized cohort, there was a significant reduction in unstimulated 
circulating procoagulant platelets with RIPC (Figure 5.6). Additionally, RIPC decreased 
agonist-induced procoagulant platelet formation, showing significant effects with all 
agonists used in the randomised cohort (Figure 5.6). There was also a significant 
reduction in procoagulant platelet formation in response to the PAR-4 agonist AYPGFK 
(6.4% (5.3-8.2) vs 5.1 (4.2-6.5), P=0.006, n=24). 
 
 
  
Chapter 5 
 
156 
 
Table 5.3 Baseline characteristics of exploratory procoagulant platelet cohort 
Characteristic RIPC treated 
(n=25) 
Age - years 66.0 ± 9.6 
Male – no. (%) 23 (92) 
Clinically stable – no. (%) 25 (100) 
Significant CAD – no. (%) 20 (80) 
Prior myocardial infarction – no. (%) 3 (12) 
Prior PCI – no. (%) 3 (12) 
Prior CABG- no. (%) 3 (12) 
Heart failure – no. (%) 0 (0) 
Prior stroke – no. (%) 6 (24) 
Peripheral vascular disease – no. (%) 2 (8) 
Hypertension – no. (%) 14 (56) 
Diabetes – no. (%) 11 (44) 
Dyslipidaemia – no. (%) 20 (80) 
Current smoking – no. (%) 3 (12) 
Medications*   
Aspirin – no. (%) 24 (96) 
P2Y12 antagonist – no. (%) 9 (36) 
Clopidogrel – no. (%) 9 (36) 
Ticagrelor – no. (%) 0 (0) 
Prasugrel – no. (%) 0 (0) 
Aspirin monotherapy – no. (%) 15 (60) 
Dual antiplatelet therapy – no. (%) 9 (36) 
Warfarin/ NOAC – no. (%) 0 (0) 
Heparin – no. (%) 0 (0) 
Statin – no. (%) 19 (76) 
Beta blocker – no. (%) 10 (40) 
ACEi or ARB – no. (%) 10 (40) 
Nitrate – no. (%) 3 (12) 
Parameters during admission  
Systolic blood pressure – mmHg 142.3 ± 20.5 
Heart rate – beats/min 67.7 ± 10.9 
Haemoglobin concentration – g/L 131.0 ± 15.5 
Platelet count – 109/L 219.4 ± 72.1 
eGFR - mL/min/1.73m
2
 81.7 ± 13.5 
 
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary 
artery bypass grafting; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; NOAC, 
novel oral anticoagulant; PCI, percutaneous coronary intervention;  
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Figure 5.6 The effect of remote ischaemic preconditioning on procoagulant platelet 
formation in exploratory platelet cohort 
Effect of RIPC on procoagulant platelets in unstimulated basal samples or in response to ADP, SFLLRN, 
thrombin and thrombin + collagen in exploratory platelet cohort. Basal, ADP, SFLLRN, thrombin, T+C, 
n=24, 24, 23, 23 and 23 respectively; P values compare measurements from patients pre and post RIPC 
treatment using the paired t test for parametrically distributed data or the Wilcoxon signed rank test for 
non-parametrically distributed data. 
ADP, adenosine diphosphate; RIPC, remote ischaemic preconditioning; T+C, thrombin + collagen; 
SFLLRN, PAR-1 agonist;  
 
RIPC was also associated with a significant reduction in procoagulant platelet formation 
in response to a range of thrombin and thrombin + collagen concentrations (Figure 5.7). 
The effect of RIPC commenced at low doses and was maximal at 1 U/mL thrombin and 
between 0.5 – 1 U/mL thrombin + 10 μg/mL collagen.  
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a) 
 
b) 
 
 
Figure 5.7 The effect of remote ischaemic preconditioning on procoagulant platelet 
formation in response to a range of thrombin and thrombin + collagen 
concentrations 
The effect of RIPC on procoagulant platelet formation in response to a range of thrombin (a) and 
thrombin + 10 μg/mL collagen (b) doses. Symbol and bars represent mean ± SEM. * - P<0.05; ** - 
P<0.01;  Thrombin 0 U/mL, 0.5 U/mL, 1 U/mL, 2 U/mL, 5 U/mL: n=24, 7, 7, 23, 16 respectively; 
Collagen 10 μg/mL + Thrombin 0 U/mL, 0.5 U/mL, 1 U/mL, 2 U/mL, 5 U/mL: n=24, 7, 7, 23, 16 
respectively; P values compare measurements from patients pre and post RIPC treatment using the paired 
t test for parametrically distributed data or the Wilcoxon signed rank test for non-parametrically 
distributed data. 
RIPC, remote ischaemic preconditioning;  
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5.3.6 The effect of remote ischaemic preconditioning on platelet mitochondrial 
membrane potential  
Procoagulant platelet formation is dependent on cyclophilin D dependent regulated cell 
death and characterised by opening of the MPTP. Thus, a marker of mitochondrial 
membrane potential, TMRE, was used to investigate whether stabilisation of 
mitochondrial membrane potential is mechanistically related to the RIPC-mediated 
attenuation of platelet procoagulant activity. Patients with significant CAD on aspirin 
monotherapy (n=5) were treated with RIPC to assess mitochondrial membrane potential 
in response to agonist stimulation and procoagulant platelet formation in parallel over a 
range of thrombin and thrombin + collagen concentrations.  There was a positive 
correlation between CD62P+/GSAO+ platelets and TMRE- events in this cohort (Figure 
5.8).  
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Figure 5.8 Correlation between procoagulant platelets and TMRE-negative events  
Correlation between CD62P+/GSAO+ (procoagulant) platelets and TMRE- events based on flow 
cytometry analysis of platelets after stimulation with a range of agonists in the exploratory cohort. n=78 
procoagulant platelet/ TMRE- pairs; Correlations between variables was assessed by Spearman rank 
correlation. 
TMRE, tetramethylrhodamine ethyl ester;  
 
A representative example of the RIPC-induced change in TMRE- and TMRE+ platelet 
populations after thrombin + collagen stimulation as measured by flow cytometry in one 
patient is displayed in Figure 5.9a. RIPC was associated with a significant reduction in 
TMRE- platelets in response to increasing doses of thrombin (Figure 5.9b) and also the 
strong agonist combination of thrombin + collagen (Figure 5.9c).  
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a) 
 
b) 
 
c) 
 
 
Figure 5.9 The effect of remote ischaemic preconditioning on platelet 
mitochondrial membrane depolarisation in response to agonists 
Representative example of RIPC-induced shift in TMRE- and TMRE+ populations in one patient. 
Histogram demonstrating absence of staining (left peaks, TMRE-) and staining (right peaks, TMRE+) by 
TMRE in platelets, from the same patient with CAD before RIPC (red) and after RIPC (blue) after 
stimulation with thrombin + collagen (a). The effect of RIPC on TMRE- platelet population in response 
to thrombin (b) and thrombin + collagen (c). Red and blue symbols and bars represent mean ± SEM with 
lines representing linear regression of data points. n=5; P values represent comparison of dose curves pre 
and post RIPC treatment using curve analysis software. 
CAD, coronary artery disease; RIPC, remote ischaemic preconditioning; TMRE, tetramethylrhodamine 
ethyl ester perchlorate; 
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In these same 5 patients, there was a significant reduction in procoagulant platelet 
formation in response to the range of thrombin concentrations and also to the range of 
thrombin + collagen concentrations which approached statistical significance (Figure 
5.10). There was a significant correlation between the change in TMRE- platelets and 
the change in procoagulant platelets (r=0.35, P=0.03, n=39 pairs). In support of the 
previously demonstrated reduction in circulating procoagulant platelets with RIPC, 
there was a RIPC-mediated reduction in TMRE- platelets under unstimulated conditions 
which approached statistical significance (9.3% (6.8-17.9) vs 6.7% (5.4-15.1), P=0.06). 
 
a) 
 
b) 
 
 
Figure 5.10 The effect of remote ischaemic preconditioning on procoagulant 
platelet formation in patients with conditioning-mediated reduction in platelet 
mitochondrial membrane depolarisation 
The effect of RIPC on procoagulant platelet formation in response to a range of thrombin (a) and 
thrombin + 10μg/mL collagen (b) doses in patients assessed with platelet TMRE flow cytometry assay. 
Red and blue symbols and bars represent mean ± SEM with lines representing linear regression of data 
points. Thrombin 0 U/mL, 0.5 U/mL, 1 U/mL, 2 U/mL: n=5, 5, 5, 4 respectively; Collagen 10 μg/mL + 
Thrombin 0 U/mL, 0.5 U/mL, 1 U/mL, 2 U/mL: n=5, 5, 5, 5 respectively; n=5 patients; P values represent 
comparison of dose curves pre and post RIPC treatment using curve analysis software. 
RIPC, remote ischaemic preconditioning; TMRE, tetramethylrhodamine ethyl ester perchlorate; 
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5.4 Discussion 
 
Platelets have sub-populations with different functions. Classical activation is required 
for haemostasis as well as promoting thrombosis, thus standard anti-platelets agents 
inevitably increase bleeding risk.  It is now well recognised that a subset of highly 
activated platelets, procoagulant platelets, can change their membrane surface to 
assemble the coagulation complexes tenase and prothrombinase, which generate 
thrombin and localise fibrin formation to the platelet thrombus (122,179). Excess 
procoagulant platelets are implicated in pathological thrombosis, however, previous 
studies on hyperactive platelets and cardiovascular risk have concentrated on classical 
platelet activation rather than procoagulant platelets (186). Recent studies show that 
strategies to selectively reduce procoagulant platelets including targeting intracellular 
calcium (Orai1 deficiency) (187), ATP regulation (14-3-3ζ,) (188) and membrane water 
channels (aquaporin) protect against murine models of arterial thrombosis (121) without 
an increase in bleeding. The study of procoagulant platelets is particularly exciting as 
specific inhibition of procoagulant platelet formation could reduce pathological 
thrombosis in CVD without increasing bleeding.   
Procoagulant platelets are characterized by externalization of PS in a process involving 
Cyclophilin D-regulated formation of the MPTP (121,178). Clinical studies of the role 
of procoagulant platelets in CVD have been hampered by the lack of a sensitive and 
specific assay. It is known that PS exposure is a prerequisite for procoagulant platelets, 
but there is an imperfect correlation between PS and procoagulant function. It was 
recently established that a labelled cell death marker GSAO  [(4-(N-(S-
glutathionylacetyl)amino) phenylarsonous acid] can detect procoagulant platelets ex 
vivo and in vivo (120) with very good correlation with activated factor binding (r
2 
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=0.98, p <0.0001) (120,123). This subset of activated platelets, which take up GSAO, 
undergo cyclophilin D-mediated necrosis and provide a procoagulant surface (120). A 
recent major review contrasting varying methods to identify procoagulant platelets, 
including PS exposure and formation of the MPTP identified GSAO as an important 
means of evaluating the role of procoagulant platelets in disease and mechanism studies 
(189). A flow cytometry assay to detect procoagulant platelets using the platelet uptake 
of a GSAO and co-staining with CD62P (GSAO+/CD62P+ platelets) was adapted to 
identify procoagulant platelets in whole blood and was used in this study (120,123).  
Patients with CAD have increased circulating procoagulant platelets and an increased 
propensity to form procoagulant platelets in response to soluble agonists (123). This 
hyper-reactivity, compared to healthy volunteers, is greatest in response to soluble 
agonist thrombin (8.8±2 vs 18.9±11%, P<0.0001) unaffected by aspirin and was not 
associated with other markers of platelet function including aggregation, dense granule 
release and activation of GPIIb-IIIa (123). 
In the present study, RIPC reduced the number of circulating procoagulant platelets, and 
attenuated the formation of procoagulant platelets in response to a range of thrombin 
and thrombin + collagen agonist concentrations. This effect on procoagulant platelet 
formation appeared to be due to an effect of RIPC on platelet mitochondrial membrane 
depolarisation as demonstrated by a flow cytometry assay utilising the mitochondrial 
potential sensitive dye TMRE. The effect of RIPC on circulating procoagulant platelets 
is supported by the greater reduction in percentage change with RIPC than sham, which 
may have been statistically significant had the cohort sizes been larger. 
It is traditionally believed only strong agonists activate platelet MPTP and procoagulant 
platelet formation. The presence of procoagulant platelets in the circulation of patients 
with CAD suggests that a low level of agonist stimulation, possibly as a result of 
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exposure to collagen and thrombin in atheromatous lesions, occurs in patients with 
CAD. The present study demonstrates that RIPC ameliorates this. The effect of RIPC in 
reducing procoagulant platelets under unstimulated circulating conditions was apparent 
in the subgroup of patients with significant CAD. There was no correlation between the 
effect of RIPC on the levels of procoagulant platelets and on GPIIb-IIIa activation, 
implying that RIPC modulates these processes independently.  
Depolarisation of the platelet mitochondrial membrane by formation of the MPTP is 
thought to be a pivotal step during the formation of a procoagulant phenotype (178). 
Stabilisation of the membrane may be detected by retention of TMRE within the platelet 
mitochondria and this was defined as a TMRE+ platelet event in this study. There was a 
significant increase in the proportion of platelets which were TMRE+ after RIPC. 
Additionally, RIPC significantly increased platelet mitochondrial membrane 
stabilisation after stimulation with low dose thrombin, which would be expected to be 
more likely to occur in vivo in patients with stable coronary disease. This effect was 
also seen at higher concentrations of thrombin, with and without collagen. There was a 
significant correlation between the decrease in the proportion of circulating pro-
coagulant platelets after RIPC and the change in the number of platelets with stable 
mitochondrial membrane potential, suggesting this pathway is a relevant mechanism 
during RIPC.  
The MPTP is a non-specific, high conductance channel that forms in the inner 
mitochondrial membrane upon myocardial reperfusion. It mediates cell death by 
uncoupling oxidative phosphorylation leading to depletion of ATP (190). Ischaemic 
preconditioning and postconditioning have been shown to inhibit the opening of the 
MPTP in cardiac myocytes by causing resistance to calcium induced MPTP formation 
in a cyclophilin D-dependent process (191,192). There are also suggestions that RIPC 
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may also affect MPTP opening during IR injury, leading to cardiac protection(193). 
Thus it is possible that RIPC would inhibit the opening of the MPTP in circulating cells 
such as platelets.  RIPC could influence mitochondrial membrane potential stability by 
affecting formation of the MPTP. Hence the effect of RIPC on procoagulant platelet 
formation may be a manifestation of an effect on the MPTP. 
This study demonstrated a novel effect of RIPC on platelet activity. Procoagulant 
platelets are increasingly recognised contributors to the pathogenesis of thrombotic 
diseases and the reduction in procoagulant platelet activity may help explain the 
beneficial effects of RIPC in clinical settings including acute myocardial infarction. The 
apparent greater effect of RIPC in patients of aspirin monotherapy will require further 
exploration as will the effect of antiplatelet therapy on mitochondrial membrane 
potential and the changes induced by conditioning. 
 
5.5 Conclusions 
 
Remote ischaemic preconditioning reduces the proportion of circulating procoagulant 
platelets and their formation in response to thrombin based stimulation in patients with 
coronary artery disease. This appears to occur by stabilising the platelet mitochondrial 
membrane potential, preventing depolarisation. This effect of RIPC may be important in 
diseases associated with extensive thrombus formation such as STEMI and may help 
explain the benefit of preconditioning in this clinical context. 
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Chapter 6: The effect of remote ischaemic preconditioning on 
circulating microRNAs 
 
6.1 Introduction 
 
MicroRNAs are short (approximately 22 nucleotides in length), non-coding segments of 
RNA that have gene regulatory functions in human biology (194). They play a role in 
post-transcriptional regulation of protein expression, by direct regulation of messenger 
RNA (mRNA) or by inhibition of translation of the target mRNA (195,196). 
MicroRNAs are synthesised as a primary transcript, pri-miRNA, in the nucleus by RNA 
polymerase II (197). This primary transcript is cleaved to form pre-miRNA. Once 
transported out of the nucleus the pre-miRNA is cleaved in the cytoplasm by the RNAse 
III enzyme DICER to form a duplex which is between 20-22 nucleotides long 
(198,199). The two miRNA strands are indicated by the suffixes -5p and -3p, 
respectively. Although both strands can perform the miRNA function, usually only one 
strand is incorporated into the RNA induced silencing complex (RISC), where the 
miRNA and target mRNA interact (200). 
There is evidence supporting the role for miRNAs in the development of atherosclerosis 
and coronary artery disease (201). Lipid homeostasis can be influenced by miRNAs, 
with inhibition of miRNA-122 leading to reduction in plasma cholesterol in animal 
models (202,203). Further, other miRNA species promote atherosclerotic plaque 
development and the formation of high risk plaque features while others have 
atheroprotective properties (204-207). Specific miRNA species have been shown to 
promote endothelial cell dysfunction and promote leukocyte invasion into the vessel 
wall leading to vascular inflammation (208,209). Activation of human platelets can lead 
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to changes in miRNA expression, which consequently affects protein expression, 
integrin activity and inflammatory pathways (199,210). Further, specific miRNA 
profiles may influence the cardiac response to IR injury and hence the degree of 
myocardial injury and the potential for repair (211,212). Finally, endothelial 
regeneration and smooth muscle proliferation are influenced by miRNA expression 
(213), which has implications for revascularisation by PCI and CABG. 
 
6.1.1 MicroRNA and remote ischaemic preconditioning  
There is precedent that RIPC may affect miRNA expression in some experimental 
models. MicroRNA-144 is upregulated by RIPC in both mouse myocardium and 
plasma, and in this species is associated with promotion of cellular survival pathways 
and down-regulation of mammalian target of rapamycin (45).  In this same study, 
miRNA-144 was also upregulated in the plasma of healthy human volunteers subjected 
to RIPC. While local ischaemic preconditioning is associated with a rise in myocardial 
miRNA-1 and miRNA-21 in the rat heart, RIPC and ischaemic postconditioning 
reduced miRNA-1 in the myocardium and had no effect on miRNA-21 (50). Changes in 
miRNA-1 and miRNA-21 have also been suggested by other studies. The reports 
describing these animal studies did not comment on the effect of RIPC on other miRNA 
species. 
In patients undergoing CABG, RIPC altered the atrial myocardial expression of specific 
miRNAs, attenuating expression of miRNA-1 in response to surgery and promoting 
miRNA-338-3p expression (51). A rat model demonstrated a more complex relationship 
between RIPC and expression within the myocardium. MicroRNA-1 was initially 
decreased by RIPC after IR injury, but after 6 h RIPC had increased miRNA-1 levels in 
the myocardium (214). Changes in plasma miRNA profiles with RIPC were not 
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reported in these studies. In a separate study, children undergoing cardiopulmonary 
bypass for congenital heart disease surgery were treated with RIPC and this was 
associated with an increase in levels of miRNA-21 in urine and blood and a reduction in 
markers of acute kidney injury compared to patients in the control arm (215).  
RIPC is thought to have protective effects beyond the heart and animal studies have 
demonstrated the contribution of miRNA to the protection of other organs against IR 
injury and against the effects of sepsis (216-218). As discussed in chapter 1, the 
mediators of RIPC are most likely transported to distant target organs in the circulation. 
Hence the aim of this study was to study the effect of RIPC on the plasma miRNA 
profile in patients undergoing coronary angiography for the investigation of CAD.  
 
6.2 Methods 
 
6.2.1 Patient population 
Patients referred for coronary angiography were recruited for participation in this study 
prior to their planned procedure. The patients were randomised to receive RIPC or sham 
treatment and had blood collected before and after the allocated treatment. This patient 
population was described in chapters 4 and 5.  
 
6.2.2 Blood collection and plasma storage 
The blood collection and storage of plasma was performed as described in sections 2.4 
and 2.5. In brief, a 20G cannula was inserted into a large cubital fossa vein in the 
contralateral arm to the limb where RIPC/sham treatment was delivered. After the first 
3 mL of blood was discarded, blood was slowly drawn through the cannula, without a 
tourniquet or haemostatic valve, at a rate of 0.5 mL/s into a syringe and gently 
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transferred into tubes containing 3.2 % buffered sodium citrate. The blood collection 
procedure was repeated in an identical manner after the patient’s allocated treatment. 
Blood was transported carefully at room temperature for processing within 20 min of 
collection. The blood was centrifuged twice at 2500 g for 15 min at room temperature 
and aliquoted for storage. Plasma was stored at -80 °C for miRNA extraction at a later 
time, without previously being thawed. 
 
6.2.3 Remote ischaemic preconditioning 
As described in section 2.1, RIPC was delivered to the left upper limb by inflation of a 
sphygmomanometer to 200 mmHg or 50 mmHg greater than systolic blood pressure 
(whichever was greater) for 5 min, followed by deflation for 5 min. This cycle was 
performed a total of 3 times. Sham treatment was delivered in an identical manner 
except the sphygmomanometer was inflated to 10 mmHg. Patients were randomised to 
RIPC or sham treatment by way of a closed envelope system. 
 
6.2.4 Assessing for haemolysis in stored plasma  
The degree of haemolysis in the stored plasma was determined by spectrophotometry in 
duplicate on an EnSpire Multimode Plate Reader as described in section 2.7.1, using 
A414nm as this is the absorbance peak of free haemoglobin (127). Haemolysis has been 
shown to alter the miRNA profile of plasma (127,128).  
  
6.2.5 MicroRNA extraction from plasma 
MicroRNA was extracted as described in section 2.7.2.5 using the NucleoSpin miRNA 
Plasma kit as per the manufacturer’s recommendations. The extraction was performed 
in duplicate from 100 µL of each patient sample with mussel glycogen added during the 
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extraction process to increase the extraction efficiency. After extraction, the RNA 
sample was eluted in 30 μL of water.  
The RNA extracted from the duplicate plasma samples was pooled and underwent a 
precipitation step as described in section 2.7.2.5. In brief, the miRNA was mixed with 
0.1 volumes of 3 M sodium acetate, 2.5 ng mussel glycogen and 2.5 volumes ice cold 
100% ethanol before incubation overnight at -80 °C. Once thawed, the sample was 
centrifuged and the pellet was carefully washed with 1 mL 80% (v/v) of ice cold 
ethanol. After further centrifugation, for 10 min at 4 °C, the supernatant was carefully 
removed and the pellet air dried at room temperature for 10 min before being 
resuspended in 10 μL of RNase free water. The miRNA was stored at -80 °C and used 
within 10 days.  
 
6.2.6 MicroRNA array 
A total of 4 patients who were treated with RIPC were selected from the larger cohort of 
60 randomised patients for the purpose of miRNA profiling by TaqMan qPCR array 
cards. Patients with the greatest attenuation of PAC-1 binding in response to thrombin 
and collagen and with insignificant amounts of haemolysis in both pre and post RIPC 
stored plasma samples were chosen. After miRNA extraction, miRNAs were measured 
using the TaqMan Array MicroRNA Cards (A and B cards) together with the 
Megaplex
TM 
primers, human Pool Set v3.0 (Thermofisher). Each card (A or B) allowed 
assessment of up to 381 specific miRNA species. Megaplex RT reaction and card arrays 
were performed as instructed by the manufacturer with reactions performed with the 
Viia 7 system and analysed with the QuantStudio software.  
Prior to the RT reaction, miRNA-16 specific RT and qPCR reactions were performed to 
assure successful isolation of miRNA. Additionally, after the megaplex RT reaction, 
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specific qPCR reactions for miRNA-16 (card A samples) and miRNA-1274B, another 
common species in plasma (card B samples), were performed to ensure the multiplex 
RT reaction was successful. The RT and qPCR reactions were performed as described 
in section 2.7.2.5. 
After the miRNA array, microRNA species with at least a 2-fold increase with RIPC, in 
at least 3 of the 4 patients, were deemed to be potentially upregulated by RIPC. These 
candidate species were validated by specific RT and qPCR reactions in the larger study 
cohort. A threshold of 2-fold increase was chosen to improve the chances of validation 
(219). 
 
6.2.7 Validation of array findings with reverse transcription, pre-amplification and 
quantitative polymerase chain reactions 
To validate the results of the array, RNA was extracted from the 60 patients randomised 
to RIPC or sham described in chapters 4 and 5. In order to increase consistency, a 
multiplex RT reaction, with all 8 miRNA-specific RT primers placed in the same 
reaction was performed, after confirming that combining the primers did not interfere 
with the RT reaction. The multiplex RT reactions were performed using specific 
primers for the 2 reference species (miRNA-16 and RNU6-1) and the 6 candidate 
miRNA species that appeared to be upregulated by RIPC according to the array 
analysis. The multiplex RT reaction was performed in 10 μL with 1.67 μL of RNA, 1 
nM dNTPs, 33 U MultiScribe reverse transcriptase, 1 μL 10x RT buffer, 2.4 U RNAse 
inhibitor, 4 μL of an equal mix of each of the 8 primers (5x) and 2.45 μL water, using 
the same RT cycle settings: 16 °C for 30 min, then 42 °C for 30 min then 85 °C for 5 
min. Each primer concentration in the multiplex RT reaction was 4-fold lower than 
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individual RT reactions preformed. After the multiplex RT reaction, 57.8 μL of water 
was added to dilute each cDNA sample for subsequent qPCR analysis.  
To ensure that the 8 primers were compatible, a multiplex reaction was compared to 
separate individual RT reactions for the same 8 miRNA species using miRNA extracted 
from 2 separate patients with significant CAD. The multiplex RT reaction was 
performed as described above. The individual RT reactions were performed as 
described in section 2.7.2.5 except 28.9 μL of water was added to each sample after the 
reaction was complete.  
Specific miRNA-16 qPCR reactions were performed on the cDNA from 12 random 
samples from the entire cohort of 60 randomised patients. This was performed to ensure 
the multiplex RT reaction had worked prior to processing all samples for the 6 
candidate and 2 reference miRNAs.  
As average Ct values for some miRNA species were > 35 cycles in the array, a pre-
amplification step prior to the specific qPCR reactions in the validation cohort was 
introduced to more accurately assess any changes in miRNAs. Each pre-amplification 
was performed in 20 μL containing 1x KAPA Probe Fast Master Mix, 1x Rox Low, 5 
μL of 1:100 dilution of the 8 miRNA probes (final concentration 0.05x) and 0.1 μL 
water. Pre-amplification conditions were 95 °C for 10 min followed by 10 cycles of 95 
°C for 15 sec and 60 °C for 4 min and were performed on a Viia 7 system. After pre-
amplification, samples were diluted with 20 μL of water. To ensure this step was 
effective in increasing the amount of cDNA, the cDNA of the two patients whose 
samples were used to test the multiplex RT reaction underwent pre-amplification as 
above. These results were compared with the results of qPCR reactions for the 6 
candidate and 2 reference miRNA species with non-pre-amplified cDNA.  
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RNA from all patients was reverse transcribed using the multiplex RT reaction, then 
pre-amplified as described, above after which specific qPCR reactions for each of the 6 
miRNA candidate species and the 2 reference species were performed in duplicate. The 
qPCR reactions were performed in a 96 well plate in 10 μL as described in section 
2.7.2.5. The patient treatment (RIPC/sham) allocations were concealed until after the 
experiments and data analysis was completed.  
There were several samples which showed high Ct values for each of the miRNA 
species investigated, including the reference miRNAs. This suggested reduced quality 
or quantity of miRNA in these samples. The samples resulting in the highest Ct values 
in at least 6 of the 8 miRNA species were identified. These outlying samples were 
excluded from the analysis together with their corresponding pre or post sample. This 
resulted in exclusion of 14 subjects from the cohort.  
 
6.2.8 Statistical analysis 
The mean of the Ct values for duplicate reactions was used in each analysis. With 
respect to the array, the reference species used was RNU6-1 in all samples as this 
species was present on both card A and card B. In addition, for card A samples, a 
separate analysis was performed with miRNA-16 as the reference species. For the 
validation PCR reactions, both RNU6-1 and miRNA-16 were included as reference 
miRNA species. The fold change in miRNA species with RIPC or sham treatment was 
calculated using the double delta method. In short, for each sample, the Ct value of the 
reference miRNA species was subtracted from the Ct of the miRNA species in question. 
This was performed in pre and post RIPC/sham samples (ΔCt-pre and ΔCt-post 
respectively). To determine the double delta Ct value (ΔΔCt), the difference between 
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ΔCt-post and ΔCt-pre was calculated. The fold change in miRNA species expression 
with RIPC or sham was calculated by 2
- ΔΔCt. 
The fold change in miRNA species expression with the allocated treatment was 
expressed as median (IQR) and were compared with the Mann-Whitney U tests for non-
parametric data. Correlations between variables were assessed by Pearson r correlation 
or Spearman rank correlation for parametrically and non-parametrically distributed data 
respectively. Calculations and statistical analyses were performed with Excel 
(Microsoft, Redmond, Washington, USA) and GraphPad Prism. 
 
6.3 Results 
 
6.3.1 Baseline clinical characteristics 
The baseline characteristics of the 60 patients recruited to study the effects of RIPC 
were described in section 4.3.1 and Table 4.1. Amongst this cohort, 4 patients treated 
with RIPC were selected for the array. These 4 patients were all male, presented with 
stable angiographically significant CAD, showed an average attenuation of PAC-1 
binding by 8.2 ± 10.8% by RIPC and had insignificant levels of haemolysis in both pre 
and post plasma samples (data not shown). 
 
6.3.2 Changes in plasma microRNA based on card array analysis 
6.3.2.1 Verification of microRNA-16 levels after extraction  
Following extraction and precipitation of small RNA the presence of miRNA-16 was 
assessed to ascertain successful isolation of miRNA. MiRNA-16 specific RT and qPCR 
reactions demonstrated similar Ct values (Figure 6.1). The consistency of the miRNA-
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16 Ct values implied similar miRNA-16 levels across the samples and suggested 
successful miRNA isolation. 
 
 
 
Figure 6.1 MicroRNA-16 content of plasma microRNA samples for array analysis 
MicroRNA was extracted from the stored plasma of 4 patients with CAD who received RIPC. Specific 
miRNA-16 RT and qPCR reactions were performed. Values represent mean Ct value of duplicate 
reactions for each sample pre and post RIPC, with lower values indicating a greater concentration of 
miRNA-16 in the sample. The blank sample was a control reaction with water added rather than miRNA. 
Bars represent range. 
CAD, coronary artery disease, Ct, cycle threshold; miRNA, micro ribonucleic acid; RIPC, remote 
ischaemic preconditioning; 
 
6.3.2.2 Verification of Megaplex Pool A and B reverse transcription reactions  
After establishing successful miRNA extraction, RT reactions using the Megaplex 
primer pools A and B were performed. Prior to array card analysis, miRNA-16 (pool A) 
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and miRNA-1274B (pool B) levels were checked. Specific qPCR reactions identified 
consistent levels of miRNA-16 and miRNA-1274B in the cDNA produced after the 
Megaplex RT reactions (Figure 6.2). This indicated that the RT reaction was successful 
and the cDNA could be used for analysis with the array cards. 
 
a) 
  
b) 
 
 
Figure 6.2 MicroRNA-16 and microRNA-1274B levels in complementary 
deoxyribonucleic acid produced by the Megaplex reverse transcription reactions 
After a Megaplex RT reaction, specific qPCR reactions were performed on the cDNA. Values represent 
mean Ct value of duplicate reactions for each sample pre and post RIPC, with lower values indicating a 
greater concentration of miRNA-16 (a) or miRNA-1274B (b) in the sample. The blank sample was a 
control reaction with water added rather than cDNA. Bars represent range. 
cDNA, complementary deoxyribonucleic acid; Ct, cycle threshold; miRNA, micro ribonucleic acid; 
RIPC, remote ischaemic preconditioning; RT, reverse transcription; 
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6.3.2.3 Array results 
In total, 8 A cards and 8 B cards were processed. The reference species RNU6-1 was 
present in similar levels across the samples for both A and B cards, indicating similar 
levels of miRNA and successful running of the card PCR reactions (Figure 6.3). 
 
a) 
 
b) 
 
 
Figure 6.3 RNU6-1 content in TaqMan array card samples 
Results of TaqMan array card based qPCR reactions for RNU6-1. Values represent mean Ct valve of 4 
qPCR reactions for each sample, pre and post RIPC, with lower values indicating a greater concentration 
of RNU6-1 in card A samples (a) and card B samples (b). Bars represent ± SD. 
Ct, cycle threshold; RIPC, remote ischaemic preconditioning; qPCR, quantitative polymerase chain 
reaction; 
 
After the fold change with RIPC was calculated for each miRNA species in each 
patient, 6 miRNA species emerged as potentially being upregulated by conditioning. 
The species from card A were miRNA-15b, miRNA-143, miRNA-331 and miRNA-
425-5p (Figure 6.4), while the species from card B were miRNA-30e-3p and miRNA-
151-3p (Figure 6.5). The average fold change in each of these species with RIPC is 
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demonstrated in Table 6.1 demonstrating large differences in fold change between 
different patients. 
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Figure 6.4 MicroRNA species which appeared to be upregulated by remote 
ischaemic preconditioning amongst TaqMan array card A samples 
Card A species with at least a 2-fold increase in expression with RIPC in at least 3 of 4 patients. Fold 
change calculated with RNU6-1 (left panels) or miRNA-16 (right panels) as the reference species. A 
value >1 implies an increase in expression with the treatment, whereas a value <1 implies a decrease. 
Where no fold change reported, amplification curve of either pre RIPC or post RIPC sample did not reach 
threshold. The dotted line denotes a fold change of 1. 
miRNA, micro ribonucleic acid; RIPC, remote ischaemic preconditioning; 
 
 
    
Figure 6.5 MicroRNA species which appeared to be upregulated by remote 
ischaemic preconditioning amongst TaqMan array card B samples 
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Card B species with at least a 2-fold increase in expression with RIPC in at least 3 of 4 patients. Fold 
change calculated with RNU6-1 as the reference species. A value >1 implies an increase in expression 
with the treatment, whereas a value <1 implies a decrease. Where no fold change reported, amplification 
curve of either pre RIPC or post RIPC sample did not reach threshold. The dotted line denotes a fold 
change of 1. 
miRNA, micro ribonucleic acid; RIPC, remote ischaemic preconditioning; 
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Table 6.1 Fold change in candidate microRNA species with remote ischaemic 
preconditioning 
Species RNU6-1 miRNA-16 
miRNA-15b 6.9 ± 8.7 3.8 ± 2.7 
miRNA-30e-3p* 3.0 ± 2.0  
miRNA-143 6.8 ± 7.0 5.0 ± 3.2 
miRNA-151-3p* 2.9 ± 1.2  
miRNA-331 2.8 ± 2.5 1.9 ± 1.5 
miRNA-425-5p 13.4 ± 19.3 6.2 ± 6.6 
 
Values represent mean ± SD fold change in each miRNA species with RIPC corrected for RNU6-1 or 
miRNA16. A value >1 or <1 implies an increase or decrease in expression with the treatment, 
respectively. n=4.  
* miRNA-16 reaction not present on card B. 
miRNA, micro ribonucleic acid; RIPC, remote ischaemic preconditioning; 
 
Prior studies have demonstrated RIPC-induced increases in miRNA-144 and miRNA-21 
in the circulation of healthy volunteers and children undergoing cardiopulmonary 
bypass respectively. MicroRNA-1 has been shown to be reduced while miRNA-338-3p 
increased in atrial tissue of patients undergoing CABG after treatment with RIPC. The 
array data demonstrated that miRNA-144 was increased in 2 of the 4 patients while 
miRNA-21 was increased in 1 of the 4 patients after RIPC (data not shown). All of the 
qPCRs for miRNA-1 and miRNA-338-3p did not reach the threshold, indicating 
inadequate levels of these species to reliably assess changes in any of these miRNA 
species after RIPC in this study cohort. 
 
 
 
Chapter 6 
 
183 
 
6.3.3 Validation of array findings 
6.3.3.1 Comparison of multiplex and individual reverse transcription reactions 
A comparison of the Ct values derived after specific qPCR reactions showed similar 
miRNA levels between the multiplexed RT sample and the individual RT samples for 
the 6 candidate and the 2 reference species (RNU6-1 and miRNA-16), suggesting the 
multiplex RT reaction was successful and that combining the primers did not lead to 
interference in the subsequent qPCR reaction (Figure 6.9). These results indicated that 
the primers for the 8 miRNA species were compatible in the multiplex RT reaction. 
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Figure 6.6 Comparison of multiplex and individual reverse transcription reactions 
Values represent mean Ct value of duplicate reactions for each sample that underwent either a multiplex 
RT (M) or individual RT (I) reactions. Lower values indicate a greater concentration of the miRNA 
species. Bars represent range.  
Ct, cycle threshold; miRNA, miRNA, micro ribonucleic acid;   
 
6.3.3.2 Comparison of pre-amplified and non-pre-amplified samples 
The effect of pre-amplification on the Ct values resulting from qPCR reactions for the 6 
candidate and 2 reference miRNA species is displayed in Figure 6.7. Pre-amplification 
was effective in reducing the Ct values by 5-7 cycles compared to qPCR of non-pre-
amplified cDNA in all miRNA species and thus, was used as part of the validation study 
in the larger patient cohort. 
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Figure 6.7 Comparison of non-pre-amplified and pre-amplified samples 
Values represent mean Ct value of duplicate reactions for the product of the multiplex RT reaction with 
no pre-amplification (NP) or with pre-amplification (P). Lower values indicate a greater concentration of 
the miRNA species. MicroRNA-16 could not be quantified after pre-amplification in one reaction for 
patient B due to an error during setup. Bars represent range.   
Ct, cycle threshold; miRNA, miRNA, micro ribonucleic acid; RT, reverse transcription; 
 
6.3.3.3 Results of specific quantitative polymerase chain reactions to validate array 
findings  
In order to validate the findings of the array, specific RT and qPCR reactions were 
performed for the 6 candidate miRNA species and the 2 reference miRNA species in 
RNA extracted from plasma stored before and after either RIPC or sham treatment in 60 
patients. After a multiplex RT reaction, a random sample from each batch of miRNA 
extractions was assessed for miRNA-16 with qPCR. This demonstrated the presence 
and comparable levels of miRNA-16 in each of the tested samples (data not shown). 
Subsequently all samples underwent pre-amplification and specific qPCR reaction for 
the 6 candidate miRNA species and the 2 reference species. A representative example 
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of the amplification curves for RNU6-1 and miRNA-16 for a subset of samples from the 
entire cohort is shown in Figure 6.8.  
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a) 
 
b) 
 
 
Figure 6.8 Amplification curves from quantitative polymerase chain reactions for 
RNU6-1 and microRNA-16 
Representative amplification curves from qPCR reactions for RNU6-1 (a) and miRNA-16 (b) for 24 
patients, with samples pre and post RIPC/sham treatment. Duplicate reactions represented by the same 
colour in each figure. The threshold for each curve is indicated by the horizontal red line. The magnitude 
of the fluorescent signal generated by the qPCR reaction is denoted by ΔRn.  
miRNA, micro ribonucleic acid; qPCR, quantitative polymerase chain reaction; RIPC, remote ischaemic 
preconditioning; 
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There were samples which resulted in late amplifying curves during the qPCR reaction 
(Figure 6.9) including reactions for miRNA-16 (Figure 6.8b). The reactions with the 
highest Ct values, across the 8 miRNA species, were predominantly from the plasma of 
14 patients (6 RIPC, 8 sham), who were excluded from the analysis, leaving 92 samples 
and 46 patients with paired plasma miRNA samples for analysis. There was a 
moderately strong correlation between the Ct values for the two reference species, 
RNU6-1 and miRNA-16 (Figure 6.10). 
 
 
Figure 6.9 Amplification curves with samples amplifying at late cycles 
Representative amplification curves from qPCR reactions for miRNA candidate species for 24 patients, 
with samples pre and post RIPC/sham treatment. Duplicate reactions represented by the same colour. The 
threshold for each curve is indicated by the horizontal blue line. The magnitude of the fluorescent signal 
generated by the qPCR reaction is denoted by ΔRn. Late amplifying samples indicated by arrow. 
miRNA, micro ribonucleic acid; qPCR, quantitative polymerase chain reaction; 
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Figure 6.10 Correlation between cycle threshold values for RNU6-1 and 
microRNA-16  
Correlation between Ct values for RNU6-1 and miRNA-16 from qPCR reaction of multiplex reverse 
transcribed and pre-amplified cDNA. Each value represents the mean Ct value of the duplicate reactions 
for each species. n=92. 
cDNA, complementary deoxyribonucleic acid; Ct, cycle threshold; miRNA, micro ribonucleic acid;  
 
Amongst the 4 RIPC patients that were initially studied with the TaqMan card array 
system, the specific qPCR data demonstrated similar patterns of enhanced miRNA 
expression in the validation study but only with RNU6-1 as the reference species. There 
was a fold change greater than 1 in the majority of RIPC treated patients and species 
after RNU6-1 adjustment. However, the finding of increased expression with RIPC was 
not supported by the miRNA-16 adjusted data with only a minority displaying a fold 
change greater than 1 (Figure 6.11). This suggested more variability in the miRNA-16 
data. A comparison of the fold change with RIPC in these 4 patients in the array and the 
validation data, corrected for RNU6-1, demonstrated larger magnitudes of change 
suggested by the array data (Table 6.2).  
Chapter 6 
 
192 
 
  
  
  
Figure 6.11 Changes in microRNA species with remote ischaemic preconditioning 
in patients assessed with array - Validation data 
Fold change with RIPC in the 4 patients who were analysed with the array card system. RNU6-1 (U6) or 
miRNA-16 (16) used as the reference species. A value >1 implies an increase in expression with RIPC, 
whereas a value <1 implies a decrease. The dotted line denotes a fold change of 1. 
miRNA, micro ribonucleic acid; RIPC, remote ischaemic preconditioning; 
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Table 6.2 Comparison of fold change in candidate microRNA species 
demonstrated by array and specific quantitative polymerase chain reactions 
Species Array card qPCR validation 
miRNA-15b  6.9 ± 8.7 1.5 ± 0.1 
miRNA-30e-3p 3.0 ± 2.0 1.3 ± 0.2 
miRNA-143 6.8 ± 7.0 2.3 ± 1.0 
miRNA-151-3p 2.9 ± 1.2 1.5 ± 0.4 
miRNA-331 2.8 ± 2.5 1.8 ± 0.2 
miRNA-425-5p 13.4 ± 19.3 1.4 ± 0.4 
 
Values represent the mean ± SD fold change in each candidate miRNA species, corrected for RNU6-1, as 
demonstrated by the TaqMan card array and specific qPCR reactions in the same 4 patients treated with 
RIPC. n=4. 
miRNA, micro ribonucleic acid; RIPC, remote ischaemic preconditioning; 
 
Considering the larger study cohort of 46 patients, 25 treated with RIPC and 21 with 
sham, there was no significant increase in expression of any of the 6 candidate miRNA 
species with conditioning (Table 6.3). This was the case after adjustment with either 
RNU6-1 or miRNA-16. There was a significantly greater increase in expression of 
miRNA-151-3p and miRNA-425-5p with sham treatment over RIPC, when correction 
with RNU6-1 was performed. This difference was not significant when the data was 
corrected for miRNA-16. 
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Table 6.3 Fold change in microRNA species with remote ischaemic preconditioning  
Species* RIPC (n=25) Sham (n=21) P 
RNU6-1 
miRNA-15b  1.0 (0.4-1.5) 1.2 (0.8-2.7) 0.24 
miRNA-30e-3p 0.8 (0.5-1.5) 1.1 (0.6-2.6) 0.25 
miRNA-143 0.7 (0.4-1.6) 1.1 (0.6-3.3) 0.20 
miRNA-151-3p 0.7 (0.4-1.4) 1.4 (0.7-2.3) 0.04 
miRNA-331 0.7 (0.4-1.6) 1.5 (0.6-2.6) 0.08 
miRNA-425-5p 0.7 (0.4-1.1) 1.4 (0.9-3.1) 0.006 
miRNA-16 
miRNA-15b  1.1 (0.9-1.7) 1.0 (0.7-1.3) 0.13 
miRNA-30e-3p 1.2 (0.7-1.9) 0.9 (0.5-1.2) 0.15 
miRNA-143 1.0 (0.7-2.1) 0.8 (0.4-1.6) 0.18 
miRNA-151-3p 1.0 (0.6-1.3) 0.9 (0.7-1.3) 0.90 
miRNA-331 1.1 (0.7-1.5) 1.0 (0.7-1.7) 0.56 
miRNA-425-5p 0.8 (0.5-1.5) 1.2 (0.7-1.5) 0.28 
 
Values represent median fold change in Ct value in each miRNA species with RNU6-1 or miRNA-16 as 
the reference. A value >1 implies an increase in expression with the treatment, whereas a value <1 
implies a decrease. P values compare fold changes in miRNA species in patients treated with RIPC and 
sham treatment using the Mann-Whitney U test for non-parametrically distributed data. 
Ct, cycle threshold; miRNA, micro ribonucleic acid; RIPC, remote ischaemic preconditioning; 
 
6.3.3.4 Haemolysis in plasma samples 
Despite careful plasma preparation, there was a significant degree of haemolysis in 85 
(70.8%) of the 120 samples processed for the validation study based on 
spectrophotometry. Figure 6.12a demonstrates the absorbance at 414 nm for each of the 
120 samples. Although plasma miRNA-16 has been shown in prior studies to be 
increased by haemolysis, there was no significant correlation between the absorbance at 
414 nm on spectrophotometry and the Ct values for miRNA-16 (Figure 6.12b). 
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Figure 6.12 Haemolysis in plasma samples and correlation with miRNA-16 
Absorbance at 414 nm (A414) was used as a measure of haemolysis in each plasma sample. Each symbol 
represents the mean of the duplicate measurements for each sample. The threshold of 0.2 is marked by a 
dotted line, with an A414>0.2 indicative of a significant degree of haemolysis in the sample (a). 
Correlation between A414 and the Ct value of qPCR reactions for miRNA-16 (b). n=120. 
Ct, cycle threshold; miRNA, micro ribonucleic acid;   
 
6.4 Discussion 
 
In recent years there has been increased interest in studying miRNA as regulators of 
many biological and pathological processes including cardiovascular disease 
(201,204,205,208,213). These small, non-coding RNAs have been implicated in the 
pathogenesis and development of atherosclerosis and have been studied as biomarkers 
of disease. MicroRNA species have also been associated with cardiac repair and 
regeneration in animal models, raising further interest as potential therapeutic targets in 
the treatment of CAD (212). Given the benefits conferred by RIPC in clinical studies 
(83,138,220-222), miRNA have been considered as potential mediators of RIPC-
mediated cardiac protection. Prior studies have demonstrated an effect of RIPC on 
miRNA expression, both in cardiac tissues and in the circulation (45,50,51). For 
Chapter 6 
 
196 
 
example, miRNA-144 has been shown to be upregulated in the plasma of healthy 
volunteers by RIPC and to be associated with cellular protection in animal models (45). 
However, changes in miRNAs have not been investigated in CAD patients after RIPC.  
One of the predominant theories behind the protective effects of RIPC is the humoral 
hypothesis. This theory proposes that a factor is released into the circulation by the 
tissue subject to RIPC, which circulates to the organ of interest to promote protective 
pathways (26). Given the likely role of circulating mediator and the emerging 
contribution of miRNA to both CAD pathogenesis and cardiac repair and protection, 
and prior literature indicating long-term benefits of RIPC in patients with CAD, a study 
of the effect of RIPC on plasma miRNA profile was conducted.  
A commercially available qPCR-based card array system was used to screen for RIPC-
medicated changes in 762 miRNA species in stored plasma. The results of the array 
suggested 6 candidate miRNA species that were potentially upregulated by RIPC. A 
validation study was subsequently conducted to confirm these findings in a larger 
cohort of patients. Specific RT and qPCR reactions were used to quantify the levels of 
these 6 species in miRNA extracted from stored plasma collected before and after either 
RIPC or sham treatment. The array findings were validated in the same 4 patients by the 
specific qPCRs.  However, the magnitude of fold change in miRNA species differed 
between the array and validation qPCRs in the same 4 patients, which may be explained 
by slight differences in the miniaturised array conditions in the card configuration 
compared to the standard qPCR setup. Differences in magnitude of change have been 
reported between hybridisation-based arrays and qPCR  (219). However, in the entire 
cohort there was no increased expression of the 6 candidate miRNA species with RIPC, 
suggesting that the effects of RIPC on platelet activation, as described in chapters 4 and 
5, are most likely not mediated by changes in circulating miRNAs. 
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Evaluation of miRNA levels in plasma is traditionally challenging for several reasons. 
The RNA yields are generally low with multiple methods for extraction described but 
no definite gold standard technique (137). Additionally, the quantity and composition of 
the miRNA component of RNA extracted from plasma can be altered by factors such as 
the degree of haemolysis during the blood collection process, centrifugation and storage 
(127,128) and cannot be easily assessed by standard assays such as using a Nanodrop 
(Thermofisher) or Bioanalyzer. After testing multiple commercially available extraction 
kits and techniques to optimise quality and yield of miRNA (chapter 2), a published 
method was adapted and employed to investigate the effect of RIPC on plasma miRNA 
(127). Despite checking the miRNA-16 levels at multiple time points and these levels 
appearing relatively constant, the results of the miRNA array could not be validated in a 
larger cohort. This suggests variability in the patient data and the need for a larger 
discovery cohort of patients to study circulating miRNA.  
Analysis of circulating miRNA includes multiple steps, introducing various sources of 
extra variability and error. The entire process involves blood collection, preparation of 
plasma, plasma storage, miRNA extraction, miRNA precipitation, RT reaction and 
qPCR with or without pre-amplification. A small degree of variability during any of 
these steps could lead to significant discrepancies between samples, which may not 
have been accounted for by the modest cohort size. As fold-change is an exponential 
calculation, any mild variation in the level of the reference species in the pre and post 
treatment samples, may also lead to significant differences in apparent expression of the 
candidate species. Therefore, stringent and critical assessment of protocols and data and 
a large patient cohort is necessary. 
Specific qPCRs demonstrated a similar pattern of enhanced expression of the candidate 
miRNA species in the 4 patients assessed by array. This was only the case however, 
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after correction for RNU6-1 with discrepant results after correction with miRNA-16. 
There was also incongruence between RNU6-1 and miRNA-16 corrected data in the 
larger study cohort. There was a moderate correlation between the Ct values of the two 
reference species (Figure 6.10), indicating some variability between the two species 
which may explain some of the discrepant results. The fold change in each of the 
miRNA species is corrected with either of the reference species, hence variability in the 
reference will lead to unreliable calculation of fold changes in expression. The use of 
reference genes is common in RNA research, with miRNA-16 and U6 previously used 
as reference species for the study of circulating miRNA (223,224). However, debate 
exists about which species is most suitable in investigating circulating miRNAs and as 
this study shows, different results may be obtained using different reference miRNA 
species.  
Certain miRNA species can be affected by significant levels of haemolysis in plasma. 
These include miRNA-16 and miRNA-425-5p which are increased by haemolysis 
(127). Haemolysis, identified by spectrophotometric absorbance at 414 nm, was 
observed in 70.8% of the samples, despite careful plasma preparation. However, there 
was no significant correlation between absorbance at 414 nm and the level of miRNA-
16 in the samples and only weak correlation with miRNA-425-5p levels (data not 
shown). Due to the significant levels of haemolysis in the majority of samples, a 
sensitivity analysis in patients without haemolysis could not be performed. Hence, it 
was not possible to exclude that haemolysis was confounding the miRNA-16 corrected 
data or the analysis of miRNA-425-5p. The other candidate miRNA species studied 
have been reported not to be significantly affected by haemolysis. Hence, it is unlikely 
that haemolysis affected the RNU6-1 corrected results or the analysis of the other 
miRNA species.  
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Samples with high Ct values in reference miRNAs, indicative of lower quantities or 
lower quality miRNA, were excluded from the analysis. Despite the apparent changes in 
miRNA expression by RIPC based on the 4 patients studied with the array, in the larger 
study cohort, there was no evidence to support an increased expression of any of the 
candidate miRNA species by RIPC over sham treatment. There was a numerically 
greater increase in miRNA expression with sham treatment, reaching statistical 
significance for miRNA-151-3p and miRNA-425-5p when corrected for RNU6-1. 
There was a discrepancy with the miRNA-16 corrected results, with the differences in 
expression of these two miRNA species with sham treatment no longer reaching 
statistical significance. It is unclear why these two miRNA species might be increased 
by sham treatment. Furthermore, for both miRNA species the increase was 1.4-fold with 
sham. Previously studies have demonstrated fold changes in miRNA species of at least 
2.5 in response to RIPC (45,215). Hence the clinical and physiological significance of 
these changes with sham treatment are unclear.  
Prior studies have demonstrated upregulation of miRNA-144 and miRNA-21 after 
RIPC in healthy volunteers and children undergoing cardiopulmonary bypass. In the 4 
patients assessed with the array, 2 had an increased expression of miRNA-144 and 1 
had an increased expression of miRNA-21. These initial results in 4 patients did not 
suggest an effect of RIPC on these miRNA species and was therefore not investigated 
further.  
The small size of the derivation cohort may be seen as a limitation of this study. A 
cohort of 4 patients (8 samples) was chosen as a balance between increasing the 
accuracy of the results and managing the significant costs of the card array system. 
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Given the method optimisation studies performed prior to conducting this study, it is 
likely that these results are valid and accurate. However, a larger derivation cohort may 
have led to array results which were more likely to be validated.  
 
6.5 Conclusions 
 
MicroRNAs are increasingly being recognised as important regulators of a vast range of 
biological and pathological processes. RIPC had been shown to alter miRNA expression 
in animal models and in the plasma of healthy volunteers. The results of this 
methodologically rigorous study did not identify miRNAs that may mediate the 
beneficial effects of RIPC in CAD patients. As there are however several limitations in 
methodology in this area, future developments are necessary to adequately assess 
circulating plasma miRNA as biomarkers of disease or efficacy of theraputic 
interventions.  
 
Chapter 7 
 
201 
 
Chapter 7: Conclusion and future directions 
 
7.1 General conclusions 
 
Remote ischaemic preconditioning is supported by extensive animal data demonstrating 
protection against myocardial injury. The clinical trials of RIPC prior to elective and 
primary PCI have demonstrated a reduction in myocardial injury and a suggestion of 
reduced ischaemic events during long term follow up. This thesis has explored novel 
mechanisms which may contribute to improved outcomes at the time of PCI including: 
1) the effect of RIPC on coronary physiology assessed by invasively measured indices 
of microcirculatory function; 2) the effect of RIPC on specific pathways of platelet 
activation and procoagulant platelet formation; and, 3) the effect of RIPC on the plasma 
miRNA profile of patients with suspected CAD.  
In patients who had clinical indications for FFR measurement, RIPC was associated 
with a significant reduction in microcirculatory resistance and a significant increase in 
coronary flow reserve. This was mediated by an increase in hyperaemic coronary flow. 
The mechanism behind these observed changes is unclear with no clear evidence of a 
responsible hormonal pathway based on interrogation of stored plasma samples. RIPC 
was also associated with an attenuation of platelet GPIIb-IIIa activation in response to 
SFLLRN and a combination of thrombin and collagen. RIPC was also associated with a 
reduction in basal levels of procoagulant platelets in the circulation and inhibited their 
induction by soluble agonist stimulation. The reduced GPIIb-IIIa activation was not 
associated with detectible changes in platelet intracellular signalling pathways. 
Unexpectedly, there was a reduction in plasma nitrite levels, which correlated with the 
change in GPIIb-IIIa activation, suggesting that RIPC influences nitric oxide/ nitrite 
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metabolism. The influence of RIPC on procoagulant platelet formation appeared to be 
due to stabilisation of the mitochondrial membrane which reduced depolarisation in 
response to agonists. There did not appear to be any definite effect of RIPC on the 
plasma miRNA profile when blood was collected immediately after conditioning. 
This thesis has demonstrated novel effects of RIPC which are particularly relevant to 
patients with CAD. The findings suggest that in these patients, the benefit of RIPC is 
contributed to by an improvement in microcirculatory function and an attenuation of 
platelet activation.  
 
7.2 Future directions 
 
7.2.1 Remote ischaemic preconditioning and coronary physiology  
The coronary microcirculation is recognised as an important contributor to the 
prognosis of patients with CAD. Microcirculatory function, however, is not easily 
amenable to pharmacological manipulation. Reduced microcirculatory resistance and 
improved flow reserve is associated with improved outcomes in patients with CAD, 
including those undergoing PCI. An acute improvement in microcirculatory function 
was demonstrated in this study but the duration and timing of maximal improvement 
could not be determined. Given that the clinical studies in PCI suggest that RIPC is 
ideally delivered 1-2 hours prior to PCI, defining the time course of the 
microcirculatory response to RIPC would be of clinical utility as this may help define 
the optimal timing of PCI after delivery of conditioning.  
The mechanism by which changes in microcirculatory resistance occurs has not been 
defined. The use of specific inhibitors of potential pathways is a commonly used 
strategy in animal studies. This however is more difficult in studies involving patients. 
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A potential agent with an acceptable safety profile is glibenclamide, which is an 
inhibitor of potassium ATP channels, which have previously been implicated in RIPC 
mediated protection and are also known to be involved in regulation of the 
microcirculation. Amelioration of changes in coronary microcirculatory function in 
patients taking or randomised to take glibenclamide would suggest that potassium ATP 
channels are involved in this RIPC-mediated phenomenon. This is an area for future 
exploration. 
Due to the mechanistic nature of the studies conducted, correlation between changes in 
coronary physiology with clinical outcomes could not be performed. Given the 
important role of the microcirculation in determining the prognosis of patients 
undergoing PCI, a large clinical trial powered for outcomes could ideally be conducted 
to confirm the contribution of changes in microcirculatory function to RIPC-mediated 
cardiac protection. A possible role in the setting of poor reflow after myocardial 
infarction may be clinically important.  
The observation that RIPC augments coronary microcirculatory function not only 
provides an insight into a potential mechanism of cardiac protection, but also raises the 
possibility of other areas of RIPC related research and clinical application. RIPC may 
be considered for application in disease processes where microcirculatory dysfunction is 
important such as microvascular angina and heart failure. Additionally, areas of extra-
cardiac pathology such as wound healing and microvascular complications of diabetes 
may also be potential areas for clinical application of RIPC. 
 
7.2.2 Remote ischaemic preconditioning and platelet activation 
A major component of this thesis was the exploration of the effect of RIPC on platelet 
activation. This was investigated by measuring specific pathways of platelet activation 
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through measurement of a wide range of markers in response to ex vivo platelet 
stimulation. The current study was performed in a cohort of patients with predominantly 
stable CAD and demonstrated that RIPC attenuates specific pathways of platelet 
activation. Importantly, these findings were observed in patients taking DAPT, 
indicating that RIPC provides a novel antiplatelet strategy additional to current best 
therapy. It is unclear whether patients with unstable presentations of CAD will exhibit 
the same effect with RIPC, although analysis of this subgroup of patients (data not 
shown) showed similar effects to those seen in stable patients, suggesting this is likely. 
ACS is associated with a pro-thrombotic, inflammatory state, which differs from stable 
presentations of CAD and studying platelet effects in this particular population would 
require independent confirmation in a suitably powered study.  Given that RIPC has 
been shown to be beneficial in the setting of STEMI, the effects on platelet activation 
during ACS would be an interesting area to explore. 
Clear effects on the levels of circulating procoagulant platelets and inhibition of 
procoagulant platelet induction by agonist stimulation were also identified. There was a 
clear effect of RIPC on mitochondrial depolarisation, suggesting a candidate mechanism 
for inhibition of procoagulant platelet formation. Cyclophilin D-mediated regulation of 
the mitochondrial permeability transition pore (225) may represent a key target of RIPC 
and an avenue for further investigation. While the effect of RIPC in attenuating GPIIb-
IIIa activation appeared to be additive to the effects of DAPT, its inhibition of 
procoagulant platelet formation was less evident in patients receiving both aspirin and a 
P2Y12 inhibitor, clearly dissociating the pathways involved in RIPC attenuation of 
GPIIb-IIIa activation and formation of procoagulant platelets. Further investigation into 
the effect of RIPC on procoagulant platelet pathways might best be performed in 
patients on aspirin monotherapy. Exploring the interaction between disease state, such 
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as acute coronary syndrome, antiplatelet therapy, GPIIb-IIIa activation and 
procoagulant platelet formation are areas for future research. 
This thesis did examine some potential pathways through which RIPC may attenuate 
platelet activation. Although a change in VASP phosphorylation was not detectable 
with western blotting, due to the important role of VASP in modulating GPIIb-IIIa 
activity, this may be further explored with an alternative method to assess the 
phosphorylation state of VASP. A flow cytometry based technique has been described 
to measure VASP phosphorylation (226) and this could be considered to elucidate the 
mechanism behind the changes in PAC-1 binding that were observed. We also found no 
significant effect of RIPC on cAMP, cGMP or prostacyclin. Inhibitory pathways are 
less well defined than activatory pathways in platelets and it is possible that new 
pathways, identified by array-based approaches may reveal new avenues for research.   
Importantly, the duration and sustainability of platelet inhibition was not defined by this 
study. Exploring the duration of platelet inhibition, through serial assessments of 
platelet activation, may help guide the optimal timing of RIPC delivery prior to a known 
platelet activating insult such as PCI. In a similar manner to the coronary physiology 
arm of this project, the mechanistic focus of the platelet studies did not allow correlation 
between platelet inhibition and clinical outcomes. Given the minimally invasive nature 
of the platelet activation assays, platelet assessments are an ideal adjunct to clinical 
studies of RIPC, allowing correlation between platelet inhibition and clinical outcomes. 
 
7.3 Final remarks 
 
This thesis has examined potential mechanism behind the beneficial effects of RIPC in 
the setting of PCI. Novel effects on microcirculatory function and attenuation of platelet 
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activation have been demonstrated. Although the adoption of RIPC into clinical 
management guidelines will depend on ongoing large clinical trials powered for clinical 
outcomes, these results warrant future studies to understand the biological effects of 
RIPC. These will in turn help guide clinical application, guide selection of populations 
that are likely to benefit and potentially identify novel therapeutic targets for the 
treatment of coronary artery disease. 
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